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Abstract 
          Staphylococcus aureus lipoteichoic acid (LTA) consists of a 1,3-linked 
polyglycerolphosphate chain retained in the bacterial membrane by a glycolipid 
anchor. The LTA backbone is produced by the lipoteichoic acid synthase LtaS, a 
membrane protein with five transmembrane helices and a large extracellular 
enzymatic domain (eLtaS). Proteomic studies revealed that LtaS is efficiently cleaved, 
and here it was demonstrated that the eLtaS domain is released into the culture 
supernatant as well as partially retained within the cell wall fraction. However, using 
an in vivo LtaS activity assay, it was shown that only the full-length LtaS enzyme is 
able to synthesize LTA. Neither expression of a secreted eLtaS variant, created by 
replacing the N-terminal membrane domain with a conventional signal sequence, nor 
expression of eLtaS fused to a single or multi-transmembrane domains of other 
staphylococcal proteins resulted in the production of LTA. These data indicate that the 
transmembrane domain of LtaS play an essential, yet unknown, role in LtaS enzyme 
function. In addition, the protease responsible for LtaS cleavage was identified. It was 
found that a S. aureus strain in which the gene encoding for the essential signal 
peptidase SpsB was cloned under inducible expression control showed an 
accumulation of the full-length LtaS enzyme in the absence of the inducer. These data 
suggest that SpsB is involved in LtaS cleavage. 
          Four LtaS orthologues, YflE, YfnI, YqgS and YvgJ, are present in Bacillus 
subtilis. Using an in vitro enzyme assay and purified protein, it was determined that 
all four B. subtilis proteins are Mn2+-dependent metal enzymes that use the lipid 
phosphatidylglycerol as substrate. It was shown that YflE, YfnI and YqgS are bona-
fide LTA synthases capable of producing polyglycerolphosphate chains, while YvgJ 
appears to function as an LTA primase, as indicated by the accumulation of a 
glycolipid with the expected chromatographic mobility of GroP-Glc2-DAG. Taken 
together, experimental evidence for the enzyme function of all four B. subtilis LtaS-
type proteins is provided in this work and it was shown that all four enzymes are 
involved in the LTA synthesis process.  
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1.1 Aims and objectives of this study 
          Recently, the enzyme responsible for polyglycerolphosphate LTA backbone 
synthesis, LtaS, was discovered in S. aureus and shown to be essential for bacterial 
growth under standard laboratory conditions (Gründling & Schneewind, 2007a). LtaS 
assembles in five N-terminal membrane-spanning helixes (5TM) followed by a large 
C-terminal extracellular enzymatic domain (eLtaS). The LtaS protein is cleaved 
during bacterial growth and the eLtaS released into the culture supernatant (Gatlin et 
al, 2006; Ziebandt et al, 2001). The first aim of this study was to characterize the LtaS 
enzyme in view of its functional requirements and to identify the protease responsible 
for LtaS cleavage. To this end, the contribution of the 5TM to LtaS function in vivo 
was investigated. A previously described in vivo LtaS activity assay was used to test 
the functionality of several LtaS variants in which the 5TM domain was replaced with 
either a conventional signal sequence or single or multi-transmembrane domains of 
other staphylococcal proteins. Staphylococcal proteins that were used to construct the 
LtaS hybrid fusion proteins were protein A, SrtA and LtaA and these proteins are 
discussed in the introduction.  
          S. aureus secretes a range of proteases, among which are serine, cysteine and 
metalloproteases. Further information on these proteases is provided in the 
introduction. These proteases function on the outside of the cell and could therefore 
be responsible for LtaS processing. To assess their contribution to LtaS processing, 
LtaS protein cleavage was analyzed in S. aureus strains with defined protease 
deficiencies. Moreover, evidence is provided in the literature that LtaS-type enzymes 
are substrates for type-I signal peptidases (Antelmann et al, 2001; Powers et al, 2011). 
S. aureus expresses one functional type-I signal peptidase, SpsB, and its contribution 
to LtaS cleavage was investigated in this work.  
          Four LtaS orthologues are present in B. subtilis, namely YflE, YfnI, YqgS and 
YvgJ. A recent study demonstrated that YflE was able to restore growth and LTA 
production in a S. aureus ltaS depleted mutant strain (Gründling & Schneewind, 
2007a). Functional complementation of ltaS depletion with B. subtilis YfnI resulted in 
LTA synthesis, but the polyglycerolphosphate product displayed an altered mobility 
on SDS-PAGE compared to wild type LTA. However, YfnI expression failed to 
restore staphylococcal growth, suggesting that the function of LTA does not only rely 
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on its polyglycerolphosphate backbone. No enzyme activity was observed for B. 
subtilis YqgS and YvgJ (Gründling & Schneewind, 2007a).  
          The second aim of this study was to characterize the four B. subtilis LtaS-type 
enzymes in vitro and to identify in vivo functions for B. subtilis YqgS and YvgJ. For 
the latter aim, LTA production was analysed in S. aureus strains expression single B. 
subtilis LtaS-like proteins, and in defined B. subtilis strains lacking individual ltaS-
like genes or combinations of the four genes. In addition, investigations to identify 
structural differences between LTA polymers synthesized by S. aureus LtaS and B. 
subtilis YfnI were undertaken. To this end, LTA was extracted from S. aureus mutant 
strains expressing either wild type LtaS or B. subtilis YfnI, and the resultant 
polyglyerolphosphate products analyzed by NMR and standard biochemical assay.    
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1.2 Staphylococcus aureus 
          Staphylococcus aureus is an immotile, non-sporulating bacterium that forms 
microscopically grape like clusters. S. aureus belongs to the bacterial family of 
Staphylococcaceae within the phylum of Gram-positive Firmicutes and is closely 
related to Enterococcus, Bacillus and Listeria species. The genus Staphylococcus 
contains about thirty species, thirteen of which are associated with humans (Schleifer 
& Kroppenstedt, 1990). The Staphylococci can be divided into two groups depending 
on their ability to produce the enzyme coagulase. Coagulase is a surface protein that 
stimulates human blood to clump by activating prothrombin, which is part of the 
coagulation pathway. This reaction can be used to differentiate the coagulase-positive 
S. aureus from other species of staphylococci. Several animal models of infection 
have demonstrated that coagulase is a virulence determinant of S. aureus (Hasegawa 
& San Clemente, 1978; Jonsson et al, 1985; Sawai et al, 1997). Unlike other 
staphylococci, S. aureus produces staphyloxanthin, which protects the bacteria against 
reactive oxygen species and gives the organism its characteristic yellow pigmentation 
(Liu et al, 2005). S aureus is halotolerant, tolerating NaCl concentrations as high as 
15 % (w/v), and grows at temperatures ranging from 15-45°C. Under high NaCl stress 
conditions, S. aureus shortens its peptidoglycan interpeptide bridges in order to 
reinforce the cell wall (Vijaranakul et al, 1995). The genome of S. aureus is 
approximately 3 Mb in size with a low G+C content and contains strain specific 
combinations of variable sequence elements such as prophages, pathogenicity islands 
and staphylococcal cassette chromosomes (SCC) (Baba et al, 2008).  
          Humans are a natural reservoir of S. aureus, where the bacterium can occur as 
both a commensal and a pathogen. The most frequent sites of colonisation are on the 
skin or in the anterior nares, resulting in approximately 10-20 % of healthy 
individuals becoming life-long carriers (Peacock et al, 2001). S. aureus is capable of 
causing a variety of diseases in humans. The most common types of S. aureus 
infections are those of skin and soft tissues such as boils, impetigo and abscesses. 
Breaches of the skin or surgical incisions provide a situation where S. aureus can 
enter the bloodstream and cause bacteraemia resulting in a mortality rate of 11 to 43 
% (Lowy, 1998). Once in the bloodstream the bacteria can spread to other sites of the 
human body and infect joints (septic arthritis), bones (osteomyelitis), the lungs 
(pneumonia) and kidneys (nephritis) (Lowy, 1998). The ability of S. aureus to survive 
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and multiple inside the body is based on the expression of numerous virulence factors, 
which promote colonisation and survival of the bacteria inside the host.  
          Treatment of S. aureus infections has become extremely difficult over the past 
few decades due to the appearance of multi-drug resistance strains (Diekema et al, 
2001). Resistance to penicillin is mediated by the β-lactamase, an enzyme that 
hydrolyzes the β-lactam ring in penicillin and less than 5 % of S. aureus isolates 
remain sensitive to the drug (Lowy, 1998). Methicillin resistant S. aureus (MRSA) 
strains that are resistant to methicillin and all other β-lactam antibiotics carry the 
mecA gene, which encodes a modified penicillin binding protein, PBP 2a, with low 
affinity to β-lactam antibiotics (Hartman & Tomasz, 1984). PBP 2a cross-links 
peptidoglycan strands in the presence of β-lactam antibiotics and thus confers 
resistance to this major class of antibiotics. The mecA gene is carried on a mobile 
genetic element, SCCmec. Five SCCmec variants, which significantly vary in size, 
have been identified in S. aureus (Daum et al, 2002; Ito et al, 2001; Ito et al, 2004; 
Ma et al, 2002). In glucose-limited conditions, some of the SCCmec elements reduce 
the fitness of MRSA, which is most likely due to the transcription of other genes 
located on the SCCmec region (Lee et al, 2007). Five antibiotics, namely vancomycin, 
linezolid, quinupristin-dalfopristin, tigecycline and daptomycin, are currently in use to 
fight MRSA infections (Hancock, 2005; Schmidt-Ioanas et al, 2005). However, 
strains with either intermediate (VISA) or high (VRSA) vancomycin resistance have 
already been described. The genetic basis for the VRSA phenotype is the presence of 
the enterococcal vanA gene. The vanA gene product is a ligase allowing the 
production of a D-Ala-D-Lac depsipeptide, which replaces the normal D-Ala-D-Ala 
dipeptide in peptidoglycan (Perichon & Courvalin, 2009). This substitution reduces 
the affinity of vancomycin for the peptidoglycan precursor and results in high 
resistance to the drug (Perichon & Courvalin, 2009). VISA strains lack the vanA gene 
and these strains are thought to become resistance to vancomycin by producing excess 
amounts of peptidoglycan, which results in a thickened cell wall. It has been 
suggested that the thicker cell wall of VISA-type strains reduces the diffusion rate of 
the incoming vancomycin molecules to the tip of the division septum, where the 
concentration of the peptidoglycan precursor is high (Pereira et al, 2007). Linezolid 
and quinupristin-dalfopristin display antibacterial properties against MRSA by 
inhibiting protein synthesis; however, resistant strains to these antibiotics have already 
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been described (Hancock, 2005; Schmidt-Ioanas et al, 2005). MRSA infections are 
usually hospital associated (HA-MRSA), but also occur in otherwise healthy 
individuals (CA-MRSA). The most common isolate of CA-MRSA is USA300, which 
has been shown to be responsible for 97 % of all CA-MRSA infections (Moran et al, 
2006). CA-MRSA carry the type IV SCCmec region, which only contains the mecA 
gene and thus is small in size. Due to its small size the type IV SCCmec element 
might only have a small impact on the fitness of these strains and this might partially 
explain the success of CA-MRSA in community settings (Diep & Otto, 2008).  
 
1.3 Bacillus subtilis 
          Bacillus subtilis is a sporulating, rod-shaped, non-pathogenic bacterium. 
Taxonomally B. subtilis belongs to the bacterial family of Bacillaceae within the 
Gram-positive phylum Firmicutes. The main reservoirs of B. subtilis are the soil, 
water sources and in association with plants (Priest, 1989). The genus Bacillus 
contains more than 60 species including pathogenic and non-pathogenic strains (Claus 
& Fritze, 1989). B. subtilis was the first Gram-positive bacterium for which the 
complete genome sequence became available in 1997. This achievement revealed a 
low G+C content of the 4.2 Mb chromosome and identified more than 4100 genes 
encoded within the B. subtilis genome (Kunst et al, 1997). B. subtilis is naturally 
genetic competent. Under conditions of nutritional starvation B. subtilis expresses an 
efficient DNA uptake system that allows the bacterium to internalize exogenous 
double stranded DNA (Dubnau, 1991). B subtilis and other members of the genus (B. 
amyloliquefaciens, B. licheniformes) are able to produce and secrete high quantities of 
protein directly into the growth medium and thus are important objects in industrial 
applications (Harwood, 1992; Jensen et al, 2000). Due to the wealth of information 
available on B. subtilis and its close phylogenetic relation to other pathogens, such as 
Listeria and Staphylococci, B. subtilis became a model organism for investigating 
general biological questions. 
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1.4 The cell wall envelope of Gram-positive bacteria  
          The cell wall envelope of Gram-positive bacteria is composed of multiple layers 
of peptidoglycan that cover the entire cell surface and protect the underlying 
protoplast against mechanical and osmotic lysis (Scheffers & Pinho, 2005 and Fig. 1). 
Several other components are associated with the Gram-positive cell wall including 
proteins and teichoic acids. Two types of teichoic acids, wall teichoic acid (WTA) and 
lipoteichoic acid (LTA), are present in most Gram-positive bacteria (Weidenmaier & 
Peschel, 2008). WTA is a structure attached to the peptidoglycan layer and LTA is a 
surface polymer tethered to the bacterial membrane via a glycolipid anchor. Teichoic 
acids are further described in section 1.5. Some Gram-positive bacteria, including 
several clinical isolates of S. aureus, produce a capsule, which forms a protective 
layer around the cell (O'Riordan & Lee, 2004). The following sections discuss the 
capsule and the membrane composition of S. aureus. The structure of peptidoglycan 
and its synthesis are discussed with regard to S. aureus and B. subtilis.  
 
 
   
Figure 1: Schematic representation of the Gram-positive cell wall envelope. The cell envelope of 
Gram-positive bacteria consists of a thick peptidoglycan layer that is decorated with peptidoglycan 
linked WTA (depicted in blue) and membrane-linked LTA (depicted in yellow) polymers. In addition, 
cell surface proteins are covalently linked to the peptidoglycan or tethered to the lipid bilayer. Some 
bacteria strains express a polysaccharide capsule. 
 
 
21 
1.4.1 The S. aureus polysaccharide capsule  
          The capsule is a cell surface structure that exists outside the bacterial cell wall 
and is usually composed of polysaccharides. The capsule is common feature of S. 
aureus and produced by approximately 90 % of all S. aureus isolates (Sompolinsky et 
al, 1985). To date 11 capsule serotypes have been described for S. aureus of which 
serotype 5 and 8 are the most abundant ones (Arbeit et al, 1984; Sompolinsky et al, 
1985). Type 5 and 8 polysaccharides are structurally similar and both contain N-
acetylfucosamine and N-acetylmannosaminuronic acid (Fournier et al, 1987; Fournier 
et al, 1984; Moreau et al, 1990). However, the two polysaccharides differ in their 
sugar linkages and O-acetylation sites of the mannosaminuronic acid residues. The 
mechanism by which the capsule is anchored to the S. aureus cell wall has not been 
elucidated yet (O'Riordan & Lee, 2004). The genes involved in capsule synthesis of 
serotype 5 and 8 (cap5 and cap8) are organized in a cluster on the chromosome (Sau 
et al, 1997). The cap5 and cap8 clusters are allelic and comprise 16 genes, which are 
transcribed in one orientation (Sau et al, 1997). Expression of cap5 and cap8 is 
positively regulated by Agr and SarA, but the effect of SarA on cap5 and cap8 
expression is minor compared to that of Agr (Dassy et al, 1993; Luong et al, 2002; 
van Wamel et al, 2002). In addition, expression of cap5 is downregulated by CO2, 
indicating that CO2 serves as an environmental signal for type 5 polysaccharide 
capsule expression (Herbert et al, 1997). Bacterial capsules are thought to enhance 
virulence by preventing bacteria opsonisation and thus killing by phagocytes 
(Peterson et al, 1978; Thakker et al, 1998). It has been suggested that complement 
fragments and antibodies bind to the cell wall beneath the capsular layer, where they 
are inaccessible for recognition by phagocytic cells (Wilkinson & Holmes, 1979; 
Wilkinson et al, 1979). 
 
1.4.2 S. aureus and B. subtilis peptidoglycan  
          Peptidoglycan is a bacterial macromolecule and a major component of the cell 
wall envelope. The Gram-positive cell wall is comprised of multiple peptidoglycan 
layers that cover the entire cell surface and provide physical integrity to the cell 
(Scheffers & Pinho, 2005). The main structural features of peptidoglycan are 
repeating units of the disaccharide N-acetyl glucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) that are cross-linked via short peptide bridges. These 
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peptide bridges are attached to the D-lactyl moiety of MurNAc and cross-linked to 
peptides of adjacent glycan strands thereby generating a three-dimensional molecular 
network. In S. aureus the peptide consist of L-alanine (L-Ala), D-glutamic acid (D-
Glu), L-lysine (L-Lys) and D-alanine (D-Ala) of which the L-Lys is further modified 
with five glycine residues. The glycine pentapeptides are covalently linked to the D-
Ala residues of neighbouring wall peptides (Navarre & Schneewind, 1999). The 
presence of pentaglycine peptides in S. aureus peptidoglycan renders this organism 
susceptible to cleavage by lysostaphin, a product naturally produced by 
Staphylococcus simulans (Schindler & Schuhardt, 1964). The degree of cross-linking 
is approximately 90 % for S. aureus and 40 to 44 % for B. subtilis depending on the 
strain and growth conditions (Atrih et al, 1999; Gally & Archibald, 1993; Strominger 
et al, 1967). It has been suggested that the long and flexible pentaglycine peptide in S. 
aureus peptidoglycan connects peptide moieties from different peptidoglycan layers, 
thus allowing a high degree of cross-linking (Gally & Archibald, 1993; Lapidot & 
Irving, 1979). Moreover, the pentaglycine peptide serves as an attachment site for the 
covalent anchoring of surface proteins to the cell wall envelope of S. aureus (section 
1.4.2.1).  
          B. subtilis peptidoglycan contains meso-diaminopimelic acid (m-A2pm) in place 
of L-Lys and the glycan strands are directly interlinked via a covalent bond between 
the m-A2pm moiety of one chain and the D-Ala residue of another chain (Scheffers & 
Pinho, 2005). In B. subtilis, peptidoglycan strands have an average length of 96 
disaccharide units (Hayhurst et al, 2008; Ward, 1973). In contrast, S. aureus 
synthesizes much shorter peptidoglycan strands with an average of 6 disaccharides 
(Boneca et al, 2000). In addition, approximately 60 % of the MurNAc residues in S. 
aureus peptidoglycan are O-acetylated at position C6-hydroxyl (Bera et al, 2005; 
Ghuysen & Strominger, 1963). This modification of peptidoglycan is mediated by the 
O-acetyltransferase OatA and renders S. aureus resistant to lysozyme (Bera et al, 
2005).  
          Peptidoglycan synthesis can be divided into three stages that occur in distinct 
sub-cellular compartments. The first stage takes place in the cytoplasm and leads to 
the formation of UDP-MurNAc. The synthesis of UDP-MurNAc is a two-step 
process. First, the enolpyruvate moiety from phosphoenolpyruvate is transferred to 
position 3 of GlcNAc to yield UDP-GlcNAc enolpyruvate. In a second reaction the 
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enolpyruvate group is reduced to lactoyl to yield UDP-MurNAc. Five amino-acids (L-
Ala, D-Glu, L-Lys (S. aureus) or m-A2pm (B. subtilis) and the D-Ala-D-Ala 
dipeptide) are consecutively attached to UDP-MurNAc to generate the peptidoglycan 
precursor UDP-MurNAc-pentapeptide (Park’s nucleotide). The second stage of 
peptidoglycan synthesis occurs at the bacterial membrane and requires the activity of 
two enzymes, MraY and MurG. MraY is a membrane bound enzyme that catalyzes 
the attachment of the MurNAc-pentapeptide to the undecaprenylphosphate carrier 
molecule resulting in the production of lipid I. MurG is a glycosyltransferase which 
then transfers GlcNAc to the C4-hydroxyl MurNAc in lipid I to generate the 
disaccharide lipid II (Navarre & Schneewind, 1999; Scheffers & Pinho, 2005; van 
Heijenoort, 2001). In S. aureus lipid II is further modified by the peptidyl transferases 
FemABX, which attach five glycine residues to the ε-amino group of L-Lys (Ehlert et 
al, 1997; Schneider et al, 2004). Finally, lipid II is translocated across the bacterial 
membrane by FtsW, an essential division protein with 10 predicted transmembrane 
helices (Mohammadi et al, 2011). The third stage of peptidoglycan synthesis occurs 
on the cell surface and involves the incorporation of the peptidoglycan precursor 
molecule, lipid II, into the nascent peptidoglycan. This is achieved through the 
activity of penicillin binding proteins (PBPs). PBPs are bifunctional enzymes that 
catalyze the polymerization of glycan strands (transglycosylation) and promote the 
formation of cross-links between cell wall peptides (transpeptidation). The 
transpeptidation reaction involves the proteolytic cleavage of the D-Ala-D-Ala bond 
in the peptidoglycan precursor and the concomitant formation of an enzyme-substrate 
intermediate. The cleavage event and the release of the terminal D-Ala provide the 
energy that is required for the subsequent transpeptidation reaction.  In the next step a 
peptide bridge is formed between the penultimate D-Ala of a donor peptide and an 
amino group of an acceptor cell wall peptide (Scheffers & Pinho, 2005). 
Peptidoglycan is a unique and essential structure in bacteria and thus enzymes 
involved in its synthesis represent effective targets for antimicrobial agents (e.g. β-
lactam antibiotics).  
          In S. aureus peptidoglycan synthesis occurs exclusively at the division site 
(Pinho & Errington, 2003). In contrast, B. subtilis inserts newly synthesized 
peptidoglycan not only at the future division site, but also in helical patterns along the 
lateral wall thus allowing cell elongation before division (Daniel & Errington, 2003). 
 
 
24 
It has been suggested that the actin-like MreB proteins direct peptidoglycan synthesis 
of the sidewall and therefore play important roles in determining the cell wall 
architecture and hence the cell shape of B. subtilis (Carballido-Lopez & Errington, 
2003; Jones et al, 2001).   
 
1.4.2.1 Anchoring of S. aureus surface proteins to the cell wall 
          S. aureus expresses about 20 surface proteins that are covalently anchored to 
the cell wall envelope by a mechanism called ‘sorting’. Cell wall sorting requires the 
activity of sortase enzymes that attach the proteins to the peptidoglycan (Mazmanian 
et al, 2001). Proteins for sortase mediated cell wall anchoring contain an N-terminal 
signal peptide, which allows the sec-dependent secretion of the protein, and a C-
terminal cell wall sorting signal (Fischetti et al, 1990). The cell wall sorting signal 
consists of an LPXTG motif followed by a hydrophobic region and a positively 
charged tail (Fischetti et al, 1990; Mazmanian et al, 2001). It has been suggested that 
the charged tail serves as a retention signal to retain the polypeptide chain in the 
bacterial membrane during the cell wall sorting process (Schneewind et al, 1993). 
SrtA of S. aureus cleaves the LPXTG motif between the threonine and the glycine 
residue and subsequently forms an amide bond between the threonine and 
pentaglycine cross-bridge in the cell wall (Mazmanian et al, 1999). The protein 
portion C-terminal of the LPXTG motif is released and degraded. Experimental 
evidence suggests that SrtA uses the peptidoglycan precursor lipid II as an acceptor 
molecule; however, it is also possible that the enzyme recognizes additional, non-
cross linked sites in the mature peptidoglycan structure (Ruzin et al, 2002; Ton-That 
et al, 1998). S. aureus expresses two sortase enzymes, SrtA and SrtB (Pallen et al, 
2001). Both proteins are membrane anchored via a single N-terminal hydrophobic 
domain.  SrtA anchors proteins bearing an LPXTG motif and SrtB cleaves the iron-
regulated surface protein IsdC within an NPQTN sequence motif and attaches the 
protein to the cell wall envelope (Mazmanian et al, 1999; Mazmanian et al, 2002). An 
S. aureus srtA mutant strain displayed reduced virulence in animal infection models of 
septic arthritis and endocarditis (Jonsson et al, 2003; Weiss et al, 2004). In contrast, 
an S. aureus strain lacking srtB only showed a slight defect in establishing murine 
arthritis (Jonsson et al, 2003). 
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Figure 2: Anchoring of surface proteins in S. aureus. (i) Export. Precursor proteins bearing an N-
terminal signal peptide (SP) are initiated into the secretory (sec) translocation machinery and the SP is 
degraded. (ii) Retention. The C-terminal sorting signal retains polypeptides within the sec pathway. (iii) 
Cleavage. The sortase A enzyme cleaves between the threonine and glycine of an LPXTG motif with 
the concomitant formation of an enzyme-substrate intermediate. (iv) Linkage. Formation of an amide 
bond between the carboxyl-group of threonine and the amino-group of the pentaglycine moiety in lipid 
II. (v) Cell wall incorporation. The lipid linked surface protein is integrated into the peptidoglycan by 
transglycosylation. Finally the penultimate D-Ala of the pentapeptide subunit with attached surface 
protein is cross-linked to another cell wall peptide. CW=cell wall, MB=membrane, CP=cytoplasm. 
Adapted from Mazmanian et al, 2001. 
 
1.4.2.2 Immunoglobulin binding proteins of S. aureus 
          S. aureus expresses two immunoglobulin binding surface proteins, protein A 
(Spa) and Sbi. Spa is a 42 kDa cell wall anchored protein that is present in over 95 % 
of S. aureus strains (Forsgren & Nordstrom, 1974). The protein is comprised of 4 or 5 
immunoglobulin-binding repeats followed by a polymorphic variable sequence and a 
C-terminal cell wall anchoring domain (Moks et al, 1986; Uhlen et al, 1984). Spa is 
synthesized as a preprotein and its signal peptide contains an YSIRK/GS sequence 
motif, which has been shown to address proteins to the future division site (DeDent et 
al, 2008). Spa binds with high affinity to the Fc region of IgG and to the Fab portion 
of VH3 class immunoglobulins (Inganas, 1981; Inganas & Johansson, 1981). Binding 
of the IgG Fc region to Spa results in bacteria coating with IgG molecules in the 
incorrect orientation not recognized by the neutrophil Fc receptors. As a consequence 
the bacteria escape phagocytosis by neutrophils (Gemmell et al, 1991; Peterson et al, 
1977). Furthermore, Spa binds to the von Willebrand factor (vWF), a multimeric 
glycoprotein with the potential to immobilise platelets at the site of endothelial 
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damage resulting in the formation of a blood clot (Hartleib et al, 2000; O'Seaghdha et 
al, 2006). The interaction between Spa and vWF is thought to contribute to the ability 
of S. aureus to adhere to damaged blood vessels (O'Seaghdha et al, 2006). In addition, 
Spa binds and activates the tumour-necrosis factor-α receptor 1 on epithelial cells, 
which has been shown to induce inflammation during S. aureus pneumonia (Gomez et 
al, 2004; Gomez et al, 2006). 
          A second S. aureus immunoglobulin binding protein was identified by phage 
display and denoted Sbi (Jacobsson & Frykberg, 1995; Zhang et al, 1998). The 50 
kDa Sbi protein is present in many S. aureus strains and consists of four globular 
domains (I-IV) (Burman et al, 2008; Zhang et al, 1998). Domain I and II are 
functional immunoglobulin-binding motifs that interact with the IgG Fc fragment, but 
unlike Spa, not with the IgG Fab sequence (Atkins et al, 2008). Sbi domain IV has 
been shown to bind to β2-glycoprotein I, a protein with implications in blood 
coagulation (Zhang et al, 1999). Moreover, domains III and IV together and domain 
IV on its own bind the complement components C3 and factor H (Burman et al, 2008; 
Haupt et al, 2008). It has been suggested that Sbi is associated with the bacterial 
surface, most likely via electrostatic interactions, as the Sbi protein does not contain a 
C-terminal cell wall sorting signal (Zhang et al, 1998). However, in a more recent 
study it was suggested that Sbi is in fact secreted into the growth medium (Burman et 
al, 2008).  
 
1.4.3 The S. aureus cell membrane 
          The cell membrane of S. aureus is a phospholipid bilayer with integrated 
membrane proteins. The major membrane lipids in S. aureus are: diglucosyl 
diacylglycerol (Glc2-DAG), phosphatidylglycerol (PG), diacylglycerol (DAG) and 
lysyl-phosphatidylglycerol (Lys-PG), which represent 8 %, 50 %, 24 % and 10 % of 
the total lipid content (Koch et al, 1984). LTA is only present in the outer leaflet of 
the bacterial membrane where its concentration is approximately 12 % (Fischer, 1994; 
Koch et al, 1984). Lys-PG is synthesized by MprF, a membrane enzyme, which 
transfers the lysyl group from lysyl-tRNA to PG resulting in the production of Lys-
PG (Nesbitt & Lennarz, 1968; Staubitz et al, 2004). The amino group of Lys-PG is 
believed to impart a positive charge onto the cell membrane resulting in the repulsion 
of antimicrobial peptides (Peschel & Collins, 2001). 
 
 
27 
          PG is synthesized from phosphatidic acid and glycerolphosphate and serves as a 
central molecule in S. aureus lipid metabolism and as a substrate for LTA synthesis. 
Based on pulse-chase experiments it was estimated that the pool of PG turns over 3 
times in one bacterial doubling (Koch et al, 1984). The glycerolphosphate moiety of 
PG is utilized for LTA synthesis and the resulting DAG is either recycled to PG via 
phosphatidic acid or used for the synthesis of the glycolipid Glc2-DAG (Koch et al, 
1984). An essential enzyme in the recycling pathway is the diacylglycerol kinase 
DgkB, which phosphorylates DAG to produce phosphatidic acid. The gene encoding 
for DgkB has been identified in B. subtilis, but to date not in S. aureus (Jerga et al, 
2007).  
          During post-logarithmic growth and under high salt conditions, S. aureus 
accumulates cardiolipin (CL) with the concomitant loss of PG (Kanemasa et al, 1972; 
Short & White, 1971). CL is synthesized from the conversion of two PG molecules to 
one molecule of CL and one molecule of glycerol (Short & White, 1972). A high CL 
content may affect membrane fluidity/permeability and help S. aureus to cope with 
stress conditions. Furthermore, CL does not serve as a donor for LTA synthesis (Koch 
et al, 1984). LTA synthesis is a high energy consuming process and therefore the 
conversion of PG to CL might help S. aureus to reduce energy costs under non-
dividing or stress conditions.   
 
1.5 WTA and LTA in Gram-positive bacteria 
          Teichoic acids are polyanionic surface structures that are present in a wide 
range of Gram-positive bacteria. Two types of teichoic acids can be distinguished: 
wall teichoic acid (WTA), which is covalently linked to the peptidoglycan and 
lipoteichoic acid (LTA), which is tethered to the membrane by a lipid anchor. WTA 
polymers are commonly made up of glycerol- or ribitolphosphate subunits, but 
tetroses, hexoses or complex sugar combinations have also been reported. LTA is 
usually less diverse and often consists of a glycerolphosphate chain retained by a 
glycolipid anchor in the bacterial membrane (Fischer, 1988; Fischer et al, 1990; 
Weidenmaier & Peschel, 2008). Both types of TA can be decorated with additional 
sugars and amino acids. Most Gram-positive bacteria contain at least one WTA and 
one LTA type polymer; however, the synthesis of WTA and LTA proceeds through 
separate pathways even when the actual subunits of the two polymers are the same 
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(Fischer, 1988). S. aureus primarily makes polyribitolphosphate WTA (Baddiley et al, 
1961), while B. subtilis synthesizes two different WTAs, a major and a minor 
polymer. The major WTA in B. subtilis consists of polyglycerolphosphate or 
polyribitolphosphate subunits depending on the strain (Burger & Glaser, 1964; 
Karamata et al, 1987). The minor polymer comprised of glucose-N-acetyl-
galactosamine-phosphate repeating units (Duckworth et al, 1972; Shibaev et al, 
1973). Under phosphate limiting conditions B. subtilis produces teichuronic acid, 
which is devoid of phosphate groups (Ellwood & Tempest, 1972). Both S. aureus and 
B. subtilis synthesize LTA of the polyglycerolphosphate type (section 1.5.1).  
          While the exact function of the TAs is not clear, they are believed to play 
important roles in bacterial physiology. TAs bind Mg2+ ions and thus provide a 
storage mechanism for ions close to the membrane which might be required for 
enzyme activity (Heptinstall et al, 1970; Lambert et al, 1977). Furthermore, TAs are 
often decorated with positively charged D-alanine residues, which protect bacteria 
against cationic antimicrobial peptides (Peschel & Collins, 2001). TAs also bind to 
autolysin enzymes and this interaction might be important for proper targeting of the 
autolysins to the cell wall envelope (Fischer et al, 1981; Suginaka et al, 1979). Other 
proposed functions for TAs include biofilm formation, adhesion, cell division and 
providing a receptor for bacteriophages (Chatterjee et al, 1969; Gross et al, 2001; 
Fedtke et al, 2007; Gründling & Schneewind, 2007a). Furthermore, LTA has been 
shown to interact with the InlB protein of Listeria monocytogenes and with the 
aggregation substance protein of Enterococcus faecalis (Jonquieres et al, 1999; 
Waters et al, 2004). This interaction might provide a mechanism for the non-covalent 
attachment of proteins to the cell wall envelope of Gram-positive bacteria. A number 
of studies have demonstrated that LTA plays a crucial role in activating the immune 
system via Toll-like receptor 2 (Hermann et al, 2002; Morath et al, 2001; Morath et 
al, 2002). However, these findings have been challenged by the discovery that most of 
the commonly used LTA preparations were contaminated with lipoproteins 
(Hashimoto et al, 2006). Thus the proinflammatory potency of LTA remains to be 
clarified.  
          WTA was initially thought to be essential for bacterial growth (Bhavsar et al, 
2004). However, later it was discovered that the mutation was lethal due to the 
accumulation of a toxic intermediate and that WTA deficient mutants can be obtained 
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by deleting the tagO gene encoding for the first enzyme in the WTA pathway (D'Elia 
et al, 2006). LTA deficient mutants have only recently become available through the 
discovery of the key enzyme in LTA synthesis, LtaS (Gründling & Schneewind, 
2007a). The analysis of WTA or LTA deficient strains demonstrated that these 
polymers have distinct roles in the cell. For example the absence of WTA in B. 
subtilis leads to cell rounding (D'Elia et al, 2006), while the absence of LTA leads to 
the formation of long filaments that spiral along their long axes (Schirner et al, 2009). 
S. aureus cells lacking WTA show slight morphological alterations and are less 
virulent (Weidenmaier et al, 2004; Weidenmaier et al, 2005), while the absence of 
LTA causes severe morphological defects and bacteria are only viable under certain 
growth conditions (Gründling & Schneewind, 2007a; Oku et al, 2009). However, a 
combined absence of WTA and LTA is lethal for both S. aureus and B. subtilis (Oku 
et al, 2009; Schirner et al, 2009), making enzymes involved in their synthesis 
promising new drug targets (Falconer & Brown, 2009). 
 
1.5.1 Structure and synthesis of polyglycerolphosphate LTA in S. 
aureus and B. subtilis 
          S. aureus and B. subtilis synthesize polyglycerolphosphate LTA consisting of 
an unbranched 1,3-linked polyglycerolphosphate chain (approximately 23 repeating 
units) tethered to the bacterial membrane by a glucosyl (β1-6) glucosyl (β1-3) 
diacylglycerol (Glc2-DAG) glycolipid (Duckworth et al, 1975; Fischer, 1988; Fischer, 
1994 and Fig. 3). The hydroxyl groups at the C2 position of the glycerolphosphate 
subunits are esterified to a varying degree with D-alanine residues and glycosyl 
modifications are also present in many Bacillus sp. (Fischer, 1988; Fischer, 1994; 
Fischer & Rosel, 1980; Iwasaki et al, 1986; Iwasaki et al, 1989).  
          Polyglycerolphosphate LTA is the most widespread LTA type among Gram-
positive bacteria and is present in several important human pathogens such as Bacillus 
anthracis, E. faecalis, Group A and B Streptococci and L. monocytogenes. 
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Figure 3: Chemical structure of polyglycerolphosphate LTA. S. aureus and B. subtilis both 
synthesize polyglycerolphosphate type LTA, which is tethered to the bacterial membrane by a 
diglucosyl-diacylglycerol (Glc2-DAG) glycolipid (red box). The hydroxyl groups at the C2 position of 
the glycerolphosphate subunits are modified with D-alanine residues in both organisms. B. subtilis 
additionally incorporates N-acetylglucosamine into the LTA polymer. R1, R2 = fatty acids. Adapted 
from Reichmann & Gründling, 2011. 
 
          In S. aureus and B. subtilis LTA synthesis starts in the cytoplasm with the 
production of the glycolipid anchor Glc2-DAG (Fig. 4). Three enzymes, PgcA, GtaB 
and YpfP (UgtB in B. subtilis) are required for Glc2-DAG synthesis. PgcA is α-
phosphoglucomutase, which catalysis the conversion of glucose-6-phosphate to 
glucose-1-phosphate (Gründling & Schneewind, 2007b; Lazarevic et al, 2005; Lu & 
Kleckner, 1994). Glucose-1-phosphate is then activated by the UTP:α-glucose-1-
phosphate uridyltransferase GtaB leading to the formation of UDP-Glc (Gründling & 
Schneewind, 2007b; Pooley et al, 1987). The processive glycosyltransferase YpfP 
transfers two activated glucose moieties from UDP-Glc to DAG resulting in the 
production of the glycolipid Glc2-DAG (Jorasch et al, 1998; Kiriukhin et al, 2001). In 
the absence of pgcA, gtaB or ypfP, glycolipid synthesis is abrogated, but LTA is still 
produced. It is assumed that in these mutants the polyglycerolphosphate LTA 
backbone is directly linked to DAG  (Kiriukhin et al, 2001).  
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Figure 4: Schematic representation of the LTA synthesis pathway. The cytoplasmic proteins PgcA, 
GtaB and YpfP (UgtP in B. subtilis) are involved in the synthesis of the glycolipid anchor Glc2-DAG. 
LtaA is a membrane protein and predicted permease, which is thought to translocate the lipid anchor 
from the inner to the outer leaflet of the bacterial membrane. On the outside of the membrane, the 
lipoteichoic acid synthase LtaS attaches glycerolphosphate subunits to the glycolipid resulting in the 
formation of a linear polyglycerolphosphate chain. D-alanine esters are incorporated into the mature 
LTA polymer and proteins involved in this process are DltA-DltD. 
 
          Inactivation of ypfP in S. aureus SA113, but not RN4220, resulted in an 87 % 
reduction of cell-associated and released LTA, indicating that the strain background 
significantly contributes to the LTA phenotype (Fedtke et al, 2007). In addition, the 
autolytic activity of the SA113 ypfP mutant was strongly reduced and its ability to 
form biofilm on plastic devises completely abrogated (Fedtke et al, 2007). Using 
green fluorescent protein fusions it was demonstrated that YpfP localizes to the cell 
division site in B. subtilis (Weart et al, 2007). The same study provided in vitro 
evidence that YpfP inhibits FtsZ polymerization in a concentration dependent manner 
(Weart et al, 2007).  
          Following the synthesis of the glycolipid anchor in the cytoplasm, Glc2-DAG is 
transported to the outer leaflet of the bacterial membrane, where it is used for LTA 
synthesis. In S. aureus the LtaA protein is assumed to be involved in this process. 
LtaA is a member of a major facilitator super-family clan whose structural gene is 
located in an operon with ypfP. Inactivation of ltaA resulted in a large fraction of 
polyglycerolphosphate chains linked to DAG despite the presence of wild type Glc2-
DAG levels (Gründling & Schneewind, 2007b). The LtaA protein appears to be 
unique to staphylococci and thus it is not known how the glycolipid traverses the 
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membrane in other Gram-positive bacteria, such as B. subtilis. Once the glycolipid is 
exposed to the outside, the S. aureus LtaS enzyme polymerizes the glycerolphosphate 
LTA backbone chain (Gründling & Schneewind, 2007a). Experimental evidence 
suggests that the glycerolphosphate subunits are derived from the membrane lipid 
phosphatidylglycerol and that the subunits are added to the distal end of the growing 
LTA chain (Koch et al, 1984). Four LtaS orthologues are present in B. subtilis, YflE 
(also named LtaSBS), YfnI, YqgS and YvgJ and these enzymes are further discussed in 
section 1.5.1.2. Finally, D-alanine ester substitutions are incorporated into the mature 
LTA molecule and the proteins involved in this process are encoded by the dltABCD 
operon (Neuhaus & Baddiley, 2003). In contrast, the process and function of the LTA 
modification with glycosyl moieties in B. subtilis is largely unknown.  
 
1.5.1.1 LtaS, the lipoteichoic acid synthase of S. aureus 
          The ltaS gene coding for the lipoteichoic acid synthase in S. aureus was 
discovered in a genetic screen (Gründling & Schneewind, 2007a). LtaS presumably 
cleaves the membrane lipid PG and utilizes the glycerolphosphate moiety to 
polymerize the LTA backbone chain. Experimental evidence for these proposed 
reactions catalysed by LtaS came from the observation that depletion of ltaS in S. 
aureus resulted in the complete absence of polyglycerolphosphate LTA, while 
expression of LtaS in a Gram-negative host, which naturally lacks LTA, lead to the 
production of glycerolphosphate polymers (Gründling & Schneewind, 2007a). A S. 
aureus mutant strain deleted for the single ltaS gene is temperature sensitive and 
grows at 30°C, but not at 37°C, in media containing at least 1 % (w/v) NaCl (Oku et 
al, 2009). Temperatures at or above 37°C are only tolerated by the S. aureus ltaS 
mutant strain if the media is supplemented with high salt (7.5 % (w/v)) or high 
sucrose (40 % (w/v)) concentrations, which presumably provide osmoprotection (Oku 
et al, 2009). However, even under the permissive growth conditions the S. aureus ltaS 
mutant strain displayed aberrant placement of division septa, decreased autolysis and 
reduced levels of peptidoglycan hydrolases, highlighting the importance of LTA for 
normal cell morphology and physiology (Oku et al, 2009).  
          LtaS and its homologues in other Gram-positive bacteria are predicted 
membrane proteins composed of five N-terminal transmembrane helices followed by 
a linker region and a C-terminal extracellular enzymatic domain (eLtaS) (Fig. 5). 
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Proteomic studies on secreted proteins in S. aureus identified the eLtaS domain in the 
culture supernatant indicating that the LtaS protein is processed during bacterial 
growth (Gatlin et al, 2006; Ziebandt et al, 2001). Moreover, N-terminal protein 
sequencing suggested that the protein is cleaved C-terminal of the fifth 
transmembrane helix following the linker region after residues 215Ala-Leu-Ala217 
(Ziebandt et al, 2001). Interestingly, treatment of Staphylococcus epidermidis with the 
type I signal peptidase specific inhibitor arylomycin strongly reduced LtaS cleavage, 
suggesting an involvement of signal peptidase in LtaS processing (Powers et al, 
2011).  
 
 
Figure 5: Predicted topology of LtaS. LtaS presumably contains five N-terminal transmembrane 
helices, which are linked to the extracellular enzymatic domain (eLtaS) via a linker region. The protein 
is cleaved C-terminal of the five transmembrane domain after residues 215Ala-Leu-Ala217 and preceding 
the eLtaS domain. aa = amino acid.  
 
          The crystal structure of the S. aureus eLtaS domain alone and in complex with 
soluble glycerolphosphate has been solved and revealed a threonine as the active site 
residue (Lu et al, 2009). Substitution of this threonine residue with alanine rendered 
the LtaS protein inactive and unable to synthesize LTA (Lu et al, 2009). Moreover, 
the obtained crystal structure identified a Mn2+ ion in the active site center (Lu et al, 
2009). In agreement with these findings, a recently established in vitro assay for LtaS-
type enzymes demonstrated that the LtaS protein requires Mn2+ for activity (Karatsa-
Dodgson et al, 2010). The same study provided evidence that the eLtaS domain alone 
is sufficient to cleave the head group of fluorescently labeled PG producing DAG and 
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presumably glycerolphosphate, thus providing further evidence that PG is the 
physiological substrate for LtaS and LTA synthesis (Karatsa-Dodgson et al, 2010). 
 
1.5.1.2 LtaS homologues in B. subtilis  
          B. subtilis contains four LtaS orthologues, namely YflE (also named LtaSBS), 
YfnI, YqgS and YvgJ with more than 40 % identity to S. aureus LtaS. All four 
proteins have the same predicted membrane topology and domain structure as S. 
aureus LtaS. Furthermore, in proteomic studies processed forms of YflE and YfnI 
were detected in the culture supernatant (Hirose et al, 2000; Tjalsma et al, 2004) 
showing that at least some of the B. subtilis proteins are cleaved and the enzymatic 
domains released into the supernatant similar to what was observed for S. aureus LtaS 
(Gatlin et al, 2006; Lu et al, 2009; Ziebandt et al, 2001). In both cases the cleavage 
site was identified C-terminal of the fifth transmembrane domain following an Ala-X-
Ala sequence motif (Hirose et al, 2000). Moreover, a B. subtilis mutant strain deleted 
for the two signal peptidases sipT and sipV displayed reduced amounts of cleaved 
YfnI protein in the culture supernatant, indicating that YfnI is a substrate for SipT and 
SipV (Antelmann et al, 2001).  
          By expressing each of the four B. subtilis orthologues in an S. aureus ltaS 
depletion strain it was revealed that YflE and YfnI encode for LTA synthases, capable 
of producing polyglycerolphosphate polymers (Gründling & Schneewind, 2007a). 
However, YfnI-produced polymers could not restore the growth defect of a S. aureus 
ltaS depleted strain and displayed an altered mobility on SDS-PAGE gels, indicative 
of structural alterations (Gründling & Schneewind, 2007a). No enzyme activity was 
observed for YqgS or YvgJ. The crystal structure of the YflE enzymatic domain has 
been solved and revealed the presence of a Mg2+ ion in the active center (Schirner et 
al, 2009). These findings are somehow in contrast to the previously reported Mn2+ ion 
observed in the S. aureus LtaS active site center (Lu et al, 2009). A study on the four 
LtaS-type enzymes in B. subtilis revealed that mutants lacking YflE grew slower in 
PAB medium compared to the wild type strain and showed a defect in divalent cation 
homeostasis, an increase in cell chain length, placement of aberrant septa and 
enhanced cell bending and lysis (Schirner et al, 2009). By expressing YflE and YqgS 
as GFP-fusion proteins it was observed that both proteins localize preferentially to the 
division site or sporulation septum. Interestingly, a B. subtilis mutant strain defective 
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in yflE and yqgS expression was unable to form spores (Schirner et al, 2009). In 
contrast to S. aureus, a B. subtilis mutant with disruptions in all four genes could be 
readily constructed and was viable. However, this mutant showed severe 
morphological defects and bacteria formed long filaments that spiralled along their 
long axes (Schirner et al, 2009).  
 
1.5.2 LTA synthesis in other Gram-positive bacteria 
          Besides S. aureus and B. subtilis, LTA synthesis has been well studied in 
Listeria monocytogenes. L. monocytogenes produces glycerolphosphate type LTA, but 
the polymer is anchored to the membrane via galactosyl (α1-2) glucosyl (α1-3) DAG 
(GalGlc-DAG) instead of Glc2-DAG (Uchikawa et al, 1986). Two distinct 
glycosyltransferases, LafA (LTA anchor formation protein A) and LafB (LTA anchor 
formation protein B), are required for the synthesis of GalGlc-DAG. LafA is a 
glucosyltransferase that produces monoglucosyldiacylglycerol (Glc-DAG) and LafB 
is a galactocyltransferase necessary for adding a galactose moiety to Glc-DAG 
resulting in the formation of GalGlc-DAG (Webb et al, 2009). The genes encoding 
for lafA and lafB are organized in an operon together with a third gene lafC. 
Inactivation of lafC resulted in the synthesis of an LTA polymer with retarded 
mobility on SDS-PAGE similar to what was observed for the S. aureus ltaA mutant 
(Gründling & Schneewind, 2007b; Webb et al, 2009). However, LafC does not show 
any homology to the LtaA protein and thus the observed LTA alterations in the L. 
monocytogenes lafC mutant strain do not necessary result from an inefficient transfer 
of the glycolipid to the outer leaflet of the bacterial membrane. Two LtaS-type 
enzymes, LtaPLM and LtaSLM, are involved in polyglycerolphosphate LTA synthesis in 
L. monocytogenes. LtaPLM transfers the initial glycerolphosphate subunit onto the 
GalGlc-DAG lipid anchor and LtaSLM polymerizes the LTA backbone chain (Webb et 
al, 2009). In the absence of LtaPLM, LtaSLM still synthesizes polyglycerolphosphate, 
while deletion of ltaSLM in L. monocytogenes abrogates polyglycerolphosphate 
synthesis and leads to severe growth and cell division defects (Webb et al, 2009). 
          Recently, the presence of polyglycerolphosphate type LTA was reported in 
various species belonging to the phylum Actinomycetes (Rahman et al, 2009a; 
Rahman et al, 2009c). However, Actinomycetes appear to lack LtaS homologues and 
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thus it was suggested that LTA synthesis occurs through an alternative pathway in 
these bacteria (Rahman et al, 2009c). 
 
1.6 Extracellular proteases 
          S. aureus secretes a range of proteases that have important implications in 
virulence, tissue destruction, modification of the host immune system and alteration of 
surface proteins. These extracellular proteases can be divided into three classes based 
on their catalytic reaction mechanisms: metalloproteases, serine proteases and 
cysteine proteases. The genes coding for the proteases are organized in three distinct 
operons, which are: the staphylococcal serine protease (ssp) operon, the serine 
protease like  (spl) operon, the staphylococcal cysteine protease (scp) operon. In 
addition, S. aureus secrets the metalloprotease aureolysin and two related serine 
proteases HtrA1 and HtrA2 and the corresponding genes for the latter proteases are 
transcribed on their own (Fig. 6).  
 
 
Figure 6: Schematic representation of the chromosomal organization of genes encoding secreted 
proteases in S. aureus. Depicted are the aur, htrA1, htrA2 genes and the ssp (staphylococcal serine 
protease), spl (serine protease like) and scp (staphylococcal cysteine protease) operons. Arrows indicate 
transcriptional start sites.  
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1.6.1 Metalloproteases 
          S. aureus aureolysin is a calcium dependent metalloprotease harbouring a zinc 
ion in the catalytic centre (Banbula et al, 1998). Aureolysin is secreted as a 
proenzyme and activated upon proteolytic cleavage (Chan & Foster, 1998). 
Autocatalysis was initially excluded as the activation mechanism, based on the 
observation that a point mutation in the catalytic centre of aureolysin rendered the 
protease inactive but did not effect protein processing (Shaw et al, 2004). However, in 
a more recent work the same point mutation did not promote the production of mature 
aureolysin and only the proenzyme could be detected by western blot (Nickerson et 
al, 2008). The same study demonstrated that the aureolysin propeptide is cleaved by 
the mature aureolysin protease and suggested a role of the propeptide in proper 
folding and stabilizing of the protease (Nickerson et al, 2008). The aur gene occurs in 
two allelic forms and is highly conserved among S. aureus strains, suggesting that the 
protease may have important housekeeping functions in the processing of surface 
proteins (Sabat et al, 2000). Aureolysin activates the glutamyl endopeptidase SspA 
(V8) via proteolytic processing and mature SspA in turn cleaves the cysteine protease 
SspB from its precursor form (Drapeau, 1978; Rice et al, 2001). Aureolysin also 
cleaves S. aureus clumping factor B and the human antimicrobial peptide LL-37 
(McAleese et al, 2001; Sieprawska-Lupa et al, 2004). Further studies have 
demonstrated that aureolysin converts human plasminogen into angiostatin and mini-
plasminogen, degrades the plasminogen activator inhibitor-1 and hydrolyses α-
antiplasmin (Beaufort et al, 2008). Thus aureolysin may play a role in promoting 
bacterial spread and invasion by activating the fibrinolytic system (Beaufort et al, 
2008). In addition, aureolysin and SspA have been shown to inhibit protein-dependent 
biofilm formation in S. aureus (Marti et al, 2009). Despite the fact that aureolysin 
modulates virulence factors, an aur defective S. aureus mutant was not attenuated in 
an animal model of infection (Calander et al, 2004). However, of the three major S. 
aureus extracellular proteases (aureolysin, SspA and SspB), only aureolysin had an 
impact in survival of S. aureus inside macrophages (Kubica et al, 2008). 
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1.6.2 Serine proteases 
          S. aureus SspA is a serine protease that is synthesized as a proenzyme and  is 
activated by proteolytic cleavage. The protease aureolysin has been shown to promote 
SspA processing and subsequent activation of the protease (Drapeau, 1978; Nickerson 
et al, 2007). However, in the absence of aureolysin, SspA can also undergo activation 
by autocatalysis at low levels (Nickerson et al, 2007; Shaw et al, 2004). The sspA 
gene is organized in an operon with two other genes, which encode for the cysteine 
protease SspB and the SspB specific inhibitor SspC. Expression of SspA occurs 
maximum at post-exponentional phase being initiated by Agr (accessory gene 
regulator) and repressed by SarA (staphylococcal accessory regulator) (Shaw et al, 
2004). SspA has a narrow substrate specificity cleaving predominantly after glutamic 
acid and to a lesser extent after aspartic acid (Drapeau et al, 1972; Houmard & 
Drapeau, 1972). SspA cleaves and thus releases the cell wall bound fibronectin 
binding proteins and protein A, which may facilitate detachment and support bacterial 
spreading during infection (Karlsson et al, 2001; McGavin et al, 1997). Furthermore, 
the SspA protease has been shown to cleave the heavy chains of human 
immunoglobulins (Prokesova et al, 1992). A transposon insertion in sspA led to 
attenuation in multiple animal models, but this was most likely due to downstream 
effects as a non-polar mutation in sspA did not result in attenuated virulence in a 
tissue abscess model of infection (Coulter et al, 1998; Rice et al, 2001).  
          S. aureus secretes two related HtrA (high temperature resistance) serine 
proteases, HtrA1 and HtrA2. HtrA proteases are highly conserved in bacteria, yeasts, 
plants, and humans and are associated with stress resistance and survival. The 
protease was first described in E. coli and shown to degrade damaged proteins during 
thermal stress, but also contain chaperone activity at low temperatures (Krojer et al, 
2002; Strauch et al, 1989). Interestingly, only S. aureus HtrA1 was able to fully rescue 
the thermo-resistance phenotype to a Lactococcus lactis htrA-defective mutant 
(Rigoulay et al, 2004). It has been suggested that HtrA proteins have different roles in 
S. aureus depending on the background strain (Rigoulay et al, 2005). This was based 
on the observation that both HtrA proteins were essential for thermal stress survival in 
the COL strain, but not in RN6390 (Rigoulay et al, 2005). A htrA1/htrA2 RN6390 
double mutant displayed defects in the expression of several factors comprising the 
agr regulon and showed diminished virulence in a rat model of endocarditis. In 
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contrast, only HtrA1 played a minor role in the expression of surface proteins in the 
background strain COL, but an htrA1/htrA2 COL mutant strain was not attenuated in 
virulence (Rigoulay et al, 2005). 
 
1.6.3 Cysteine proteases and staphostatins 
          S. aureus secretes two cysteine proteases, staphopain A (ScpA) and staphopain 
B (SspB). Both proteases are members of the papain family and are organized in their 
respective operons scpAB and sspABC (Dubin, 2003). In both operons the staphopain 
genes are followed by genes coding for the staphostatins ScpB and SspC, which act as 
specific inhibitors for their respective staphopains (Massimi et al, 2002; Rzychon et 
al, 2003). Furthermore it has been demonstrated that staphostatins and staphopains 
form non-covalent 1:1 complexes (Rzychon et al, 2003). Inactivation of sspC in S. 
aureus resulted in a growth defect and reduced protein secretion most likely due to 
proteolytic inactivation of cytoplasmic proteins by SspB in the absence of SspC 
(Shaw et al, 2005). ScpA and SspB are synthezised as proenzymes and activated by 
proteolytic cleavage. The latter protease is processed and thus activated by the serine 
protease SspA (Massimi et al, 2002). In contrast, the processing and activation 
mechanism for ScpA has not been defined yet. ScpA has broad substrate specificity 
and has been shown to degrade elastin (Bjoorklind & Jornvall, 1974; Potempa et al, 
1988). In addition, ScpA inactivates the human α1-proteinase inhibitor, although less 
efficiently compared to the serine protease SspA, which is also able to cleave the 
inhibitor (Potempa et al, 1986). It has been suggested that both proteases function in a 
cooperative manner to strengthen the effect (Potempa et al, 1986). SspB has important 
implications in virulence as inactivation of sspB resulted in significant attenuation of 
virulence in a mouse abscess model (Shaw et al, 2004). 
 
1.6.4 Serine protease-like operon 
          S. aureus expresses six serine protease-like proteins, which are encoded by the 
splA-F genes and these genes are organized in an operon. Expression of the spl operon 
occurs maximally at post-exponentional phase being positively regulated by Agr 
(Reed et al, 2001). The Spl proteins share significant amino acid sequence identity 
with each other and with the serine protease SspA. These proteins harbour signal 
peptides, but lack profragments suggesting that their enzymatic activities do not 
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depend on activation by proteolytic cleavage (Reed et al, 2001). In addition, all Spl 
proteins contain the conserved amino acids, which make up the classical triad of 
trypsin like proteases. Proteolytic activities of SplB and SplC were demonstrated and 
both proteins were shown to degrade casein (Reed et al, 2001). SplB has narrow 
substrate specificity and only cleaves efficiently after the sequence Try-Glu-Leu-Gln 
(Dubin et al, 2008). However, no staphylococcal protein could be identified that 
contains this sequence, indicating that SplB might function specifically on 
mammalian proteins (Dubin et al, 2008). The structure of SplB has been solved and 
suggested an unusual activation mechanism in which the protease only forms a 
functional catalytic machinery upon docking of a substrate with the correct cleavage 
sequence (Dubin et al, 2008). A mutant strain carrying a deletion of the spl operon 
was not attenuated in a rat systemic infection model, suggesting that the Spl proteins 
do not play a profound role in S. aureus virulence (Reed et al, 2001). 
 
1.7 Signal peptides and signal peptidases 
          The majority of proteins that are destined for cell export contain an N-terminal 
signal peptide. Signal peptides are first recognized in the cytoplasm by soluble 
factors, which guide the polypeptides to the membrane where they interact with the 
translocation machinery (van Roosmalen et al, 2004). Several translocation 
machineries have been identified in bacteria of which the general secretion (sec) 
complex appears to be utilized by the majority of secreted proteins (Rusch & Kendall, 
2007). In general, the protein transport across the membrane is an energy dependent 
process and driven by the hydrolysis of nucleoside triphosphates (Chen & Tai, 1987). 
After or during the protein transport the signal peptide is cleaved off by signal 
peptidases and the mature protein is released from the translocase (van Roosmalen et 
al, 2004). The signal peptide is subsequently degraded by signal peptide peptidase 
(Hussain et al, 1982). Notably, membrane proteins that contain signal-like peptides 
are thought to diffuse laterally from the translocase. Signal peptides of Gram-positive 
bacteria are on average 32 amino acids long and contain three distinct regions, the N-, 
H- and C- domain (Nielsen et al, 1997b; von Heijne, 1990 and Fig. 7). The N-domain 
contains positively charged residues and is thought to interact with the translocase and 
with the negatively charged lipid bilayer (Akita et al, 1990; Batenburg et al, 1988). 
Following the N-domain is the H-domain, which consists of a stretch of hydrophobic 
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residues that are thought to form an α−helical conformation in the membrane (Briggs 
et al, 1986). In the middle of the H-domain, helix breaking residues such as glycine or 
proline are often present and these residues are thought to allow the loopwise insertion 
of the signal peptide into the membrane (Inouye & Halegoua, 1980; Inouye et al, 
1977). The C-domain, following the H-domain, contains the recognition site for the 
signal peptidase, which removes the signal peptide and subsequently releases the 
mature protein from the translocase (von Heijne, 1990). Signal peptidases can be 
divided in two groups, type I and type II. Type I signal peptidases remove signal 
peptides from secreted preproteins whereas type II signal peptidases are involved in 
the processing of lipid modified preproteins. The two types of signal peptidases are 
further discussed below. 
 
 
Figure 7: Schematic representation of a secretory preprotein. The signal peptide consists of a 
positively charged n-domain, a hydrophobic, helical h-domain and a c-domain, which contains the 
cleavage site. Type I signal peptidases preferentially cleave after an A-X-A motif. Numbers indicate 
amino-acid positions relative to the cleavage site. Adapted from Buzder-Lantos et al, 2009.  
 
1.7.1 Type I signal peptidases 
          Type I signal peptidases are membrane anchored serine proteases that remove 
signal peptides from secretory preproteins. These enzymes are highly conserved in 
bacteria and essential for cell viability. Type I signal peptidases differ from the 
classical serine proteases in that they use a serine/lysine catalytic dyad for catalysis 
(Black, 1993). The cleavage sites for type I signal peptidases contain the consensus 
sequence Ala-X-Ala at position -3 to -1 relative to the cleavage site of which the 
alanine at position -1 appears to be especially important (Nielsen et al, 1997a). Proline 
seems to be excluded from the +1 position and a proline residue at this position was 
shown to convert signal peptidase substrates to competitive inhibitors (Barkocy-
Gallagher & Bassford, 1992; Bruton et al, 2003). Typically, cleavage sites are placed 
3-7 residues after the hydrophobic h-domain of a N-terminal signal peptide (Jain et al, 
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1994). This spacing is critical for processing as the signal peptidase active sites are 
located in close proximity to the bacterial membrane (Jain et al, 1994). In general, 
cleavage by type I signal peptidase is restricted to the first hydrophobic core of a 
secreted protein; however, signal peptidase processing within a polytopic membrane 
protein has also been reported (Beltzer et al, 1989). 
          S. aureus expresses two type I signal peptidases, SpsA and SpsB. The genes 
encoding for the two signal peptidases are organized in an operon together with a 
third gene, which encodes for a membrane protein with unknown function. SpsA is 
conserved in all sequenced staphylococcal genomes (Sibbald et al, 2006). However, 
the enzyme is lacking two of the essential residues for catalysis. Thus it is assumed 
that SpsA is enzymatically inactive. In agreement with this, SpsB, but not SpsA, 
displayed proteolytic activity in a peptidase in vitro enzyme assay (Kavanaugh et al, 
2007). SpsB is assumed to be the only active signal peptidase present in S. aureus and 
the corresponding gene was shown to be essential in this organism (Cregg et al, 
1996). The SpsB protein has been expressed in E. coli and it was shown that the 
purified protein cleaves E. coli preproteins in vivo (Cregg et al, 1996). Furthermore, 
SpsB was shown to remove the N-terminal leader peptide of AgrD, indicating a role 
of signal peptidase in quorum sensing (Kavanaugh et al, 2007). A truncated SpsB 
version lacking the N-terminal transmembrane domain retained in vitro activity; 
however, the enzymatic activity of the shortened SpsB protein was reduced compared 
to the wild type enzyme, underscoring the importance of the membrane segment for 
optimal activity (Rao et al, 2009). 
          In contrast to S. aureus which has a single functional type I signal peptidase 
(SpsB), B. subtilis contains five chromosomal encoded type I signal peptidases (SipS, 
SipT, SipV, SipU, SipW). Some B. subtilis strains harbour two additional type I signal 
peptidases (SipP) and the corresponding genes are encoded on plasmids (Meijer et al, 
1995). SipT, SipS and SipP are classified as major signal peptidases as B. subtilis 
requires at least one of these proteases for viability (Tjalsma et al, 1998; Tjalsma et al, 
1999b). In contrast, SipU, SipV and SipW play minor roles in prepeptide processing. 
SipS, SipT, SipV and SipU have overlapping substrate specificity and expression of 
SipS and SipT is upregulated in the post exponentional growth phase (Tjalsma et al, 
1997). All B. subtilis type I signal peptidases contain a single N-terminal 
transmembrane domain, with the exception of SipW, which appears to have both, an 
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N-terminal and a C-terminal membrane anchor. SipW shows a high degree of 
sequence similarity to eukaryotic type I signal peptidases and contains a histidine 
residue in place of the catalytic lysine base, a typical feature for eukaryotic type I 
signal peptidase (Tjalsma et al, 1998).  
 
1.7.2 Type II signal peptidases 
          Type II signal peptidase (Lsp-lipoprotein signal peptidase) are membrane 
anchored enzymes that remove signal peptides from lipid modified preproteins. 
Proteins that are anchored to the membrane after translocation contain a conserved 
lipobox at the C-terminus of their signal peptides (von Heijne, 1989). This lipobox 
possesses a unique cysteine residue, which is lipid modified by the diacylglyceryl 
transferase (Lgt-lipoprotein diacylglycerol transferase) (Sankaran & Wu, 1994). Thus, 
after translocation and subsequent lipid modification the corresponding proteins 
remain attached to the membrane by their N-terminal lipid modified cysteine residue. 
Finally, the signal peptide is processed by the type II signal peptidase at the conserved 
cleavage site within the lipobox and upstream of the conserved cysteine residue 
(Hutchings et al, 2009). 
          Type II signal peptidases are highly conserved and found in Gram-negative and 
Gram-positive bacteria, but appear to be absent in eukaryotes (Paetzel et al, 2002). 
Most bacteria, including S. aureus and B. subtilis, contain a single Lsp and Lgt 
protein. Type II signal peptidases have a conserved topology and are predicted to span 
the membrane four times (Paetzel et al, 2002). These enzymes are thought to belong 
to a novel class of proteases that utilize an aspartic acid catalytic dyad for catalysis 
(Tjalsma et al, 1999c). An lgt defective S. aureus strain was unable to process 
lipoproteins, indicating that signal peptides can not be removed by type II signal 
peptidase prior to diacylglycerol acylation (Bubeck Wardenburg et al, 2006). 
Lipoprotein processing by type II signal peptidase is essential for viability in E. coli, 
but not in B. subtilis or S. aureus (Bubeck Wardenburg et al, 2006; Tjalsma et al, 
1999a; Yamagata et al, 1982). Furthermore, a Mycobacterium tuberculosis strain 
inactivated for lsp displayed reduced virulence in an animal model of infection 
(Sander et al, 2004). A signature-tagged mutagenesis screen in S. aureus identified lsp 
as a potential factor required for virulence in this organism (Mei et al, 1997). 
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However, the calculated LD50 value of the S. aureus lsp mutant was similar compared 
to that of the WT strain in a murine model of bacteraemia (Mei et al, 1997).  
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Materials and Methods 
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2.1 Bacterial strains, growth conditions and storage 
          Bacterial strains used in this study are listed in Table 1. Escherichia coli strains 
were grown at 37°C with shaking in Luria Bertani broth (LB) or at 37°C on LB agar. 
Staphylococcus aureus strains were grown at 37°C with shaking in Tryptic Soy Broth 
(TSB) or at 37°C on Tryptic Soy Agar (TSA). Bacillus subtilis strains were grown at 
30°C with shaking in Difco Antibiotic Medium 3 (PAB) or at 30°C on LB agar. When 
appropriate the medium was supplemented with antibiotics, 0.5-1 mM isopropyl β-D-
thiogalactoside (IPTG) or 300 ng/ml anhydrotetracycline (Atet) (unless otherwise 
stated) as indicated in Table 1 or in the text. Antibiotics were used at the following 
concentrations: for E. coli cultures: Ampicillin (Amp), 100 µg/ml; Kanamycin (Kan), 
30 µg/ml; Tetracycline (Tet), 10 µg/ml; for S. aureus cultures: Erythromycin (Erm), 
10 µg/ml; Chloramphenicol (Cam), 7.5 to 10 µg/ml; Kanamycin, 90 µg/ml and IPTG 
at 1 mM; for B. subtilis cultures: Erythromycin, 5 µg/ml; Chloramphenicol, 10 µg/ml; 
Kanamycin, 10 µg/ml; Spectinomycin (Spec), 100 or 200 µg/ml. 
          For long-term storage of bacterial strains, 500 µl of an overnight culture was 
mixed with 500 µl freezer medium (10 % (w/v) BSA, 10 % (w/v) monosodium 
glutamate) and stored at -80°C. 
 
2.2 Recombinant DNA techniques 
 
2.2.1 Purification of plasmid DNA from E. coli 
          Plasmid DNA was isolated from E. coli cells using either miniprep (5 ml 
overnight culture, Macherey-Nagel plasmid DNA purification kit) or midiprep (200 
ml overnight culture, QIAGEN plasmid midi kit) purification systems. The purified 
plasmids were dissolved in 150 µl ddH2O (midiprep) or 40 µl 5 mM Tris pH 8 
(miniprep) and stored at -20ºC. 
 
2.2.2 Isolation of chromosomal DNA from S. aureus 
          To isolate chromosomal DNA from S. aureus, 1.5 ml of an overnight culture 
was centrifuged for 3 min at 16,000 × g. The pellet was suspended in 50 µl TSM 
buffer (50 mM Tris pH 7.5, 0.5 M sucrose, 10 mM MgCl2) and lysostaphin (AMBI 
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Products LLC) at a final concentration of 100 µg/ml was added to the cell suspension. 
The mix was incubated for 1 h at 37ºC and the subsequent preparation steps were 
completed with the Wizard Genome Purification Kit (Promega, Madison USA) 
according to the manufacturer’s instructions. The isolated chromosomal DNA was 
rehydrated in 25 µl ddH2O for 1 h at room-temperature (RT) and stored at -20ºC. 
 
2.2.3 Estimation of DNA concentration 
          The presence and quality of isolated DNA was either estimated by agarose gel 
analysis or, when a more accurate measurement was required, determined 
spectrophotometrically by measuring the absorbance at 260 nm using a NanoDrop 
Spectrophotometer ND-1000 (Labtech). 
 
2.2.4 Separation of DNA by agarose gel electrophoresis 
          DNA was visualized by gel electrophoresis using 1 % (w/v) agarose gels. For 
preparing the gel, electrophoresis grade agarose was dissolved in 1 × Tris-Boric Acid-
EDTA buffer (TBE; 89 mM Tris base, 89 mM boric acid, 2 mM EDTA) or 1 × Tris-
Acetic Acid-EDTA buffer (TAE; 40 mM Tris base, 40 mM acetic acid, 1 mM EDTA) 
and SYBR Safe solution (Invitrogen) was added to the molten agarose according to 
manufacture’s guidelines. The gel was immersed in 1 × TBE or 1 x TAE, and the 
electrophoresis was carried out in a Bio-rad mini agarose gel cell at 100 V. Before 
loading the gel, DNA samples were mixed with 6 × DNA loading dye (0.25 % (w/v) 
bromophenol blue, 30 % (w/v) glycerol) and a 1 kb DNA ladder (Invitrogen) was run 
alongside the samples to size the separated DNA fragments. The DNA bound SYBR 
safe dye was visualized by exposing the gel to ultraviolet light using a BioDoc-It 
(Anachem) and the resultant image printed out on a video graphic printer (Sony). 
 
2.2.5 Restriction digestion of DNA 
          To screen for plasmids containing correct inserts, restriction digestions of the 
purified plasmids were carried out in a total volume of 20 µl, which included 2 µl 
buffer (10 ×), 0.1-1 µg DNA and 1 U enzyme. For cloning purposes the reaction was 
scaled up to 100 µl and 10 µg BSA was added to the mix. All restriction enzymes 
were purchased from New England Biolabs and digestions were incubated for 3 h 
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(except digestions using BglII and SalI which were incubated overnight) in a 37ºC 
water bath. Depending on the enzyme, reaction specific buffers were used as directed 
by the manufacturer’s guidelines. Double digestions using two restriction enzymes 
simultaneously were preformed for restriction analysis provided that both enzymes 
are active in the same buffer. For cloning purposes, digested DNA was purified using 
the QIAGEN PCR clean-up gel extraction kit and eluted in 40 µl 5 mM Tris pH 8. 
 
2.2.5.1 Vector preparation 
          Plasmid vectors used for cloning purposes were isolated from E. coli cells using 
the midiprep DNA purification system described in section 2.2.1. Purified plasmid 
DNA (7.5 µg) was digested with appropriate restriction enzymes and subsequently 
utilized for ligation reactions. 
 
2.2.6 Polymerase chain reaction (PCR) 
          PCR was conducted to amplify DNA fragments in vitro. Primers used in this 
study were purchased from Sigma-Aldrich and are listed in Table 2. Specific 
oligonucleotide primers were designed to introduce appropriate restriction sites to 
both the 5’ and 3’ ends. This subsequently allowed the cloning of the PCR-fragment 
into the target vector. In general, PCR reactions were carried out in a total volume of 
50 µl, which included 5 µl Taq buffer (10 ×) or 10 µl Herculase buffer (5 ×), 1 µl 
forward and reverse primer (10 µM of each), 2 µl dNTPs (40 mM), 10-100 ng 
template DNA and 1 µl Herculase (Agilent) or 0.5 µl Taq (NEB). The PCR 
programme comprised of an initial denaturation step at 95ºC for 2 min followed by 5 
cycles in which DNA was denatured at 95ºC for 45 sec, annealed at 45ºC for 45 sec, 
and extended at 72ºC for 1 min/kb. For the next 25 cycles, the annealing temperature 
was raised to 53ºC. A final extension step of 7 min was carried out before the 
temperature was dropped and subsequently held at 10ºC. PCR products were purified 
using the QIAGEN PCR clean-up or gel extraction kit and DNA was eluted in a final 
volume of 40 µl 5 mM Tris pH 8. 
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2.2.7 Ligation of DNA fragments 
          Ligations of cut PCR fragments and cut plasmid vectors were performed using 
the T4 DNA ligase from New England Biolabs. Typically, reactions were set up in a 
total volume of 20 µl containing 2 µl ligase-buffer (10 ×), 2 µl vector-DNA, 12 µl 
Insert-DNA and 1 µl T4-DNA-Ligase. Ligation reactions were incubated at 17ºC 
overnight and the next day the enzyme was heat inactivated for 20 min at 60ºC in a 
heat block.  
 
2.2.8 Transformation of E. coli cells 
 
2.2.8.1 Preparation of rubidium chloride competent XL1 Blue cells 
          E. coli XL1 Blue cells were made chemically competent by culturing cells 
overnight in 10 ml LB medium supplemented with tetracycline. The following day, 
the culture was diluted 1:100 in 500 ml PSI broth (5 g/l bacto yeast extract, 20 g/l 
bacto tryptone, pH 7.6, 20 mM MgSO4) and grown at 37ºC with agitation to an optical 
density (OD600) of 0.6. Cells were then incubated on ice for 15 min and subsequently 
harvested by centrifugation at 6,000 × g for 10 min. The supernatant was discarded 
and the cell pellet suspended in 10 ml of ice-cold TfbI (30 mM CH3COOK, 100 mM 
RbCl, 10 mM CaCl2, 50 mM MnCl2, 15 % (v/v) glycerol, pH 5.8). After adding an 
additional 190 ml ice-cold TfbI, cells were incubated on ice for a further 15 min and 
collected by centrifugation as described above. The final pellet was suspended in 15 
ml ice-cold TfbII (10 mM MOPS, 75 mM CaCl2, 10 mM RnCl, 15 % (v/v) glycerol, 
pH 6.5) and 500 µl aliquots were snap frozen in a dry ice/ethanol bath and stored at -
80ºC.  
 
2.2.8.2 Transformation of rubidium chloride competent XL1 Blue cells 
          For transformation of XL1 Blue cells, 100 µl rubidium chloride competent XL1 
Blue cells were thawed on ice. Subsequently, 20 µl ligation product was added to the 
cells and the cells were incubated on ice for 30 min. After heat-shocking at 42ºC for 
45 sec, cells were placed on ice for a further 5 min, then immediately transferred to 
900 µl SOC medium (5 g/l bacto yeast extract, 20 g/l bacto tryptone, 3.6 g/l glucose, 
2.5 mM KCl, pH 7.0) and incubated for 1 h at 37ºC for recovery. An aliquot (100 µl) 
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of this cell suspension was plated on LB agar containing appropriate antibiotics. The 
remaining culture was pelleted by centrifugation at 11,000 × g for 3 min. The 
supernatant was discarded and the cells were suspended in a small volume of LB 
medium and plated on LB agar containing appropriate antibiotics. Plates were 
incubated at 37ºC overnight. 
 
2.2.8.3 Preparation of electrocompetent CLG190 cells 
          To make E. coli CLG190 cells competent, the cells were grown overnight in 10 
ml LB supplemented with tetracycline. The following day, the culture was diluted 
1:100 in 100 ml LB and grown at 37ºC with agitation to an OD600 of 0.6. After a 15 
min incubation period on ice, the cells were harvested by centrifugation at 9,700 × g 
for 10 min.  The supernatant was discarded and the pellet suspended in 5 ml of ice-
cold sterile ddH2O. An additional 100 ml ice-cold sterile ddH2O was added to the cells 
before repeating the centrifugation step. The final pellet was dissolved in 1.2 ml 
sterile 10 % (v/v) glycerol and 300 µl aliquots were snap frozen in a dry ice/ethanol 
bath and stored at -80ºC.  
 
2.2.8.4 Electroporation of CLG190 cells 
          For electroporation of CLG190 cells, 100 µl electrocompetent cells were 
thawed on ice. Meanwhile, 10 µl ligation product was dialyzed against ddH2O for 45 
min on a nitrocellulose filter (Millipore) before being added to the cells. The mix was 
transferred to a 1 mm electroporation cuvette (Equibio) and electroporated using a 
Biolabs Gene Pulser with the following settings: 200 Ω (Resistance), 1.8 kV (Volts), 
25 µFD (Capacitance). Immediately after electroporation, the cell suspension was 
transferred to 900 µl SOC medium and incubated for 1 h at 37ºC for recovery. An 
aliquot (100 µl) of this cell suspension and the remaining cells were plated on LB agar 
containing appropriate antibiotics as described in section 2.2.8.2. Plates were 
incubated at 37ºC overnight. 
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2.2.9 Transformation of S. aureus cells 
 
2.2.9.1 Preparation of electrocompetent S. aureus cells 
          To make S. aureus cells competent, an overnight culture was grown in 4 ml 
TSB at 37ºC with agitation in the presence of appropriate antibiotics and supplements. 
The following day the bacterial culture was diluted 1:100 in 150 ml TSB containing 
appropriate antibiotics and supplements and grown for 3 h to an OD600 of 
approximately 2. The subsequent steps were as described in 2.2.8.1 except that cold 
sterile 0.5 M sucrose was used as wash solution, and the washing step was repeated 3 
times. The final pellet was suspended in 1 ml cold sterile 0.5 M sucrose and 120 µl 
aliquots were snap frozen in a dry ice/ethanol bath and stored at -80ºC.  
 
2.2.9.2 Electroporation of S. aureus cells 
          Aliquots (100 µl) of frozen electrocompetent S. aureus cells were thawed on 
ice. The plasmid preparation and electroporation process were carried out as described 
in section 2.2.8.4 except with the following modifications. Electroporation settings 
were: 100 Ω, 2.5 kV, 25 µFD. Cultures were recovered in 900 µl brain heart infusion 
(BHI) 0.5 M sucrose medium supplemented with IPTG when appropriate and 
incubated for 1 h at 37ºC for recovery. Two volumes (75 µl and 150 µl) were plated 
on TSA containing appropriate antibiotics and supplements, and plates incubated at 
37ºC overnight.  
 
2.2.10 Phage transduction 
          Chromosomal deletions marked with antibiotic-resistance cassettes were 
transferred between S. aureus strains by transduction using phage 85. The first step in 
the transduction process involved the preparation of a phage plate lysate as follows. 
The strain containing the marker to be transduced was grown overnight in 2 ml 
LB/TSB (2:1) at 37ºC with agitation in the presence of appropriate antibiotics and 5 
mM CaCl2. The following day, the culture was diluted 1:50 in 5 ml LB/TSB (2:1) 
supplemented with appropriate antibiotics and 5 mM CaCl2 and grown at 37ºC with 
agitation for 3 h. One hundred µl of undiluted phage stock, and 100 µl of 10-1, 10-2, 10-
3 and 10-4 phage stock dilutions in TMG (10 mM Tris pH 7.5, 10 mM MgSO4, 0.1 % 
(w/v) gelatin) were used to infect 500 µl of this bacterial cell suspension. The mixture 
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was incubated at RT for 30 min to allow for one cycle of replication. Next, 5 ml of 
molten top agar (0.8 % (w/v) NaCl, 0.8 % (w/v) Bacto-agar) was added to the infected 
culture and the mixture was spread on TSA containing appropriate antibiotics. Plates 
were incubated at 37ºC overnight. The following day, plates that displayed confluent 
lysis were overlayed with 4 ml TMG and incubated at RT for 30 min. The liquid 
containing the desired phage particles was transferred from the plates to a falcon tube 
and centrifuged for 20 min at 3,220 × g. The supernatant was removed and filtered 
though a 0.2 µm filter. Phage plate lysates were stored at 4ºC. 
          A 25 ml culture of the recipient strain was grown overnight in LB/TSB (2:1) 
supplemented with appropriate antibiotics and 5 mM CaCl2. The following day, the 
culture was harvested by centrifugation at 3,220 × g for 10 min.  The supernatant was 
discarded and the pellet was suspended in 5 ml LB/TSB (2:1) containing 5 mM CaCl2. 
An aliquot (250 µl) of this concentrated culture was mixed with 200 µl phage lysate 
and the suspension was incubated at 37ºC with shaking for 20 min. Cells were placed 
on ice and 24 µl ice-cold 1M sodium citrate was added to the mixture. Cultures were 
subsequently washed twice, each time by pelleting the cells for 3 min at 11,000 × g, 
discarding the supernatant and resuspending the pellet in 1 ml ice-cold 40 mM sodium 
citrate. The final pellet was suspended in 300 µl 40 mM sodium citrate and two 
volumes (100 µl and 200 µl) were plated on TSA containing appropriate antibiotics 
and 40 mM sodium citrate. Colonies obtained were restreaked once on TSA 
supplemented with 40 mM sodium citrate and appropriate antibiotics, then twice more 
on TSA containing appropriate antibiotics but no sodium citrate.  
 
2.3 Cell fractionation 
          S. aureus overnight cultures were diluted 1:100 and grown at 37°C for 3 ½ h. 
One ml aliquots of these mid-log cultures were removed and centrifuged at 7,000 × g 
for 15 min. The supernatant was transferred to a fresh tube and proteins therein 
precipitated with trichloroacetic acid (TCA; referred to as supernatant fraction). The 
remaining bacterial pellet was suspended in 1 ml lysostaphin digestion buffer (30 % 
(w/v) raffinose, 50 mM Tris-HCl pH 7.5, 20 mM MgCl2,) and incubated for 1 h at 
37°C in the presence of 200 µg/ml lysostaphin (AMBI Products LLC). Resultant 
protoplasts were collected by centrifugation at 6,000 × g for 20 min, the supernatant 
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removed and centrifuged at 100,000 × g at 4°C for 1 h. Proteins in the supernatant 
fraction were subsequently precipitated with TCA (referred to as cell wall fraction). 
Protoplasts were suspended in 1 ml membrane buffer (100 mM Tris-HCl pH 7.5, 10 
mM MgCl2, 60 mM KCl), lysed by five cycles of freeze-thawing, and proteins TCA 
precipitated (referred to as membrane/cytoplasmic fraction). In order to precipitate 
proteins in the different sample fractions, 10 % (w/v) TCA final concentration was 
added to the samples. Samples were vortexed briefly, incubated on ice for 1 h and 
then centrifuged at 17,000 × g for 10 min. The supernatant was aspirated and the TCA 
precipitated protein pellet was washed twice with ice-cold acetone, each time by 
suspending the pellet in 1 ml ice-cold acetone, incubating the sample on ice for 10 
min and centrifugating at 17,000 × g for 10 min. After the final centrifugation step, 
the pellet was air dried and suspended in 2 × sample buffer normalized for OD600 of 
bacterial cultures; that is samples from 1 ml culture with an OD600 of 3 were 
suspended in 45 µl 2 × sample buffer. Samples were boiled for 5 min, centrifuged at 
17,000 × g for 5 min, and 15 µl aliquots were subsequently separated on a 10 % (w/v) 
SDS-PAGE and analyzed by western blot. LtaS and control proteins were detected by 
western blot using rabbit polyclonal primary antibodies at a 1:20,000 dilution and the 
HRP-linked donkey anti-rabbit IgG antibody (GE Healthcare) at a 1:10,000 dilution.  
 
2.4 S. aureus growth curves 
          For growth curves, S. aureus strains were grown overnight at 37ºC in 4 ml TSB 
medium containing 1 mM IPTG and appropriate antibiotics. The following day, 
bacteria from 1 ml culture were washed 3 times with 1 ml TSB by centrifugation and 
re-suspension. Next, 5 ml TSB containing 300 ng/ml Atet and appropriate antibiotics 
were inoculated with 50 µl washed bacterial suspensions (1:100 dilution) and cultures 
incubated at 37ºC with shaking. At time 0 and then every 2 h, culture aliquots were 
removed and OD600 values determined. At 4 h all cultures and at 8 h indicated cultures 
were diluted 1:100 into 5 ml fresh TSB containing 300 ng/ml Atet and appropriate 
antibiotics to maintain bacteria in the logarithmic growth phase. Growth curves using 
the inducible spsB S. aureus strain ANG2009 were performed with the following 
slight modifications. Overnight cultures of strain ANG2009 were washed as described 
above and then diluted 1:100 into 7 ml TSB medium with and without IPTG and 
appropriate antibiotics. Cultures were grown at 37°C with shaking and bacterial 
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growth was monitored by determining OD600 readings every two hours. At the 4 h time 
point the culture was washed as described above and back-diluted, and at the 8 h time 
point bacteria were back-diluted again 1:100 into fresh media to keep bacteria in the 
logarithmic growth phase.  
 
2.5 LTA and protein detection by western blot  
          For the detection of S. aureus cell associated LTA and proteins by western blot, 
1 ml culture samples were withdrawn from bacterial cultures at the 4 or 8 h time point 
as indicated in the results sections. Samples were mixed with 0.5 ml of 0.1 mm glass 
beads and subsequently lysed by vortexing upside down for 45 min at 4°C. Glass 
beads were sedimented by centrifugation for 1 min at 200 × g and 0.5 ml of culture 
supernatant was transferred to a fresh tube. Bacterial debris and LTA were collected 
by centrifugation at 17,000 × g for 15 min and suspended in sample buffer normalized 
for OD600 of bacterial cultures; that is, samples from a culture with on OD600 of 1 were 
suspended in 15 µl 2 × sample buffer. Samples were boiled for 20 min, centrifuged at 
17,000 × g for 5 min and 10 µl aliquots were separated on a 10 or 15 % (w/v) SDS-
PAGE gel and analyzed by western blot. For protein detection in the culture 
supernatant, 1 ml culture aliquots were centrifuged at 17,000 × g for 5 min and 900 µl 
of the supernatant was transferred to a fresh tube, and proteins were TCA precipitated 
as described in section 2.3. The protein pellet was air dried and suspended in 2 × 
sample buffer normalized for OD600 readings as described above. Samples were boiled 
for 5 min, centrifuged at 17,000 × g for 5 min and 10 µl aliquots were separated on a 
10 % (w/v) SDS-PAGE gel and analyzed by western blot. For LtaS detection in E. 
coli, 1 ml of an overnight culture was harvested by centrifugation at 17,000 × g for 10 
min. The supernatant was discarded and the cell pellet suspended in 2 × sample buffer 
normalized for OD600 that is, samples from a culture with on OD600 of 1 were 
suspended in 45 µl 2 × sample buffer. Samples were boiled for 30 min, centrifuged at 
17,000 × g for 5 min and 7.5 µl aliquots were separated on a 10 % (w/v) SDS-PAGE 
and analyzed by western blot.  For LTA detection, the polyglycerolphosphate-specific 
LTA antibody (Clone 55 from Hycult biotechnology) and HRP-conjugated anti-
mouse IgG (Cell Signaling Technologies, USA) were used at 1:5,000 and 1:10,000 
dilutions, respectively. For LtaS protein detection the polyclonal eLtaS specific 
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antibody (Lu et al, 2009) and the HRP-conjugated anti-rabbit antibody (Cell Signaling 
Technologies, USA) were used at 1:20,000 and 1:10,000 dilutions, respectively. His-
tagged proteins were detected with the HRP-conjugated anti-His antibody (Sigma) 
used at a 1:10,000 dilution. 
 
2.6 B. subtilis LTA detection by western blot  
          For LTA detection in B. subtilis, wild type and mutant strains were grown for 
20 to 22 h at 30°C in 5 ml PAB medium with shaking. Samples for LTA analysis 
were prepared from whole cells as follows: bacteria from 3 to 4 ml culture were 
collected by centrifugation for 30 min at 17,000 × g. Bacterial pellets were suspended 
in 2 × protein sample buffer normalized for OD600 readings; that is 100 µl 2 × sample 
buffer was used per ml culture of OD600 = 3. Samples were boiled for 45 min, 
centrifuged for 5 min at 17,000 × g and 10 µl analyzed on a 15 % (w/v) SDS-PAGE 
gel. The humanized monoclonal LTA antibody (Biosynexus Incorporated; 
Gaithersburg, MD) and the HRP-conjugated polyclonal rabbit anti-human IgA, IgG, 
IgM, Kappa, Lambda antibody (DakoCytomation) were used at 1:10,000 dilutions for 
LTA detection. Membrane blocking and antibody incubations were performed in 
TBST buffer containing 3 % (w/v) BSA. 
 
2.7 Standard techniques for protein analysis 
 
2.7.1 Protein quantification 
          The quantity of protein samples was determined with the BCA kit from Pierce. 
The assay was completed as directed by manufacture’s guidelines.  
 
2.7.2 Sodium Dodecyl Sulphate Poly-Acrylamide Gel Electrophoresis 
(SDS-PAGE) 
          SDS-PAGE was performed in order to separate proteins according to their 
molecular weights as well as to analyze LTA. Ten or 15 % (w/v) Tris/glycine SDS-
PAGE gels were prepared as described by Sambrook et al (1989) and, if not stated 
otherwise, these gels were used for protein and LTA analysis. The electrophoresis was 
carried out in 1 × SDS running buffer (14.4 g/l glycine, 3 g/l Tris-base, 1 g/l SDS) 
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using Hoefer´s Mini Protein Electrophoresis system. Samples were electrophoresed 
for 45 min at 200 V and a protein ladder (Bench MarkTMPrestained, Invitogen) was 
run alongside the samples to size the proteins. Fifteen % (w/v) trycine SDS-PAGE 
gels were prepared as described by Schagger & von Jagow (1987) and these gels were 
used in a Bio-rad Mini-PROTEAN tetra cell according to manufacturer’s guidelines. 
After separation, proteins were either visualized by coomassie staining (section 2.7.3) 
or samples were transferred to a polyvinylidene difluoride (PVDF) membrane and 
proteins or LTA detected by western blotting (section 2.7.4). 
 
2.7.3 Protein staining with Coomassie brilliant blue 
          In order to visualize proteins after separation on SDS-PAGE, gels were 
immersed in a Coomassie brilliant blue staining solution (2.5 g/l Coomassie brilliant 
blue R250, 45 % (v/v) methanol, 10 % (v/v) acetic acid) and incubated at RT for 1 h 
with moderate shaking. Gels were then repeatedly washed with a destaining solution 
(45 % (v/v) methanol, 10 % (v/v) acetic acid) and subsequently imaged to record the 
result. 
 
2.7.4 Western blotting 
          For protein and LTA detection by western blot, samples were transferred from 
SDS-PAGE gels to a PVDF membrane (Millipore) using Hoefer’s electrophoretic 
transfer cell system. The electrotransfer was conducted for 1 h in transfer buffer (3 g/l 
Tris-Base, 14.5 g/l glycine, 20 % (v/v) methanol) at 1000 mA and RT. The membrane 
was subsequently blocked for 1 h with 20 ml of 5 % (w/v) milk in Tris buffered saline 
containing 0.1 % (v/v) Tween pH 7.4 (TBST). When necessary 10 µg/ml human IgG 
(Sigma) was added to the blocking solution as well as during antibody incubation in 
order to prevent antibody binding to S. aureus protein A and Sbi. The incubation with 
the primary antibody was carried out at 4°C overnight in 20 ml of 5 % (w/v) milk in 1 
× TBST. The next day, unbound antibody was removed by washing the membrane 
three times, each time for 10 min with 20 ml 1 × TBST. If required membranes were 
incubated with a secondary antibody in 20 ml of 5 % (w/v) milk in 1 × TBST for 3 h 
and afterwards washed as described above. Subsequently, membranes were incubated 
with ECL (100 mM Tris pH 8.5, 2.5 mM Luminol, 2.5 mM P-Coumaric acid) and 
0.009 % (v/v) hydrogen peroxide and the chemiluminescent signal was captured using 
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Hyperfilm ECL (GE Healthcare). Films were developed using an automated 
developer (AGFA-Healthcare N.V.).  
 
2.8 Purification of His-tagged LtaS fragments from S. aureus 
culture supernatant 
          S. aureus strains ANG587 (pitet-ltaS-his) and ANG1370 (pitet-ltaSS218P-his) 
were used for the expression and purification of His-tagged proteins from the 
respective culture supernatants. To this end, strains ANG587 and ANG1370 were 
grown overnight at 37°C in 30-50 ml TSB medium containing 1 mM IPTG and 
appropriate antibiotics. The following day, cultures were washed three times with 30-
50 ml TSB by repeated centrifugation and suspension. Subsequently, 2 to 4 L TSB 
medium containing 300 ng/ml Atet and appropriate antibiotics were inoculated 1:100 
with washed bacterial suspensions and cultures were grown at 37°C overnight. Next 
day, bacteria were removed by centrifugation for 15 min at 13,600 × g and the culture 
supernatants filtered through 0.2 µm nylon membranes (Whatman). His-tagged 
proteins were purified from these filtered culture supernatants by gravity flow 
chromatography. Supernatants were applied to equilibrated Ni-NTA columns (1.5 ml 
column volume, 3 ml resin) (QIAGEN) and extensively washed with buffer A (50 
mM Tris pH 7.5, 150 mM NaCl, 5 % (v/v) glycerol), followed by two additional wash 
steps with buffer A containing 10 and 50 mM imidazole. Proteins were eluted in 4 × 1 
ml fractions with buffer A containing 500 mM imidazole. Fractions containing 
purified protein were pooled and protease inhibitors (Roche) were added to the 
suspension. Next, proteins were concentrated using Amicon Centricons (10 kDa 
cutoff) and 20 µl aliquots were separated on 10 % (w/v) SDS-PAGE gels and the 
proteins visualized by staining with Coomassie brilliant blue. The main protein band 
was excised from the gel and analyzed by standard tryptic digest and mass 
spectrometry at the Taplin Biological Mass Spectrometry Facility at the Harvard 
Medical School. 
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2.9 In vitro enzyme assay for LtaS-type enzymes 
 
2.9.1 Protein purification from E. coli cells 
          E. coli strains ANG1474 (Rosetta pProEX-eYflE), ANG1475 (Rosetta pProEX-
eYfnI), ANG1476 (Rosetta pProEX-eYvgJ), ANG1477 (Rosetta pProEX-eYqgS) 
were used for the expression and purification of eYflE, eYfnI, eYvgJ and eYqgS. To 
this end, respective strains were grown overnight at 37°C in 50 ml LB supplemented 
with appropriate antibiotics. The following day, bacterial cultures were diluted 1:50 in 
2 L LB medium containing appropriate antibiotics and grown at 37°C with shaking. 
Once the cultures reached an OD600 of 0.4, protein expression was induced for 3-4 h 
by the addition of 0.5 mM IPTG. Bacteria were collected by centrifugation at 6,000 × 
g for 10 min. Subsequently, bacteria pellets were suspended in 20 ml buffer A (see 
section 2.8) and cells were lysed by 2 cycles of French pressing at 1,100 psi. Lysates 
were cleared by centrifugation at 26,000 × g for 30 min and His-tagged proteins were 
purified by gravity flow chromatography as described in section 2.8. Fractions 
containing the purified proteins were pooled and further purified by size exclusion 
chromatography using a 16/60 Superdex 200 column (GE Healthcare) and a 50 mM 
Tris pH 7.4, 200 mM NaCl, 5 % (v/v) glycerol buffer system. Purified protein 
containing fractions were pooled and concentrated using Amicon centricons with a 10 
kDa cut off. The protein concentration was measured and the purity of the protein was 
estimated by separating 10 µg purified protein on 10 % (w/v) SDS-PAGE gels and 
Coomassie staining. 
 
2.9.2 Standard enzyme assay for LtaS-type enzymes 
          The enzymatic activity of purified LtaS-type proteins was measured by 
following the hydrolysis of NBD-labeled phosphatidylglycerol (NBD-PG) using a 
method described previously (Karatsa-Dodgson et al, 2010). First, the commercially 
available NBD-PG lipid (Avanti; order number 810163) was purified on TLC plates. 
To this end, 100 µg NBD-PG was spotted onto pre-run Å60 silica gel plates 
(Macherey-Nagel) and run for 15 min in a chloroform: methanol: H2O (65:25:4) 
solvent system. The major fluorescent band was excised from the TLC plate by 
scraping the silica gel of the respective area into a falcon tube. Lipids were 
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subsequently extracted for 15 min at RT with 8 ml of a 1:1 methanol-chloroform 
mixture and occasional vortexing. Samples were centrifuged at 7,000 × g for 10 min 
and the supernatant was transferred to a fresh tube. The silica gel was extracted a 
second time as described above and the supernatant was combined with the first 
extraction. Next, 7.2 ml ddH20 was added to the mixture, the samples were vortexed 
vigorously and subsequently centrifuged at 7,000 × g for 10 min for phase separation. 
The bottom phase containing the purified lipid was transferred to a glass vial. Lipids 
were dried under a stream of nitrogen and stored at -20°C until further use.   
          For setting up the standard enzyme assay, 1.8 ml of 10 mM sodium succinate 
buffer, pH 6.0, ionic strength (µ) = 50 mM (adjusted with NaCl) was added to 25 µg 
of TLC-purified NBD-PG lipid. Lipids were brought into suspension by sonication for 
45 sec at 11 amplitude microns using a Soniprep Sanyo sonicator. Next, MnCl2 or 
other divalent cations were added from a 1 M stock solution to give a final 
concentration of 10 mM, the samples were vortexed, and 303 µl (∼ 4.166 ng lipid) 
aliquots transferred into test tubes. Reactions were initiated by the addition of 1.52 
µM purified protein and assay mixtures were then incubated for 3 h in a 37ºC water 
bath. Next, reactions were halted and lipids extracted by the addition of CHCl3/MeOH 
to give a final ratio of assay volume:CHCl3:MeOH of 0.9:1:1. Tubes were vortexed 
vigorously, centrifuged for 5 min at 17,000 × g and fractions of the bottom 
chloroform phase transferred to a new tube and dried under a stream of nitrogen. 
Dried lipids were then suspended in 10 µl chloroform, spotted onto pre-run Å60 silica 
gel plates and separated using a chloroform: methanol: H2O (65:25:4) solvent system. 
Plates were dried and subsequently imaged using a Fujifilm FLA-5000 imager 
equipped with a 473 nm excitation laser and a FITC emission filter. Where indicated, 
fluorescent signals of lipid reaction products were quantified using the AIDA software 
(Raytest Isotopenmessgeräte GmbH). The phospholipase PC-PLC (PLC) from B. 
cereus (Sigma EC 3.1.4.3) was used as a positive control and assays with this enzyme 
were set up as follows: TLC-purified NBD-PG lipid (25 µg) was brought into solution 
by sonication in 1.8 ml of BPS, pH 7.4. Next, 10 mM CaCl2 final concentration was 
added to the lipid suspension. Aliquots of 303 µl (∼ 4.166 ng lipid) were transferred to 
a test tube and reactions were initiated by the addition of 2.5 U of PLC. Reactions 
were incubated at RT on a rotor for 3 h and lipids subsequently extracted as described 
above.  
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          To gain insight into enzyme kinetics, a time course experiment was performed 
by removing and analyzing samples at the indicated time points. Reaction products 
were quantified using a fluorescence plate reader and the AIDA software and percent 
hydrolysis of input lipid calculated based on the signal obtained for the PLC control 
reaction, which proceeds to near completion. Reactions were set up with triplicate 
samples and average values and standard deviations were plotted. Experiments were 
performed three times and a representative result is shown. Maximal enzyme reaction 
rates were determined from the slope of the linear fit through the first three data points 
and average values with standard deviations from the three independent experiments 
calculated. To determine the enzyme specificity, the fluorescently labeled lipids 16:0-
6:0 NBD-PC (Avanti 810130), 16:0-6:0 NBD-PE (Avanti 810153) and 16:0-6:0 
NBD-PS (Avanti 810192) were purified on TLC plates and enzyme reactions set up 
as described above.  
 
2.10 S. aureus lipid extraction and glycolipid analysis by 
TLC 
          For S. aureus lipid extraction and glycolipid analysis, S. aureus strains were 
grown overnight at 37ºC in 10 ml TSB supplemented with 1 mM IPTG and 
appropriate antibiotics. The next day, cells were collected by centrifugation for 10 
min at 1,300 × g and bacterial pellets washed 3 times with 10 ml TSB. After the final 
centrifugation step, washed cultures were suspended in 10 ml TSB and diluted 1:100 
into 200 to 800 ml fresh TSB medium supplemented with 300 ng/ml Atet and 
appropriate antibiotics. Cultures were incubated at 37ºC with shaking for 5 h and then 
placed on ice for 30 min. Next, bacteria were collected by centrifugation for 10 min at 
8,000 × g, washed once with 5 ml of ice-cold 0.1 M sodium citrate buffer pH 4.7 and 
suspended in 3 ml of the same buffer. Bacteria were lysed and lipids extracted using a 
modified Bligh-Dyer method as described previously (Gründling & Schneewind, 
2007b; Kates, 1972). To this end, cultures were dispensed into three 2 ml Fast Prep 
tubes containing 0.5 ml of 0.1 mm glass beads and cells were lysed by shearing three 
times for 45 sec in a Fast-Prep machine (Thermo Servant) at setting 6. Bacteria were 
chilled on ice between each run for 5 min. Glass beads were settled by centrifugation 
at 200 × g for 1 min. The supernatant was transferred to a fresh tube and cell debris 
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collected by centrifugation at 4,050 × g for 30 min. The pellet was washed once with 
15 ml of 0.1 M sodium citrate pH 4.7 and the final pellet was dissolved in 1 ml of the 
same buffer. For lipid extraction, methanol and chloroform were added to give a final 
ratio of MeOH:CHCl3:buffer of 2:1:0.8. Lipids were subsequently extracted for 2 h at 
RT with frequent vortexing. Next, samples were centrifuged at 2,600 × g for 20 min, 
the supernatant transferred to a fresh tube and the lipids were extracted a second time 
as described above. The two extracts were subsequently combined and methanol and 
buffer was added to obtain a final ratio of MeOH:CHCl3:buffer of 1:1:0.9. Samples 
were vortexed vigorously and then centrifuged at 2600 × g for 20 min. The bottom 
chloroform phase containing the lipids was transferred to a fresh tube. Lipids were 
dried under a stream of nitrogen and suspended in chloroform to a final concentration 
of 50 mg/ml. Ten µl (500 µg lipids) were spotted onto pre-run Å60 silica gel plates 
(Macherey-Nagel) and the lipids separated using a chloroform : methanol : H2O 
(65:25:4) solvent system. Glycolipids were visualized by spraying plates with 0.5 % 
to 1.5 % (w/v) α-naphthol in 50 % (v/v) methanol and then with 95 % (v/v) H2SO4 
(Gründling & Schneewind, 2007b; Kates, 1972). Plates were subsequently heated to 
100°C until glycolipid bands became visible.  
 
2.10.1 Lipid analysis by MALDI mass spectrometry 
          MALDI mass spectrometry analysis was essentially performed as described 
previously (Webb et al, 2009), and the lipids extracted and prepared as follows: total 
membrane lipids were isolated from S. aureus strains and 5 × 0.5 mg lipids (2.5 mg 
total) were spotted and separated on a TLC plate using the same solvent system as 
described in section 2.10. Areas containing glycolipids were determined by 
developing one lane of the TLC run in parallel with α-naphthol/H2SO4. Appropriate 
silica gel areas were scraped off and lipids extracted as described previously 
(Gründling & Schneewind, 2007b). Dried lipids were suspended in 10 µl of 0.5 M 
2,5-dihydroxybenzoic acid (DHB) MALDI matrix dissolved in 1:1 methanol : 
chloroform and 1 µl was spotted directly onto MALDI plates or diluted 1:10 using 0.5 
M DHB matrix and 1 µl spotted. Spotted MALDI plates were analysed using a a 
MALDI micro MXTM machine (Waters, UK) and spectra recorded in the reflector 
positive ion mode. As an additional calibration standard, 25-50 pmoles of bradykinin 
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peptide standard (Sigma) with an absolute mass of 757,3997 (M+H+) was spotted in 
α-cyano-4-hydroxycinnamic acid (CHCA) matrix, which was suspended at 10 mg/ml 
in 70 % (v/v) acetonitrile 0.1 % (v/v) trifluoroacetic acid (TFA). Samples were 
analyzed at the Proteomics Facility at Imperial College London. 
 
2.11 LTA purification and structural analysis  
 
2.11.1 LTA purification 
          LTA was purified from S. aureus and B. subtilis cells using a previously 
described 1-butanol extraction method (Gründling & Schneewind, 2007a; Morath et 
al, 2001). Briefly, S. aureus strains were grown overnight at 37ºC with shaking in 150 
ml TSB supplemented with 1mM IPTG and appropriate antibiotics. The following 
day, cultures were centrifuged for 10 min at 1,300 × g and washed 3 times with 150 
ml TSB. Washed cultures were diluted 1:100 into 6 L (strain ANG514) or 12 L (strain 
ANG515) fresh TSB containing 300 ng/ml Atet and appropriate antibiotics and 
incubated at 37ºC with shaking for 4 to 5 h. B. subtilis strains were grown overnight at 
30ºC in 8 L (strain ANG1691 and ANG1697) or 12 L (ANG1696) PAB medium. 
LTA extraction and purification by hydrophobic interaction chromatography was 
performed as described previously (Gründling & Schneewind, 2007a). To this end, 
bacterial cultures were placed on ice for 1 h and then harvested by centrifugation at 
6,100 × g for 10 min. The supernatant was discarded and the bacterial pellet washed 
once with 80-160 ml of 0.1 M sodium citrate pH 4.7. The final pellet was suspended 
in 40 ml of the same buffer and the cell suspension was mixed with 40 ml of 0.1 mm 
glass beads. Bacteria were disrupted by shearing the cells five times for 2 min at 4ºC 
in a bead beater (Biospec). Between each run, bacteria were placed on ice for 5 min to 
chill. Glass beads were settled by centrifugation at 200 × g for 1 min and the 
supernatant was transferred to a fresh tube. Subsequently, glass beads were washed 
with 40 ml of 0.1 M sodium citrate pH 4.7, sedimented as described above, and the 
supernatant was combined with the previous one. Bacterial debris were collected by 
centrifugation at 13,300 × g for 40 min and washed once with 45 ml of 0.1 M sodium 
citrate pH 4.7. For extracting LTA, the final pellet was suspended in 40 ml of 0.1 M 
sodium citrate pH 4.7, mixed with an equal volume of 1-buthanol and stirred for 30 
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min at RT. The sample was centrifuged at 13,300 × g for 40 min and the liquid 
transferred to a fresh tube before repeating the centrifugation step. The aqueous 
(lower) phase containing the LTA was retrieved and the extraction process was 
repeated once as described above. The final extract was dialyzed against two changes 
of 4 L of 20 mM sodium citrate pH 4.7 using a Spectra/Por 6 dialysis membrane 
(1,000-Da cutoff; Spectrum Laboratories, Inc.). Next, the sample was adjusted to give 
a final concentration of 15 % (v/v) 1-propanol in 0.1 M sodium citrate pH 4.7 and 
subsequently applied to a 24 × 1.6 cm octylsepharose column equilibrated with 15 % 
(v/v) 1-propanol in 0.1 M sodium citrate pH 4.7. The column was washed with 100 ml 
of 15 % (v/v) 1-propanol in 0.1 M sodium citrate pH 4.7 and LTA eluted with a linear 
15-65 % (v/v) 1-propanol gradient in 0.05 M sodium citrate pH 4.7. LTA containing 
fractions were identified by western blot, pooled and dialyzed in the cold 7-11 times 
against 4 L ddH2O and subsequently lyophilized.  
 
2.11.2 LTA structure analysis by NMR and biochemical assays 
          For NMR analysis, 1 mg purified LTA was suspended in 500 µl D2O of 99.96 
% purity (Sigma) and lyophilized. This procedure was repeated once, and the 
lyophilized LTA sample was then suspended in 500 µl D2O of 99.99 % purity (Sigma) 
and the 1d 1H NMR spectra recorded at 600 MHz (1H) and 300 K on a Bruker 
AvanceIII spectrometer equipped with a TCI cryoprobe. To ensure accurate integrals 
of species with potentially differing 1H T1 values, spectra were recorded with a total 
recycle time of 6 s and a 1H flip angle of ca. 60o. The length of the glycerolphosphate 
chain as well as the percentage of D-alanine substitution was calculated from the 1H 
NMR integrals of the appropriate LTA specific peaks. The LTA length calculation 
was based on a C15 : C18 fatty acid composition (59 non-exchangeable protons from 
CH2/CH3 groups), which is the most abundant lipid anchor present in S. aureus LTA 
(Fischer, 1994). Glucose, phosphate and D-alanine contents of LTA samples were 
determined using standard biochemical assays, which were performed as previously 
described (Grassl & Supp, 1995; Kunst et al, 1984; Schnitger et al, 1959). Assays to 
determine the glucose content of purified LTA samples were performed as follows: 
reactions containing 2 M HCl and 0.2 or 0.4 mg purified LTA were set up in a final 
volume of 60 µl. Standard reactions containing 0 to 5 mM glucose final concentration 
were prepared in the same manner in 60 µl 2M HCl. Samples were incubated at 95ºC 
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for 2 ½ h and subsequently neutralized by the addition of 60 µl 2 M NaOH. Next, 50 
µl of neutralized sample was transferred to a fresh tube and 1 ml solution 1 (4 mM 
MgSO4, 110 mM NaH2PO4, 3.2 mM HCl, 1.9 mM ATP, 1.6 mM NADP-Na2, pH 6.5 
adjusted with 2 M NaOH) was added. The mixture was transferred into a low UV 
cuvette (Fischer) and the absorbance was determined at 339 nm. Subsequently, 10 µl 
enzyme mix (1 U hexokinase (Sigma), 1.8 U glucose-6-phosphate dehydrogenase 
(Sigma), 100 mM MgSO4) was added and the reaction was incubated for 20 min at 
RT before measuring the absorbance a second time. The increase in the absorbance 
reflects the formation of NADPH, which is proportional to the glucose concentration 
in the sample. 
          For determining the D-alanine concentration of the purified LTA samples, 
assays were set up as follows: reactions were prepared in a final volume of 80 µl 
containing 0.2 M NaOH and 0.2 or 0.1 mg purified LTA. Standard reactions with D-
alanine concentrations ranging from 0 to 5 mM final concentration were included in 
the assay. Samples were incubated for 1 h at 37ºC and subsequently neutralized by the 
addition of 4 µl 2 M NaOH. Next, 50 µl neutralized sample was transferred to a low 
UV cuvette and 917 µl reaction buffer (0.1 M Tris pH 8.5, 0.27 mM NADH, 9.2 U 
lactate dehydrogenase (Fischer), 8.5 U catalase (Sigma)) was added. The absorbance 
was measured spectrophotometrically at 339 nm. Next, 66.6 µl of 37.5 U/ml D-
amino-acid oxidase (Sigma) was added, samples were incubated at RT for 20 min, 
and the absorbance was determined. The drop in NADH, measured by the absorbance 
at 339 nm, is proportional to the D-alanine concentration in the samples.  
          The phosphate concentration in the purified LTA samples was determined as 
follows: the assay was performed in a final volume of 280 µl containing 2 M HCl and 
40 or 80 µg purified LTA. Standard solutions ranging from 0 to 2.5 mM phosphate 
final concentration were included in the assay. Samples were incubated at 98ºC for 3 
h in a heat block before cooling. Subsequently, 400 µl of an acid solution (13.9 % 
(v/v) H2SO4, 2.6 % (v/v) HClO4) was added and samples incubated at 150ºC for 
further 3 h. Next, samples were cooled to RT and mixed with 2 ml reduction solution 
(19.1 mM (NH4)2MoO4, 0.25 M CH3COONa, 56.8 mM C6H8O6). The preparation was 
incubated at 37ºC for 2 h before measuring the absorbance at 578 nm. The regression 
line obtained from the standard solutions was used to determine the phosphate 
concentration in the LTA samples. LTA chain length and chain modification were 
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determined by calculating the ratio of the phosphate : ½ glucose concentration (2 
glucose molecules per LTA anchor) and the ratio of phosphate : D-alanine 
concentration, respectively. 
 
2.12 Strain and plasmid construction 
          Primers used in this study are listed in Table 2. Plasmid pitet-sec-eltaS was 
constructed for the expression of a secreted eLtaS version. This plasmid was obtained 
by amplifying the protein A signal peptide sequence from S. aureus RN4220 
chromosomal DNA with primers 401/404 and the eltaS sequence from plasmid 
pCL55-ltaS using primers 405/319. The resulting products were fused by SOE (Splice 
Overlap Extension) PCR (Horton et al, 1989) using primers 401/319. The final PCR 
product was digested with AvrII/BglII and ligated with plasmid pitet, which had been 
digested with the same enzymes. Plasmid pitet-sec-eltaS was initially obtained in E. 
coli XL1 Blue (strain ANG590) and subsequently integrated into the lipase gene geh 
of S. aureus ANG499, yielding strain ANG595 (pitet-sec-eltaS). 
          Plasmids pitet-TMsrtA-eltaS and pitet-5TMltaA-eltaS were constructed for the 
expression of LtaS variants with altered staphylococcal membrane domains. The 
TMsrtA sequence was amplified from S. aureus RN4220 chromosomal DNA using 
primers 427/432 and the eltaS coding sequence from plasmid pCL55-ltaS using 
primers 433/319. The 5TMltaA sequence was amplified from plasmid pCL55-ypfP/ltaA 
using primers 260/438 and the linker + eltaS sequence from plasmid pCL55-ltaS 
using primers 439/319. Appropriate PCR fragments were fused by SOE PCR with 
primers 427/319 (TMsrtA-eltaS) or 260/319 (5TMltaA-eltaS). The final PCR products 
were cloned as AvrII/BglII fragments into plasmid pitet as described above and 
recovered in E. coli XL1 Blue (strains ANG1211 and ANG1214). The plasmids were 
subsequently electroporated into S. aureus ANG499, yielding strains ANG1217 
(pitet-TMsrtA-eltaS) and ANG1220 (pitet-5TMltaA-eltaS). 
          Plasmids pitet-1TM-eltaS and pitet-3TM-eltaS were constructed for the 
expression of LtaS variants with shortened membrane domains. Gene fragments 
coding for the first or the first three TM helices of ltaS were amplified using primer 
318 in combination with primer 434 or 436 and the linker + eltaS sequence was 
amplified using primer 319 in combination with primer 435 or 437, respectively. 
pCL55-ltaS was used as template DNA for all PCR reactions. Respective PCR 
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products were fused by SOE PCR using primers 318/319 and the final PCR fragments 
were restriction digested with AvrII/BglII and ligated with plasmid pitet. The resulting 
plasmids were recovered in E. coli XL1 Blue, giving strains ANG1212 and ANG1213 
and subsequently introduced into S. aureus ANG499, yielding strains ANG1218 
(pitet-1TM-eltaS) and ANG1219 (pitet-3TM-eltaS). 
          Plasmids pCN34itet-sec-eltaS, pCN34itet-TMsrtA-eltaS, pCN34itet-1TM-eltaS, 
pCN34itet-3TM-eltaS, and pCN34itet-5TMltaA-eltaS were constructed for expression 
of the corresponding fusion proteins from a multi-copy plasmid vector. Respective 
gene-fusions and the pitet promoter region were amplified from plasmids pitet-sec-
eltaS, pitet-TMsrtA-eltaS, pitet-1TM-eltaS, pitet-3TM-eltaS and pitet-5TMltaA-eltaS 
using primer pair 159/877. The resulting PCR products and vector pCN34 were 
restriction digested with KpnI/PstI and ligated together. Plasmids were initially 
obtained in E. coli strain XL1 Blue (strains ANG2158-2162) and subsequently 
introduced into S. aureus ANG499, yielding strains ANG2165 (pCN34itet-sec-eltaS), 
ANG2166 (pCN34itet-TMsrtA-eltaS), ANG2167 (pCN34itet-1TM-eltaS), ANG2168 
(pCN34itet-3TM-eltaS), ANG2169 (pCN34itet-5TMltaA-eltaS).  
          Plasmids pCN34-5TM, pCN34-ltaS and pCN34itet-ltaST300A were constructed to 
investigate the functionality of a split enzyme. For the construction of plasmids 
pCN34-ltaS and pCN34-5TM, the full-length ltaS gene or the 5TM region were 
amplified including the ltaS promoter region from plasmid pCL55-ltaS using primer 
pairs 86/87 or 86/424, respectively. The PCR products and the pCN34 vector were 
digested with BamHI/SalI and ligated. For construction of plasmid pCN34itet-
ltaST300A, ltaST300A and the pitet promoter region were amplified from plasmid pitet-
ltaS-T300A using primers 159/800. The PCR product and pCN34 vector were 
restriction digested with KpnI/SalI and ligated. Plasmids were recovered in E. coli 
XL1 Blue resulting in strains ANG1221, ANG1222 and ANG1689. These three 
plasmids and the empty pCN34 vector were then electroporated into S. aureus 
ANG595, yielding strains ANG1226 (pCN34), ANG1227 (pCN34-5TM), ANG1228 
(pCN34-ltaS) and ANG1690 (pCN34itet-ltaST300A), respectively.  
          Plasmids pitet-ltaSS218P and pitet-ltaSE174 were constructed for the expression of 
LtaS variants with either a serine to proline substitution at amino acid position 218 or 
with a glutamate to proline substitution at amino acid position 174. The mutations 
were initially introduced by QuikChange mutagenesis (Stratagene) in vector pOK-ltaS 
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using primers 487/488 or 711/712 and the resulting plasmids pOK-ltaSS218P and pOK-
ltaSE174P were recovered in E. coli XL1 Blue (strains ANG1242 and ANG2182). The 
mutant ltaS alleles were then amplified using primers 318/319 and cloned as 
AvrII/BglII fragments into vector pitet. The plasmids pitet-ltaSS218P and pitet-ltaSE174P 
were recovered in E. coli XL1 Blue (strains ANG1244 and ANG2183) and 
subsequently electroporated into S. aureus strain ANG499, yielding strains ANG1246 
(pitet-ltaSS218P) and ANG2184 (pitet-ltaSE174P).  
          Plasmids pitet-ltaS-his and pitet-ltaSS218P-his were constructed for the 
expression of WT LtaS and the LtaSS218P variant fused to a C-terminal His-tag and 
used for protein purification from supernatants of S. aureus cultures. Respective genes 
were amplified from plasmids pCL55-ltaS and pitet-ltaSS218P using primers 318/420. 
The PCR products and the pitet plasmid were restriction digested with AvrII/BglII and 
ligated. Plasmids were obtained in E. coli XL1 Blue (strains ANG584 and ANG1368) 
and subsequently electroporated into S. aureus ANG499, yielding strains ANG587 
(pitet-ltaS-his) and ANG1370 (pitet-ltaSS218P-his).  
          Plasmids pitet-yfnITMlink-eltaS, pitet-ltaSTmlink-eyfnI-his, pitet-yqgSTmlink-eltaS, 
pitet-ltaSTmlink-eyqgS-his, pitet-ltaSTM-linkeyfnI-his, pitet-yfnITM-linkeltaS, pitet-ltaSTM-
linkeyflE-his, pitet-yflETM-linkeltaS, pitet-yflETM-linkeyfnI-his, pitet-yflETmlink-eyfnI-his were 
constructed to study the function of hybrid fusions between S. aureus/B. subtilis LtaS-
type enzymes. Plasmids pitet-yfnITMlink-eltaS and pitet-yfnITM-linkeltaS were constructed 
by amplifying the yfnITM and the yfnITM + linker sequence from plasmid pCL55-yfnI 
using primer 322 in combination with primer 495 or 525. The eltaS and the linker + 
eltaS sequence were amplified from plasmid pCL55-ltaS using primer 319 in 
combination with primers 494 or 524. Appropriate PCR fragments were fused by 
SOE PCR with primers 322/319. The final PCR products were digested with 
AvrII/BglII and ligated with plasmid pitet, which has been digested with the same 
enzymes. Plasmids were recovered in E. coli XL1 Blue (strains ANG1330 and 
ANG1335) and subsequently electroporated into S. aureus ANG499, yielding strains 
ANG1340 (pitet-yfnITMlink-eltaS) and ANG1345 (pitet-yfnITM-linkeltaS). For the 
construction of plasmids pitet-ltaSTmlink-eyfnI-his and pitet-ltaSTM-linkeyfnI-his the ltaSTM 
and the ltaSTM + linker sequence were amplified from plasmid pCL55-ltaS using 
primer 318 in combination with primers 497 or 523. The eyfnI and the linker + eyfnI 
sequence were amplified from plasmid pCL55-yfnI using primer 504 in combination 
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with primer 496 or 522 and C-terminal His-tags were introduced with the downstream 
primers. Respective PCR fragments were fused by SOE PCR using primers 318/504. 
The final PCR products were cloned as AvrII/BglII fragments into plasmid pitet as 
described above and recovered in E. coli XL1 Blue (strains ANG1331 and ANG1334) 
The plasmids were subsequently electroporated into S. aureus ANG499, yielding 
strains ANG1341 (pitet-ltaSTmlink-eyfnI-his) and ANG1344 (pitet-ltaSTM-linkeyfnI-his). 
Plasmids pitet-yflETM-linkeyfnI-his and pitet-yflETmlink-eyfnI-his were created by 
amplifying the yflETM and the yflETM + linker sequence from plasmid pCL55-yflE 
using primer 326 in combination with primers 615/617. The eyfnI and the linker + 
eyfnI sequence were amplified from plasmid pCL55-yfnI using primer 504 in 
combination with primer 614 or 616 and C-terminal His-tags were introduced with the 
downstream primers. Appropriate PCR fragments were fused by SOE PCR using 
primers 318/504. The final PCR products were cloned as AvrII/BglII fragments into 
plasmid pitet as described above. Plasmids were initially obtained in E. coli XL1 Blue 
(strains ANG1338 and ANG1339) and subsequently electroporated into S. aureus 
strain ANG499, yielding strains ANG1348 (pitet-yflETM-linkeyfnI-his) and ANG1349 
(pitet-yflETmlink-eyfnI-his). Plasmids pitet-ltaSTM-linkeyflE-his and pitet-ltaSTmlink-eyqgS-
his were constructed by amplifying the ltaSTM and the ltaSTM + linker sequence from 
plasmid pCL55-ltaS using primer 318 in combination with primers 528/501. The 
eyqgS sequence was amplified from plasmid pCL55-yqgS with primer pair 500/503 
and the linker + eyflE sequence was amplified from plasmid pCL55-yflE with primer 
pair 529/502. C-terminal His-tags were introduced with the downstream primers. 
Respective PCR fragments were fused by SOE PCR using primers 318/503 (ltaSTmlink-
eyqgS-his) and 318/502 (ltaSTM-linkeyflE-his). The final PCR products were cloned as 
AvrII/BglII fragments into plasmid pitet as described above. Plasmids were recovered 
in E. coli XL1 Blue (strain ANG1333) and CLG190 (strain ANG1336) and 
subsequently introduced into S. aureus strain ANG499, yielding strains ANG1343 
(pitet-ltaSTmlink-eyqgS-his) and ANG1346 (pitet-ltaSTM-linkeyflE-his). For the 
construction of plasmids pitet-yqgSTmlink-eltaS and pitet-yflETM-linkeltaS the yqgSTM + 
linker sequence was amplified from plasmid pCL55-yqgS using primers 330/499 and 
the yflETM sequence was amplified from plasmid pCL55-yflE using primers 326/526. 
The eltaS and the linker + eltaS sequence were amplified from plasmid pCL55-ltaS 
using primer 319 in combination with primers 498/527. Appropriate PCR fragments 
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were fused by SOE-PCR using primer pairs 330/319 (yqgSTmlink-eltaS) and 326/319 
(yflETM-linkeltaS). The final PCR products were cloned as AvrII/BglII fragments into 
plasmid pitet as described above. Plasmids were recovered in E. coli XL1 Blue 
(strains ANG1332 and ANG1337) and subsequently electroporated into S. aureus 
strain ANG499, yielding strains ANG1342 (pitet-yqgSTmlink-eltaS) and ANG1347 
(pitet-yflETM-linkeltaS). S. aureus strain ANG1350 and ANG1351 were constructed as 
follows. The yfnITM and the yfnITM + linker sequence were amplified from plasmid 
pCL55-yfnI using primer 322 in combination with primers 619/621. The eyflE and the 
linker + eyflE sequence were amplified from plasmid pCL55-yflE using primer 502 in 
combination with primers 618/620 and C-terminal His-tags were introduced with the 
downstream primers. Appropriate PCR fragments were fused by SOE PCR using 
primers 322/502. The final PCR products were cloned as AvrII/BglII fragments into 
plasmid pitet as described above. Plasmids were directly electroporated into S. aureus 
ANG499, yielding strains ANG1350 (pitet-yfnITM-linkeyflE-his) and ANG1351 (pitet-
yfnITmlink-eyflE-his). Plasmids pCL55-yfnI and pCL55-yflE, which were used as DNA 
templates in PCR reactions described above were constructed as follows: yfnI and yflE 
genes were amplified from B. subtilis 168 chromosomal DNA using primer pair 
320/321 and 324/325. Resulting PCR products were restriction digested with BamHI 
and KpnI and ligated with plasmid pCL55, which had been digested with the same 
enzymes. Plasmids were subsequently transformed into E. coli strain XL1 Blue giving 
strain ANG504 (pCL55-yfnI) or CLG190 giving strain ANG505 (pCL55-yflE). 
          A S. aureus strain with IPTG inducible spsB expression was constructed to 
study the effect on LtaS cleavage upon SpsB depletion. For this strain construction the 
plasmid pCN34itetH, which contains an Atet inducible promoter system, was used. 
This plasmid was constructed by amplifying the Atet promoter / repressor region from 
plasmid pALC2073 using primers 909/948 in the first and primers 908/948 in a 
second PCR reaction to extend the multiple cloning site. The PCR product and vector 
pCN34 were digested NarI/XmaI and ligated. The resulting plasmid pCN34itetH was 
recovered in E. coli XL1 Blue yielding ANG1631. Next, the spsB gene was amplified 
from S. aureus RN4220 chromosomal DNA using primers 1007/1008. The PCR 
product and the plasmid pCN34itetH were digested KpnI/SalI and ligated. The 
resulting plasmid pCN34itetH-spsB was initially recovered in E. coli XL1 Blue (strain 
ANG1811) and subsequently introduced into S. aureus SEJ1, yielding strain 
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ANG1816 (pCN34itetH-spsB). Plasmid pTS1-ΔspsB::erm was constructed for the 
deletion of the spsB gene. One kb fragments up- and downstream of spsB were 
amplified from RN4220 genomic DNA with primers 1010/1011 and 1013/1015 and 
the erm cassette was amplified from plasmid pMutin-HA using primers 1012/1014. 
The three purified PCR products were fused by SOE PCR using primers 1010/1015 
and the final PCR product and vector pTS1 were digested KpnI/EcoRI and ligated. 
The plasmid pTS1-ΔspsB::erm was recovered in E. coli XL1 Blue (strain ANG1815) 
and subsequently introduced into S. aureus ANG1816 (SEJ1 pCN34itetH-spsB) and 
stably maintained at 30°C in the presence of chloramphenicol (Cam) and Kanamycin 
(Kan). Shifting the temperature to 43°C resulted in a single cross over event and 
integration of the pTS1-ΔspsB::erm plasmid into the chromosome. After confirming 
the chromosomal integration by PCR, the culture was shifted back to 30°C and 
growth in the absence of Cam but presence of 50 ng/ml Atet (to induce SpsB 
expression from the covering plasmid pCN34itetH-spsB) allowed for the second 
crossover event and deletion/replacement of the chromosomal spsB gene with an erm 
marker. Erm resistance of the resulting S. aureus strain ANG1820 (SEJ1 spsB::erm 
pCN34itetH-spsB) was confirmed on selective antibiotic plates and the replacement of 
the spsB gene with the erm marker was verified by PCR. The basal expression of 
SpsB from the covering plasmid pCN34itetH-spsB, even in the absence of Atet, was 
too high to use this strain for any further analysis. To this end, S. aureus strain 
ANG2009 with tightly controlled spsB expression was constructed, by transducing the 
chromosomal spsB::erm deletion from strain ANG1820 into S. aureus strain 
ANG2008 that contained a copy of the spsB gene under IPTG inducible spac 
promoter control at a different chromosomal location. For this strain construction, an 
internal BamHI site in spsB needed to be inactivated for cloning purposes. This was 
done by introducing a T to C nucleotide substitution at position 114 within the spsB 
coding sequence by QuikChange mutagenesis in plasmid pCN34itetH-spsB using 
primers 1203/1204. This mutation does not alter the protein sequence. Plasmid 
pCN34itetH-spsB-T114C was recovered in E. coli XL1 Blue yielding strain 
ANG1963. Next, the mutated spsB allele was amplified using primers 896/1183 and 
the resulting product and vector pMutin-HA were digested HindIII/KpnI and ligated. 
The plasmid pMutinHA-spsB-T114C was recovered in E. coli XL1 Blue giving strain 
ANG1964. Subsequently, the mutated spsB allele including the IPTG inducible spac 
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promoter and lacI repressor region were excised by restriction digesting plasmid 
pMutinHA-spsB-T114C with BamHI and the appropriate DNA fragment was gel 
purified and ligated with the BamHI cut S. aureus single site integration vector 
pCL55. The plasmid pCL55spac-spsB-T114C was obtained in E. coli XL1 Blue 
(strain ANG2007) and subsequently electroporated into S. aureus SEJ1, yielding 
strain ANG2008 (SEJ1 Pspac-spsB). The spsB::erm region from strain ANG1820 
described above was then transduced using phage Φ85 into strain ANG2008, yielding 
strain ANG2009 (SEJ1 spsB::erm Pspac-spsB) with tightly controlled IPTG inducible 
spsB expression.  
          Plasmids pCN34itet-ltaS, pCN34itet-yfnI, pCN34itet-yflE, pCN34itet-yvgJ and 
pCN34itet-yqgS were constructed to study the functions of the corresponding proteins 
in an S. aureus ltaS depletion strain. For the construction of plasmids pCN34itet-ltaS 
and pCN34itet-yfnI, respective genes and the pitet promoter region were amplified 
from plasmids pitet-ltaS and pitet-yfnI using primer pairs 159/800 and 159/821, 
respectively. The resulting PCR products were restriction digested with KpnI/SalI 
(ltaS) or KpnI (yfnI) and cloned into pCN34 that has been digested with KpnI/SalI 
(ltaS cloning) or KpnI/SmaI (yfnI cloning). For pCN34itet-yflE, pCN34itet-yvgJ and 
pCN34itet-yqgS plasmid construction, the respective genes and the pitet promoter 
were amplified from plasmids pitet-yflE, pitet-yvgJ and pitet-RBltaS-yqgS using 
primer pair 159/877. The resulting PCR products were restriction digested with KpnI 
and PstI and ligated with pCN34, which has been digested with the same enzymes. 
Plasmids were subsequently transformed into E. coli XL1 Blue resulting in strains 
ANG1512, ANG1514, ANG1660, ANG1656 and ANG1652. These plasmids and the 
empty pCN34 control vector were then electroporated into the ltaS-inducible S. 
aureus strain ANG499, yielding strains ANG1130 (pCN34), ANG1571 (pCN34itet-
ltaS), ANG1573 (pCN34itet-yfnI), ANG1662 (pCN34itet-yflE), ANG1658 
(pCN34itet-yvgJ) and ANG1654 (pCN34itet-yqgS). Plasmid pitet-RBltaS-yqgS, 
which was used to amplify yqgS for the construction of pCN34itet-yqgS, contains the 
yqgS gene proceeded by the S. aureus ltaS ribosome binding site (RBS) under 
tetracycline inducible promoter control. This plasmid was obtained by amplifying the 
ltaS promoter and ribosomal binding site from plasmid pCL55-ltaS using primer pair 
086/775 and the yqgS coding sequence from plasmid pCL55-yqgS using primer pair 
796/331. The resulting PCR products were fused by SOE PCR using primer pair 
 
 
72 
826/331. The final PCR product was digested with AvrII/BglII and yqgS with the ltaS 
RBS was placed under tetracycline inducible promoter control by ligating the digested 
PCR product with the AvrII/BglII digested plasmid pitet. The resulting plasmid pitet-
RBltaS-yqgS was transformed into E. coli strain XL1 Blue, yielding strain ANG1615.  
          Plasmids pCN34itet-ltaS-his, pCN34itet-yfnI-his, pCN34itet-yflE-his, 
pCN34itet-yvgJ-his and pCN34itet-yqgS-his were constructed for protein detection 
purposes in S. aureus. For the construction of plasmids pCN34itet-ltaS-his and 
pCN34itet-yfnI-his, respective genes and the pitet promoter region were amplified 
from plasmids pitet-ltaS-his and pitet-yfnI-his using primer pairs 159/800 and 
159/821, respectively. The resulting PCR products were restriction digested with 
KpnI/SalI (ltaS) or KpnI (yfnI) and cloned into pCN34 that has been digested with 
KpnI/SalI (ltaS cloning) or KpnI/SmaI (yfnI cloning). Plasmids were initially 
recovered in E. coli XL1 Blue (strains ANG1513 and ANG1515) and subsequently 
electroporated into S. aureus strain ANG499, yielding strains ANG1572 (pCN34itet-
ltaS-his) and ANG1574 (pCN34itet-yfnI-his). Plasmids pCN34itet-yflE-his, 
pCN34itet-yvgJ-his and pCN34itet-yqgS-his were constructed by amplifying 
respective genes and the pitet promoter region from plasmids pitet-yflE, pitet-yvgJ and 
pitet-RBltaS-yqgS using primer 159 in combination with primer 912/879/895. The C-
terminal His-tags were introduced with the downstream primers. The PCR products 
and the pCN34 vector were restriction digested with KpnI/PstI and ligated. Plasmids 
were initially obtained in E. coli XL1 Blue (strains ANG1661, ANG1657 and 
ANG1653) and subsequently introduced into S. aureus strain ANG499, yielding 
strains ANG1663 (pCN34itet-yflE-his), ANG1659 (pCN34itet-yvgJ-his) and 
ANG1655 (pCN34itet-yqgS-his). Plasmid pitet-yfnI-his, which was used to amplify 
yfnI for the construction of pCN34itet-yfnI-his, was constructed as follows: the yfnI 
gene was amplified from pitet-yfnI using primer 504/322 and the C-terminal His-tag 
was introduced with the downstream primer. The resultant PCR product was 
restriction digested with AvrII/BglII and ligated with pitet, which has been digested 
with the same enzymes. The plasmid was initially obtained in E. coli strain XL1 Blue 
(strain ANG1280) and subsequently electroporated into S. aureus strain ANG499, 
yielding strains ANG1282 (pitet-yfnI-his). 
          Plasmids pCN34PltaS-sipT, pCN34PltaS-sipV, pCN34PltaS-sipT/S and pCN34PltaS-
sipV/S were constructed to investigate YfnI processing in the presence of B. subtilis 
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signal peptidases. For the construction of plasmids pCN34PltaS-sipT and pCN34PltaS-
sipV the native ltaS promoter region was amplified from plasmid pCL55-ltaS using 
primer 086 in combination with primers 623/627 and the sipT and sipV genes were 
amplified from B. subtilis 168 chromosomal DNA using primers 622/624 and 
626/628. Appropriate PCR fragments were fused by SOE PCR with primers 086/624 
(PltaS-sipT) or 086/628 (PltaS-sipV). The final PCR products were restriction digested 
with BamHI/SalI and ligated with plasmid pCN34, which has been digested with the 
same enzymes. Plasmids were transformed into E. coli XL1 Blue, giving strains 
ANG1355 and ANG1357. These plasmids and the empty pCN34 vector control were 
introduced into S. aureus ANG1282, yielding strains ANG1708 (pCN34), ANG1359 
(pCN34 PltaS-sipT) and ANG1361 (pCN34 PltaS-sipV). Plasmids pCN34PltaS-sipT/S and 
pCN34PltaS-sipV/S were constructed by amplifying the sipT or sipV gene and the native 
ltaS promoter region from plasmids pCN34 PltaS-sipT and pCN34 PltaS-sipV using primer 
086 in combination with primers 743/745. The sipS gene was amplified from B. 
subtilis 168 chromosomal DNA using primers 742/714 and 744/714. Respective PCR 
fragments were fused by SOE PCR using primers 087/714. The final PCR products 
were cloned into BamHI/SalI sides of plasmid pCN34 as described above and 
recovered in E. coli XL1 Blue (strain ANG1526) and CLG190 (ANG1522). The 
plasmids were subsequently electroporated into S. aureus ANG1282, yielding strains 
ANG1524 (pCN34PltaS-sipT/S) and ANG1528 (pCN34PltaS-sipV/S). 
          Plasmids pCN34PltaS-sipT-his, pCN34PltaS-sipV-his, pCN34PltaS-sipT/S-his and 
pCN34PltaS-sipV/S-his were constructed for detection of the corresponding proteins in 
S. aureus. For the construction of plasmids pCN34PltaS-sipT-his and pCN34PltaS-sipV-
his the respective genes were amplified from B. subtilis 168 chromosomal DNA using 
primers 622/625 and 626/629 and C-terminal His-tags were introduced with the 
downstream primers. The ltaS promoter region was amplified from plasmid pCL55-
ltaS using primer 086 in combination with primers 623/627. Appropriate PCR 
fragments were fused by SOE PCR with primers 086/625 (PltaS-sipT-his) or 086/629 
(PltaS-sipV-his). The final PCR products were restriction digested with BamHI/SalI and 
ligated with plasmid pCN34, which has been digested with the same enzymes. 
Plasmids were initially recovered in E. coli XL1 Blue (strain ANG1356 and 
ANG1358) and subsequently electroporated into strain ANG1282, yielding strain 
ANG1360 (PltaS-sipT-his) and ANG1362 (PltaS-sipV-his). Plasmids pCN34PltaS-sipT/S-his 
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and pCN34PltaS-sipV/S-his were constructed by amplifying the sipT or sipV gene and 
the native ltaS promoter region from plasmids pCN34 PltaS-sipT and pCN34 PltaS-sipV 
using primer 086 in combination with primers 743/745. The sipS gene was amplified 
from B. subtilis 168 chromosomal DNA using primers 742/715 and 744/715 and the 
C-terminal His-tags were introduced with the downstream primers. Respective PCR 
fragments were fused by SOE PCR using primers 087/715. The final PCR products 
were cloned into BamHI/SalI sides of plasmid pCN34 as described above and 
recovered in E. coli XL1 Blue (strain ANG1527) and CLG190 (ANG1523). The 
plasmids were subsequently electroporated into S. aureus ANG1282, yielding strains 
ANG1525 (pCN34PltaS-sipT/S-his) and ANG1529 (pCN34PltaS-sipV/S-his). S. aureus 
strain ANG1598 served as a control strain and this strain was obtained by introducing 
the empty pCN34 vector control plasmid into S. aureus strain ANG587, yielding 
strain ANG1598 (pCN34). Sequences of all inserts were verified by fluorescence 
automated sequencing at the MRC Clinical Science Center Sequencing Facility at 
Imperial College London. Note that the following plasmids and strains were 
constructed by Dr. A. Gründling: pCL55-yfnI, pCL55-yflE, pitet-ltaS-his, pCN34itetH, 
pCN34itet-ltaS, pCN34itet-ltaS-his, pCN34itet-yfnI, pCN34itet-yfnI-his and S. aureus 
strain ANG587 (pitet-ltaS-his). 
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Tables 
Table 1: Bacterial strains used in this study 
Strain Relevant features Reference 
 Escherichia coli strains  
XL1 Blue Cloning strain, TetR – ANG127 Stratagene 
CLG190 Cloning strain, which reduces plasmid copy number, TetR – ANG1141 Dana Boyd 
(Gründling et al, 2003) 
ANG126 pTS1 in DH5α; vector with temperature sensitive replication in S. aureus; AmpR (O'Connell et al, 1993) 
ANG201 pCN34 in E. coli; E. coli / S. aureus shuttle vector; KanR and AmpR (Charpentier et al, 2004) 
ANG243 pCL55 in XL1 Blue; S. aureus single-site integration vector; AmpR (Lee et al, 1991) 
ANG284 pitet in XL1 Blue; pCL55 containing Atet-inducible promoter; AmpR (Gründling & 
Schneewind, 2007b) 
ANG374 pCL55-ypfP/ltaA in XL1 Blue: AmpR (Gründling & 
Schneewind, 2007b) 
ANG474 
 
ANG482 
pMutin-HA in E. coli; AmpR 
 
pOK in XL1 Blue; KanR 
Bacillus Genetic Stock 
Center 
(Gründling & 
Schneewind, 2007a) 
ANG483 pOK-ltaS in XL1 Blue; KanR (Gründling & 
Schneewind, 2007a) 
ANG503 pCL55-ltaS in XL1 Blue; AmpR (Wörmann et al, 2011) 
ANG504 pCL55-yfnI in XL1 Blue; AmpR Lab strain 
ANG505 pCL55-yflE in CLG190; AmpR Lab strain 
ANG506 pCL55-yqgS in XL1 Blue; AmpR (Wörmann et al, 2011) 
ANG508 pitet-ltaS in XL1 Blue; ltaS under Atet inducible promoter; AmpR (Gründling & 
Schneewind, 2007a) 
ANG509 pitet-yfnI in XL1 Blue; yfnI under Atet inducible promoter; AmpR (Gründling & 
Schneewind, 2007a) 
ANG510 pitet-yflE in XL1 Blue; yflE under Atet inducible promoter; AmpR (Gründling & 
Schneewind, 2007b) 
ANG512 pitet-yvgJ in XL1 Blue; yvgJ under Atet inducible promoter; AmpR (Gründling & 
Schneewind, 2007b) 
ANG584 pitet-ltaS-his in XL1 Blue; ltaS with C-terminal His-tag under Atet inducible 
promoter control; AmpR 
Lab strain 
ANG590 pitet-sec-eltaS in XL1 Blue; protein A signal peptide fused to eltaS domain under 
Atet inducible promoter control; AmpR 
This study 
ANG1112 pitet-ltaS-T300A in XL1 Blue; ltaS-T300A allele under Atet inducible promoter 
control; AmpR 
(Lu et al, 2009) 
ANG1211 pitet-TMsrtA-eltaS in XL1 Blue; sortase TM fused to eltaS domain under Atet 
inducible promoter control; AmpR 
This study 
ANG1212 pitet-1TM-eltaS in XL1 Blue; first TM of ltaS fused to linker + eltaS domain 
under Atet inducible promoter control; AmpR 
This study 
ANG1213 pitet-3TM-eltaS in XL1 Blue; first 3TM of ltaS fused to linker + eltaS domain 
under Atet inducible promoter control; AmpR 
This study 
ANG1214 pitet-5TMltaA-eltaS in XL1 Blue; first 5TM of ltaA fused to linker + eltaS domain 
under Atet inducible promoter control; AmpR 
This study 
ANG1221 pCN34-5TM in XL1 Blue; 5TM of ltaS under native promoter control; KanR, 
AmpR 
This study 
ANG1222 pCN34-ltaS in XL1 Blue; ltaS under native promoter control; KanR, AmpR This study 
ANG1242 pOK-ltaSS218P in XL1 Blue; ltaS-S218P allele under native promoter control; 
KanR 
This study 
ANG1244 pitet-ltaSS218P in XL1 Blue; ltaS-S218P allele under Atet inducible promoter 
control; AmpR 
This study 
ANG1280 pitet-yfnI-his in XL1 Blue; yfnI with C-terminal His-tag under Atet inducible 
promoter control; AmpR 
This study 
ANG1330 pitet-yfnITMlink-eltaS in XL1 Blue; 5TM and linker of yfnI fused to eltaS domain 
under Atet inducible promoter control; AmpR 
This study 
ANG1331 pitet-ltaSTmlink-eyfnI-his in XL1 Blue; 5TM and linker of ltaS fused to eyfnI 
domain with C-terminal His-tag under Atet inducible promoter control; AmpR 
This study 
ANG1332 pitet-yqgSTmlink-eltaS in XL1 Blue; 5TM and linker of yqgS fused to eltaS domain 
under Atet inducible promoter control; AmpR 
This study 
ANG1333 pitet-ltaSTmlink-eyqgS-his in XL1 Blue; 5TM and linker of ltaS fused to eyqgS 
domain with C-terminal His-tag under Atet inducible promoter control; AmpR 
This study 
ANG1334 pitet-ltaSTM-linkeyfnI-his in XL1 Blue; 5TM of ltaS fused to linker + eyfnI domain 
with C-terminal His-tag under Atet inducible promoter control; AmpR 
This study 
ANG1335 pitet-yfnITM-linkeltaS in XL1 Blue; 5TM of yfnI fused to linker + eltaS domain 
under Atet inducible promoter control; AmpR 
This study 
ANG1336 pitet-ltaSTM-linkeyflE-his in CLG190; 5TM of ltaS fused to linker + eyflE domain 
with C-terminal His-tag under Atet inducible promoter control; AmpR 
This study 
ANG1337 pitet-yflETM-linkeltaS in XL1 Blue; 5TM of yflE fused to linker + eltaS domain 
under Atet inducible promoter control; AmpR 
This study 
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ANG1338 pitet-yflETM-linkeyfnI-his in XL1 Blue; 5TM of yflE fused to linker + eyfnI domain 
with C-terminal His-tag under Atet inducible promoter control; AmpR 
This study 
ANG1339 pitet-yflETmlink-eyfnI-his in XL1 Blue; 5TM and linker of yflE fused to eyfnI 
domain with C-terminal His-tag under Atet inducible promoter control; AmpR 
This study 
ANG1355 pCN34PltaS-sipT in XL1 Blue; sipT under ltaS promoter control; KanR, AmpR This study 
ANG1356 pCN34PltaS-sipT-his in XL1 Blue; sipT with C-terminal His-tag under ltaS 
promoter control; KanR, AmpR 
This study 
ANG1357 pCN34PltaS-sipV in XL1 Blue; sipV under ltaS promoter control; KanR, AmpR This study 
ANG1358 pCN34PltaS-sipV-his in XL1 Blue; sipV with C-terminal His-tag under ltaS 
promoter control; KanR, AmpR 
This study 
ANG1368 pitet-ltaSS218P-his in XL1 Blue; ltaS-S218P allele with C-terminal His-tag under 
Atet inducible promoter control; AmpR 
This study 
ANG1474 pProEX-eYflE in Rosetta strain; strain use for overexpression of eYflE protein 
with N-terminal His tag; AmpR 
(Wörmann et al, 2011) 
ANG1475 pProEX-eYfnI in Rosetta strain; strain use for overexpression of eYfnI protein 
with N-terminal His tag; AmpR 
(Wörmann et al, 2011) 
ANG1476 pProEX-eYvgJ in Rosetta strain; strain use for overexpression of eYvgJ protein 
with N-terminal His tag; AmpR 
(Wörmann et al, 2011) 
ANG1477 pProEX-eYqgS in Rosetta strain; strain use for overexpression of eYqgS protein 
with N-terminal His tag; AmpR 
(Wörmann et al, 2011) 
ANG1512 pCN34itet-ltaS in XL1 Blue; ltaS under Atet inducible promoter; KanR, AmpR (Wörmann et al, 2011) 
ANG1513 pCN34itet-ltaS-his in XL1 Blue; ltaS with C-terminal His-tag under Atet 
inducible promoter; KanR, AmpR 
Lab strain 
ANG1514 pCN34itet-yfnI in XL1 Blue; yfnI under tetracycline inducible promoter; KanR, 
AmpR 
(Wörmann et al, 2011) 
ANG1515 pCN34itet-yfnI-his in XL1 Blue; yfnI with C-terminal His-tag under Atet 
inducible promoter; KanR, AmpR 
Lab strain 
ANG1522 pCN34PltaS-sipT/S in CLG190; sipT and sipS under ltaS promoter control; KanR, 
AmpR 
This study 
ANG1523 pCN34PltaS-sipT/S-his in CLG190; sipT and sipS with C-terminal His-tag under 
ltaS promoter control; KanR, AmpR 
This study 
ANG1526 pCN34PltaS-siV/S in XL1 Blue; sipV and sipS under ltaS promoter control; KanR, 
AmpR 
This study 
ANG1527 pCN34PltaS-sipV/S-his in XL1 Blue; sipV and sipS with C-terminal His-tag under 
ltaS promoter control; KanR, AmpR 
This study 
ANG1577 pALC2073 in XL1 Blue; AmpR – ANG1577 (Bateman et al, 2001) 
ANG1615 pitet-RbltaS-yqgS in XL1 Blue; yqgS with ltaS ribosomal binding site under 
tetracycline inducible promoter; AmpR 
This study 
(Wörmann et al, 2011) 
ANG1631 pCN34itetH in XL1 Blue; pCN34 containing Atet inducible promoter from 
pALC2073; KanR, AmpR 
Lab strain 
ANG1652 pCN34itet-yqgS in XL1 Blue; yqgS under tetracycline inducible promoter; KanR, 
AmpR 
This study 
(Wörmann et al, 2011) 
ANG1653 pCN34itet-yqgS-his in XL1 Blue; yqgS with C-terminal His-tag under Atet 
inducible promoter; KanR, AmpR 
This study 
ANG1656 pCN34itet-yvgJ in XL1 Blue; yvgJ under tetracycline inducible promoter; KanR, 
AmpR 
This study 
(Wörmann et al, 2011) 
ANG1657 pCN34itet-yvgJ-his in XL1 Blue; yvgJ with C-terminal His-tag under Atet 
inducible promoter; KanR, AmpR 
This study 
ANG1660 pCN34itet-yflE in XL1 Blue; yflE (ltaSBS) under tetracycline inducible promoter; 
KanR, AmpR 
This study 
(Wörmann et al, 2011) 
ANG1661 pCN34itet-yflE-his in XL1 Blue; yflE with C-terminal His-tag under Atet 
inducible promoter; KanR, AmpR 
This study 
ANG1689 pCN34itet-ltaST300A in XL1 Blue; ltaS-T300A allele under Atet inducible 
promoter control; KanR, AmpR 
This study 
ANG1811 pCN34itetH-spsB in XL1 Blue; spsB under Atet inducible promoter; KanR, AmpR This study 
ANG1815 pTS1-ΔspsB::erm in XL1 Blue; AmpR This study 
ANG1963 pCN34itetH-spsB-T114C in XL1 Blue; spsB with point mutation T114C under 
Atet inducible promoter control; KanR, AmpR 
This study 
ANG1964 pMutinHA-spsB-T114C in XL1 Blue; spsB with point mutation T114C under 
IPTG inducible promoter control; AmpR 
This study 
ANG2007 pCL55spac-spsB-T114C in XL1 Blue; spsB with point mutation T114C under 
IPTG inducible promoter control; KanR, AmpR 
This study 
ANG2158 pCN34itet-sec-eltaS in XL1 Blue; protein A signal peptide fused to eltaS domain 
under Atet inducible promoter control; KanR, AmpR 
This study 
ANG2159 pCN34itet-TMsrtA-eltaS in XL1 Blue; sortase TM fused to eltaS domain under Atet 
inducible promoter control; KanR, AmpR 
This study 
ANG2160 pCN34itet-1TM-eltaS in XL1 Blue; first TM of ltaS fused to linker + eltaS 
domain under Atet inducible promoter control; KanR, AmpR 
This study 
ANG2161 pCN34itet-3TM-eltaS in XL1 Blue; first 3TM of ltaS fused to linker + eltaS 
domain under Atet inducible promoter control; KanR, AmpR 
This study 
ANG2162 pCN34itet-5TMltaA-eltaS in XL1 Blue; first 5TM of ltaA fused to linker + eltaS 
domain under Atet inducible promoter control; KanR, AmpR 
This study 
ANG2182 
 
 
pOK-ltaSE174P in XL1 Blue; ltaS-E174P allele under native promoter control; 
KanR 
This study 
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ANG2183 pitet-ltaSE174P in XL1 Blue; ltaS-E174P allele under Atet inducible promoter 
control; AmpR 
This study 
   
 Staphylococcus aureus strains  
RN4220 Transformable laboratory strain – ANG113 (Kreiswirth et al, 1983) 
SEJ1 RN4220Δspa – ANG314 (Gründling & 
Schneewind, 2007a; 
Gründling & Schneewind, 
2007b) 
COL methicillin resistance clinical strain – ANG527 (Sabath et al, 1972) 
ANG499 RN4220-iltaS; strain with IPTG-inducible ltaS expression; ErmR, IPTG (Gründling & 
Schneewind, 2007a) 
ANG513 pitet integrated in strain ANG499; ErmR, CamR, IPTG (Gründling & 
Schneewind, 2007a) 
ANG514 
 
ANG515 
pitet-ltaS integrated in strain ANG499; ErmR, CamR, IPTG 
 
pitet-yfnI integrated in strain ANG499; ErmR, CamR, IPTG 
(Gründling & 
Schneewind, 2007a) 
(Gründling & 
Schneewind, 2007a) 
ANG587 pitet-ltaS-his integrated in strain ANG499; ErmR, CamR, IPTG Lab strain 
ANG595 pitet-sec-eltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1130 ANG499 with pCN34; ErmR, KanR, IPTG This study 
(Wörmann et al, 2011) 
ANG1217 pitet-TMsrtA-eltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1218 pitet-1TM-eltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1219 pitet-3TM-eltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1220 pitet-5TMltaA-eltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1226 ANG595 with pCN34; ErmR, CamR, Kan, IPTG This study 
ANG1227 ANG595 with pCN34-5TM; ErmR, CamR, Kan, IPTG This study 
ANG1228 ANG595 with pCN34-ltaS; ErmR, CamR, Kan, IPTG This study 
ANG1246 pitet-ltaSS218P integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1282 pitet-yfnI-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1340 pitet-yfnITmlink-eltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1341 pitet-ltaSTmlink-eyfnI-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1342 pitet-yqgSTmlink-eltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1343 pitet-ltaSTmlink-eyqgS-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1344 pitet-ltaSTM-linkeyfnI-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1345 pitet-yfnITM-linkeltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1346 pitet-ltaSTM-linkeyflE-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1347 pitet-yflETM-linkeltaS integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1348 pitet-yflETM-linkeyfnI-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1349 pitet-yflETmlink-eyfnI-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1350 pitet-yfnITM-linkeyflE-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1351 pitet-yfnITmlink-eyflE-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1359 ANG1282 with pCN34PltaS-sipT; ErmR, CamR, Kan, IPTG This study 
ANG1360 ANG1282 with pCN34PltaS-sipT-his; ErmR, CamR, Kan, IPTG This study 
ANG1361 ANG1282 with pCN34PltaS-sipV; ErmR, CamR, Kan, IPTG This study 
ANG1362 ANG1282 with pCN34PltaS-sipV-his; ErmR, CamR, Kan, IPTG This study 
ANG1370 pitet-ltaSS218P-his integrated in strain ANG499; ErmR, CamR, IPTG This study 
ANG1524 ANG1282 with pCN34PltaS-sipT/S; ErmR, CamR, Kan, IPTG This study 
ANG1525 ANG1282 with pCN34PltaS-sipT/S-his; ErmR, CamR, Kan, IPTG This study 
ANG1528 ANG1282 with pCN34PltaS-sipV/S; ErmR, CamR, Kan, IPTG This study 
ANG1529 ANG1282 with pCN34PltaS-sipV/S-his; ErmR, CamR, Kan, IPTG This study 
ANG1571 ANG499 with pCN34itet-ltaS; ErmR, KanR, IPTG This study 
(Wörmann et al, 2011) 
ANG1572 ANG499 with pCN34itet-ltaS-his; ErmR, KanR, IPTG This study 
ANG1573 ANG499 with pCN34itet-yfnI; ErmR, KanR, IPTG This study 
(Wörmann et al, 2011) 
ANG1574 ANG499 with pCN34itet-yfnI-his; ErmR, KanR, IPTG This study 
ANG1598 ANG587 with pCN34 ErmR, CamR, Kan, IPTG This study 
ANG1654 ANG499 with pCN34itet-yqgS; ErmR, KanR, IPTG This study 
(Wörmann et al, 2011) 
ANG1655 ANG499 with pCN34itet-yqgS-his; ErmR, KanR, IPTG This study 
ANG1658 ANG499 with pCN34itet-yvgJ; ErmR, KanR, IPTG This study 
(Wörmann et al, 2011) 
ANG1659 ANG499 with pCN34itet-yvgJ-his; ErmR, KanR, IPTG This study 
ANG1662 ANG499 with pCN34itet-yflE; ErmR, KanR, IPTG This study 
(Wörmann et al, 2011) 
ANG1663 ANG499 with pCN34itet-yflE-his; ErmR, KanR, IPTG This study 
ANG1690 ANG595 with pCN34itet-ltaST300A; ErmR, KanR, IPTG This study 
ANG1708 
ANG1755 
ANG1786 
ANG1282 with pCN34 ErmR, CamR, Kan, IPTG 
SEJ1ΔsbiΔspa 
4S5- SEJ1ΔltaSΔspa;LTA negative suppressor strain that can grow without LTA 
This study 
Lab strain 
Lab strain 
ANG1816 SEJ1 with pCN34itet-spsB; KanR This study 
ANG1820 SEJ1 spsB::erm with pCN34itet-spsB; ErmR, KanR This study 
ANG2008 SEJ1 Pspac-spsB; pCL55spac-spsB-T114C integrated in strain SEJ1; CamR This study 
 
 
78 
 
ANG2009 SEJ1 spsB::erm Pspac-spsB; spsB::erm transduced from strain ANG1820 into 
strain ANG2008; ErmR, CamR, IPTG 
This study 
ANG2165 ANG499 with pCN34itet-sec-eltaS; ErmR, KanR, IPTG This study 
ANG2166 ANG499 with pCN34itet-TMsrtA-eltaS; ErmR, KanR, IPTG This study 
ANG2167 ANG499 with pCN34itet-1TM-eltaS; ErmR, KanR, IPTG This study 
ANG2168 ANG499 with pCN34itet-3TM-eltaS; ErmR, KanR, IPTG This study 
ANG2169 ANG499 with pCN34itet-5TMltaA-eltaS; ErmR, KanR, IPTG This study 
ANG2184 pitet-ltaSE174P integrated in strain ANG499; ErmR, CamR, IPTG This study 
RN6390 RN6390; virulent laboratory strain derived from NCTC 8325- ANG2153 (Peng et al, 1988) 
RN6390htrA1,htrA2 RN6390 htrA1, htrA2; CamR, SpecR - ANG1649 (Rigoulay et al, 2005) 
AH1263 LAC*; Erm sensitive CA-MRSA LAC strain - ANG1575 (Boles et al, 2010) 
AH1919 LAC* Δaur, ΔsspAB, ΔscpA, spl::erm (LAC* protease KO) – ANG2038 obtained from 
Dr. A. Horswill 
   
 Bacillus subtilis strains  
B.subtilis Bacillus subtilis 168 – Transformable lab strain, trpC2 – ANG1691 (Burkholder, 1947) 
ANG1692 Bacillus subtilis 168 yfnI::Cam (ΔyfnI) (Wörmann et al, 2011) 
ANG1693 Bacillus subtilis 168 yflE::Kan (ΔyflE)  (Wörmann et al, 2011) 
ANG1694 Bacillus subtilis 168 yqgS::Spec (ΔyqgS) (Wörmann et al, 2011) 
ANG1695 Bacillus subtilis 168 yvgJ::Erm (ΔyvgJ) (Wörmann et al, 2011) 
ANG1696 Bacillus subtilis 168 yflE::Kan, yqgS::Spec, yvgJ::Erm (yfnI only) (Wörmann et al, 2011) 
ANG1697 Bacillus subtilis 168 yfnI::Cam, yqgS::Spec, yvgJ::Erm (yflE only) (Wörmann et al, 2011) 
ANG1698 Bacillus subtilis 168 yfnI::Cam, yflE::Kan, yvgJ::Erm (yqgS only) (Wörmann et al, 2011) 
ANG1699 Bacillus subtilis 168 yfnI::Cam, yflE::Kan, yqgS::Spec (yvgJ only) (Wörmann et al, 2011) 
ANG1701 Bacillus subtilis 168 yfnI::Cam, yflE::Kan, yqgS::Spec, yvgJ::Erm (4xΔ)  (Wörmann et al, 2011) 
ANG1702 Bacillus subtilis 168 yflE::Kan, yfnI::Cam (express-yvgJ/yqgS) (Wörmann et al, 2011) 
ANG1703 Bacillus subtilis 168 yflE::Kan, yqgS::Spec (express-yvgJ/yfnI) (Wörmann et al, 2011) 
ANG1704 Bacillus subtilis 168 yfnI::Cam, yqgS::Spec (express-yvgJ/yflE) (Wörmann et al, 2011) 
L5703 Bacillus subtilis with ribitol-Pi wall teichoic acid  (ribitol-Pi WTA) (Karamata et al, 1987) 
   
Antibiotics were used at the following concentrations: for E. coli cultures: Ampicillin (AmpR) 100 µg/ml; Kanamycin (KanR) 30 
µg/ml; Tetracycline (TetR) 10 µg/ml; for S. aureus cultures: Erythromycin (ErmR) 10 µg/ml; Chloramphenicol (CamR) 7.5 to 10 
µg/ml, Kanamycin 90 µg/ml and IPTG at 1 mM; for B. subtilis cultures: Erythromycin 5 µg/ml; Chloramphenicol 10 µg/ml, 
Kanamycin 10 µg/ml; Spectinomycin (Spec) 100 or 200 µg/ml. 
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Table 2: Primers used in this study 
 
Number Name Sequence 
ANG086 5’-BamHI +P SAV0719 CGGGATCCGGAATAGAATATAGAATGCAATTAGAAATG 
ANG087 3-SalI SAV0719 ACGCGTCGACCCGAGTTCGTGTTTAAATATTATTTTTTAG 
ANG159 5-KpnI-tet GGGGTACCTTGGTTACCGTGAAGTTACCATCACGG 
ANG260 5-AvrII-SAV1016 CCGCCTAGGCATCACAACCACAAGAGATTTATGGAAAGGTTCC 
ANG318 5-AvrII-SAV719-22bp CCGCCTAGGctaaataacgggggaaagaatcATGAGTTC 
ANG319 3-BglII-SAV719 GAAGATCTCCGAGTTCGTGTTTAAATATTATTTTTTAG 
ANG320 5-BamHI-YfnI with P CGGGATCCGGTGATCGCGCTAAACATTGATGCATACAATAAC 
ANG321 3-KpnI-YfnI GGGGTACCGCAATGCGCCCGCTCAAGGCTCTTTTTCATCTTA 
ANG322 5-AvrII-YfnI-33bp CCGCCTAGGGAACTTAAAGTGTTTAAGAAAGTAGAGGTTGCC 
ANG324 5-BamHI-YflE-with P CGGGATCCCCATTTTATTCCTTTATTTCTAGAAAGATACC 
ANG325 3-KpnI-YflE GGGGTACCAAAGCGGAGAGGGCAACCTCTCCGCTTTTTCTTA 
ANG326 5-AvrII-YflE-32bp CCGCCTAGGGCTCGAACTGGATCGGAAAAAAGGAGTGTAACA 
ANG330 5-AvrII-YqgS- 34bp CCGCCTAGGCTGATTTTTTTGAGCGTGCTGCATAGGAGGTTG 
ANG331 3-BglII-YqgS GAAGATCTCCGCTCACTTCGATGCGGGAGACATTGTGATTA 
ANG401 5-AvrII protA SS CCGCCTAGG GTTATATTATGATGACTTTACAAATACATACAG 
ANG404 ProtA SS-719 front-no ala CTTTTGTTAAGTCATCTTCAGA AGCATTTGCAGCAGGTGTTACG 
ANG405 ProtA-719-no ala CGTAACACCTGCTGCAAATGCT TCTGAAGATGACTTAACAAAAG 
ANG420 3-BgIII-His6-719 GAAGATCTttaGTGATGGTGATGGTGATGaccTTTTTTAGAGTTTGCTTTAGGTCCTG 
ANG424 3-SalI_Stop_TM_719 ACGCGTCGACttaTGCTAACGCTTTTTGTTGATTATTTTCG 
ANG427 5-AvrII_SrtA_TM CCGCCTAGGtataaaaggagccttaacgtATGAAAAAATGG 
ANG432 Front-SrtA_35AA GTCATCTTCAGActgCTTATTGTCTTTACTCGCCTGTTCTTTTAC 
ANG433 Back-SrtA_35AA GACAATAAGCAGtctGAAGATGACTTAACAAAAGTATTAAATTATAC 
ANG434 Front-LtaS_1TM GTCTGTCAGTTTCaacATAATAAGAAAAATACGTCTTCAAGG 
ANG435 Back-LtaS_1TM CTTATTATGTTgaaACTGACAGACCAGAATTATTAACACG 
ANG436 Front-LtaS_3TM GTCTGTCAGTTTCtctAAAGTACACAACATTGGCATATAATAG 
ANG437 Back-LtaS_3TM GTGTACTTTAGAgaaACTGACAGACCAGAATTATTAACACG 
ANG438 Front-LtaA_5TM GTCTGTCAGTTTCcacTTTGATAAGTAGATTCATAAAAACCATAC 
ANG439 Back-LtaA_5TM CTTATCAAAGTGgaaACTGACAGACCAGAATTATTAACACG 
ANG487 F-719-cleave ALAP CTATCGAAAATAATCAACAAAAAgcgctagcacctGAAGATGACTTAACAAAAG 
ANG488 R-719-cleave ALAP CTTTTGTTAAGTCATCTTCaggtgctagcgcTTTTTGTTGATTATTTTCGATAG 
ANG494 F-YfnITM+extr.LtaS CAAAGAgcctatgcaTCTGAAGATGACTTAACAAAAGTATTAAATTATAC 
ANG495 R-YfnITM+extr.LtaS GTCATCTTCAGAtgcataggcTCTTTGCGTCTCTGTTTGAGC 
ANG496 F-LtaSTM+extr.YfnI AAAgcgctagcaAGCAGCGATGATTTAACAAGTGTCGAGAATTAC 
ANG497 R-LtaSTM+extr.YfnI AATCATCGCTGCTtgctagcgcTTTTTGTTGATTATTTTCGATAG 
ANG498 F-YqgSTM+extr.LtaS GAGAgcgttggcaTCTGAAGATGACTTAACAAAAGTATTAAATTATAC 
ANG499 R-YqgSTM+extr.LtaS GTCATCTTCAGAtgccaacgcTCTCTGTGCGGATTGCTTTGACTG 
ANG500 F-LtaSTM+extr.YqgS AAAgcgctagcaGACAGCAACAGCCTGACGGAGATTGAAAACTAC 
ANG501 R-LtaSTM+extr.YqgS GCTGTTGCTGTCtgctagcgcTTTTTGTTGATTATTTTCGATAG 
ANG502 3-BglII-His6-YflE GAAGATCTttaGTGATGGTGATGGTGATGaccTTTATCTTCGTTATCCTTTGACGTTTC 
ANG503 3-BglII-His6-YqgS GAAGATCTttaGTGATGGTGATGGTGATGaccTGATGCCTGATCAAGCATTTGTTTTTC 
ANG504 3-BglII-His6-YfnI GAAGATCTttaGTGATGGTGATGGTGATGaccTTTGATTTCTTTCTCCTTGCCGTAATG 
ANG522 F LtaS TM extr YfnI cttagcttttgctGAAAAAGACCGTCCGCAACTG 
ANG523 R LtaS TM extr YfnI gacggtctttttcAGCAAAAGCTAAGTTTAAGAAG 
ANG524 F YfnI  TM extr LtaS ctgcactatgcgGAAACTGACAGACCAGAATTATTAAC 
ANG525 R YfnI TM extr LtaS ctgtcagtttcCGCATAGTGCAGGTTGATGAAAAAC 
ANG526 R YflE TM extr LtaS ctgtcagtttcCGCAACTGCCAGGTTGATCAAG 
ANG527 F YflE TM extr LtaS ctggcagttgcgGAAACTGACAGACCAGAATTATTAAC 
ANG528 R LtaS TM extr YflE cggtctgattcAGCAAAAGCTAAGTTTAAGAAG 
ANG529 F LtaS TM extr YflE cttagcttttgctGAATCAGACCGTCCTGAATTGC 
ANG614 F-YflEtm-linkereYfnI ctggcagttgcgGAAAAAGACCGTCCGCAACTGC 
ANG615 R-YflEtm-linkereYfnI gacggtctttttcCGCAACTGCCAGGTTGATCAAG 
ANG616 F-YflEtmlinker-eYfnI cgcgcgcttgccAGCAGCGATGATTTAACAAGTG 
ANG617 R-YflEtmlinker-eYfnI atcatcgctgctGGCAAGCGCGCGCTGGCTGTTGGAC 
ANG618 F-YfnItm-linkerYflE ctgcactatgcgGAATCAGACCGTCCTGAATTGCTG 
ANG619 R-YfnItm-linkerYflE cggtctgattcCGCATAGTGCAGGTTGATGAAAAAC 
ANG620 F-YfnItmlinker-YflE gagcctatgcaGATTCCAGCGACGTAACGGAAG 
ANG621 R-YfnItmlinker-YflE gtcgctggaatcTGCATAGGCTCTTTGCGTCTCTG 
ANG622 F-PltaS-SipT ggggaaagaatcTTGACCGAGGAAAAAAATACGAATAC 
ANG623 R-PltaS-SipT ttcctcggtcaaGATTCTTTCCCCCGTTATTTAGATA 
ANG625 3-SalI-SipT-His6 ACGCGTCGACTTAGTGATGGTGATGGTGATGaccTTTTGTTTGACGCATTTCGTTAAAC 
ANG626 F-PltaS-SipV ggggaaagaatcATGAAAAAACGGTTTTGGTTTCTTG 
ANG624 3-SalI-SipT ACGCGTCGACTTATTTTGTTTGACGCATTTCGTTAAAC 
ANG627 R-PltaS-SipV cgttttttcatGATTCTTTCCCCCGTTATTTAG 
ANG628 3-SalI-SipV ACGCGTCGACTTATTCGGCATCAGAAATCACACCGAC 
ANG629 3-SalI-SipV-His6 ACGCGTCGACTTAGTGATGGTGATGGTGATGaccTTCGGCATCAGAAATCACACCGAC 
ANG711 F LtaS P in 174 CTTCTTAAACTTAGCTTTTGCTcctACTGACAGACCAGAATTATTAAC 
ANG712 R LtaS P in174 GTTAATAATTCTGGTCTGTCAGTaggAGCAAAAGCTAAGTTTAAGAAG 
ANG714 R SipS SalI ACGCGTCGACctaATTTGTTTTGCGCATTTCGTTAAAC 
ANG715 R SipS-His SalI ACGCGTCGACctaGTGATGGTGATGGTGATGaccATTTGTTTTGCGCATTTCGTTAAAC 
ANG742 F-SipT/SipS CAAACAAAATAAtgaagaccgttgtttattggagg 
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ANG743 R-SipT/SipS caacggtcttcaTTATTTTGTTTGACGCATTTCGTTAAAC 
ANG744 F-SipV/SipS GATGCCGAATAAtgaagaccgttgtttattggagg 
ANG745 R-SipV/SipS caacggtcttcaTTATTCGGCATCAGAAATCACACCGAC 
ANG775 R-YqgS-PLtaS CGTTTTTCGCATgattctttcccccgttatttagataataaatc 
ANG796 N-F-PltaS-YqgS ggggaaagaatcATGCGAAAAACGTTTTTTTCGAAGATTTC 
ANG800 3-SalI-pCL55 ACGCGTCGACCACGTTTCCATTTATCTGTATACGGATC 
ANG821 3-P-pCL55 P-CACGTTTCCATTTATCTGTATACGGATC 
ANG826 5’AvrII-PltaS-yqgS CCGCCTAGGctaaataacgggggaaagaatcATG 
ANG877 3-PstI-pCL55 CGGCTGCAGCACGTTTCCATTTATCTGTATACGGATC 
ANG879 3'PstI-YvgJ-His6 CGGCTGCAGtcaGTGATGGTGATGGTGATGaccTTCGGAAAACCTGAGCAGGTCACC 
ANG895 3'PstI-YqgS-His6 CGGCTGCAGttaGTGATGGTGATGGTGATGaccTGATGCCTGATCAAGCATTTGTTTTTC 
ANG896 5-HindIII-SpsB CCCAAGCTTcttaaaaagaggtgtcaaaaTTG 
ANG908 XmaI – pRMC2 primer TCCCCCGGGcgGAATTCGAGCTCAGATCTGTTAACGGTACCatc 
ANG909 pALC2073 primer PCR1 GCTCAGATCTGTTAACGGTACCatcaagcttattttaattatac 
ANG912 3-PstI-His6-YflE CGGCTGCAGttaGTGATGGTGATGGTGATGaccTTTATCTTCGTTATCCTTTGACGTTTC 
ANG948 3-NarI - tetR far CCTTGGCGCCTTAAGACCCACTTTCACATTTAAGTTG 
ANG1007 5-KpnI-SpsB GGGGTACCaatcttaaaaagaggtgtcaaaaTTG 
ANG1008 3-SalI-SpsB ACGCGTCGACcaaacgatgttgtatttgtttc 
ANG1010 5KpnI 1kb spsB F GGGGTACCctatattttaattaacattcaagc 
ANG1011 R-spsB-ErmAM gaaaaaggaagagtTATTTCTTTTTTCAAttttgac 
ANG1012 F-spsB-ErmAM GAAAAAAGAAATAactcttcctttttcaatattattg 
ANG1013 F-ErmAM-spsB ggaggaaataaAATTTCAATCCTGAAAATAC 
ANG1014 R-ErmAM-spsB caggattgaaattTTATTTCCTCCCGTTAAATAATAG 
ANG1015 3EcoRI 1kb spsB R CGGAATTCgctttaaatcttgattattg 
ANG1183 3-KpnI-SpsB GGGGTACCcaaacgatgttgtatttgtttc 
ANG1203 5-QC-spsB-T114C caattaaaggtgaatcaatggaCccaactttgaaagatggcgag 
ANG1204 3-QC-spsB-T114C ctcgccatctttcaaagttggGtccattgattcacctttaattg 
   
Relevant restriction sites in primer sequences are underlined. 
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Chapter 3  
Production and proteolytic cleavage of S. aureus LtaS 
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3.1 Objective of chapter 3 
          The S. aureus LtaS enzyme consists of two domains, an N-terminal 
membrane domain and a C-terminal extracellular enzymatic domain (eLtaS). 
Proteomic studies identified the eLtaS fragment in the culture supernatant suggesting 
that LtaS is processed during bacterial growth (Gatlin et al, 2006; Ziebandt et al, 
2001). In this chapter the extent to which LtaS is processed was determined, and the 
subcellular location of the protein analysed. S. aureus secretes a range of proteases 
and their contribution to LtaS cleavage was investigated in defined mutant strains. 
Furthermore, two cleavage sites have been proposed for LtaS. Mass spectrometry 
analysis of secreted S. aureus proteins suggested that the LtaS protein is cleaved after 
residues 215Ala-Leu-Ala217 (Ziebandt et al, 2001). However, a more recent study 
hypothesized that LtaS is in fact processed following residues 171Ala-Phe-Ala173, based 
on analysis using the SignalP 3.0 prediction program (Bendtsen et al, 2004; Powers et 
al, 2011). In this chapter the LtaS cleavage site was identified independently, and 
attempts to construct an uncleavable LtaS variant are discussed.  
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3.2 Analysis of the sub-cellular location of LtaS 
          The S. aureus LtaS enzyme is synthesized as a membrane protein consisting of 
five N-terminal transmembrane helices followed by a 44 amino acid (aa) linker region 
and a C-terminal extracellular enzymatic domain (eLtaS) (Fig. 8A). The latter domain 
comprises aa 245-604 and is currently annotated as a sulfatase domain. Proteomic 
studies on secreted proteins in S. aureus revealed that the LtaS enzyme is partially 
processed, releasing a 50 kDa C-terminal fragment into the culture supernatant (Gatlin 
et al, 2006; Ziebandt et al, 2001). N-terminal sequencing identified the cleavage site 
C-terminal of the fifth transmembrane helix after residues 215Ala-Leu-Ala217 and 
preceding the enzymatic domain (Ziebandt et al, 2001). To determine what percentage 
of the enzyme remains unprocessed and what remains cell wall associated, a cell wall 
fractionation experiment was performed and LtaS and fractionation-control proteins 
were detected by immuno-blotting (Fig. 8B and C). Proteins used as fractionation-
controls were the ribosomal L6 protein, located in the cytoplasm, the membrane 
protein SrtA which anchors surface proteins containing an LPXTG sequence motif to 
the cell wall envelope, the cell wall anchored protein SdrD, which is covalently linked 
to the peptidoglycan and involved in cell adhesion, and alpha-hemolysin (Hla), a 
secreted bacterial toxin that causes lysis of target cells. 
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Figure 8: LtaS is efficiently processed in S. aureus and localizes to the supernatant and cell wall 
fraction. (A) Schematic representation of S. aureus LtaS. The 74.4 kDa full-length LtaS enzyme 
assembles in five N-terminal transmembrane spanning helices followed by a 44 amino acid linker 
region and the extracelluar enzymatic domain (eLtaS). The protein is cleaved following the linker 
region between amino acids 217 and 218, following an Ala-Leu-Ala motif, and the 49.3 kDa eLtaS 
domain is released from the bacterial membrane. The solid arrow indictes the LtaS cleavage site 
identified by proteomic studies and the dashed arrow markes the cleavage site predicted by the 
computer program SignalP 3.0 (Powers et al, 2011). (B and C) Subcellular location of control 
proteins (B) and LtaS (C) in S. aureus strains RN4220, COL and SH1000. Mid-log cultures of S. 
aureus strains RN4220, COL and SH1000 were fractionated into supernatant (SN), cell wall (CW) and 
combined membrane and cytoplasmic (M/C) fractions. LtaS and control proteins SdrD (cell wall 
anchored), Hla (secreted), SrtA (membrane) and L6 (cytoplasmic) were detected by western blot using 
polyclonal rabbit antibodies as indicated on the right of the panel. Note that the polyclonal antibody 
used for LtaS detection was raised against the extracellular eLtaS domain. Sizes of protein standards in 
kDa are shown on the left.  
 
          In all S. aureus strains tested (RN4220, COL, SH1000), the 49.3 kDa eLtaS 
fragment could be detected in both supernatant and cell wall fraction (Fig. 8C). No 
signal corresponding to the full-length protein was visible in the combined membrane 
and cytoplasmic (M/C) fractions. These data indicate that despite the fact that LtaS is 
synthesized as a membrane protein, the enzyme is efficiently processed and the eLtaS 
domain released into the culture supernatant, as well as being partially retained within 
the cell wall envelope. A weak 70 kDa signal appeared in all M/C fractions following 
incubation with the anti-LtaS antibody. This signal most likely resulted from 
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unspecific antibody binding, as LtaS expression studies in E. coli suggest a slightly 
slower mobility for the full-length protein on SDS-PAGE gels (Fig. 9). It is important 
to note that the polyclonal eLtaS specific antibody was produced in Chicago before 
this study was initiated and that therefore the preimmune serum was not available to 
further analyze the specificity of the antibody.  
 
 
 
Figure 9: Western blot of LtaS protein detection in E. coli. Strains ANG482 (pOK) and ANG483 
(pOK-ltaS) were grown overnight and whole cell samples were prepared as described in the Materials 
and Methods chapter (section 2.5). Samples were analysed by western blot using an LtaS-specific 
antibody. A square ( ) indicates full-length LtaS protein and a star (*) denotes the cleaved eLtaS 
protein fragment. Sizes of protein standards in kDa are shown on the left.  
 
3.3 LtaS expression from different promoters in S. aureus  
          As the LtaS protein could be detected in wild type (WT) S. aureus, it was 
decided to test whether the protein could be detected in S. aureus mutant strains with 
inducible LtaS expression. Two strains, ANG499 and ANG514, were analyzed in this 
context. S. aureus strain ANG499 harbors the native chromosomal ltaS gene under 
IPTG inducible spac promoter control (Fig. 10). Upon IPTG depletion, strain 
ANG499 is unable to synthesize LTA and ceases to grow approximately 4 h after 
IPTG removal. S. aureus strain ANG514 is derived from the integration of the pitet 
plasmid containing the ltaS gene under anhydrotetracycline (Atet) inducible promoter 
control into the chromosome of strain ANG499 (Fig. 10). Thus, strain ANG514 
contains two copies of the ltaS gene, which are controlled by different promoters. 
Therefore, in the absence of IPTG and presence of Atet, ltaS expression from the 
native chromosomal location cloned under spac promoter control is shut down, while 
expression of the second ltaS copy, controlled by the pitet promoter, is induced. 
 
 
86 
Under these conditions bacterial growth and LTA synthesis solely depends on the 
functionality of the construct cloned under pitet promoter control. This expression 
system provides a tool to study the functionality of different constructs in terms of 
ltaS complementation and was used throughout this work. 
 
 
                     
Figure 10: Chromosomal organization of S. aureus strains ANG499 and ANG514. Strain ANG499 
harbors the chromocomal ltaS gene under IPTG inducible spac promoter control. Strain ANG514 
contains two ltaS genes, where one copy is controlled by the spac promoter and the other one by the 
Atet inducible pitet promoter.  
 
          To investigate LtaS expression levels in the different S. aureus mutant strains, 
strains ANG499, ANG514 and WT S. aureus RN4220 (positive control) were grown 
in the presence and absence of appropriate inducers (Fig. 11A). The growth curve 
depicted in figure 11A shows a predicted OD that resulted from diluting the bacteria 
into fresh media at the 4 h time point and at the 8 h time point if necessary. This was 
done to keep the bacteria in the exponential growth phase. OD readings were 
subsequently multiplied with the dilution factor introduced at the specified time 
points. This particular way of plotting a growth curve was used throughout this work. 
Samples were removed from cultures described above at mid-log phase and analyzed 
for LTA and LtaS detection by western blot (Fig. 11B and C).  
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Figure 11: Comparison of LTA and LtaS production from native, IPTG-inducible and Atet-
inducible promoters. (A) Bacterial growth curves. Washed overnight cultures of RN4220 (WT), the 
IPTG inducible ltaS expression strain ANG499 (Pspac-ltaS), and the Atet inducible ltaS expression 
strain ANG514 (Pitet-ltaS) were diluted 1:100 into fresh media and grown with or without the 
appropriate inducer. Bacterial growth was monitored by determining OD600 readings at the indicated 
time points. (B) LTA and (C) LtaS detection by western blot in S. aureus mutant strains with 
inducible ltaS expression. At the 4 h time point, 1 ml culture aliquots were removed from the S. 
aureus strains decribed above. Cell associated LTA was analyzed by western blot using an LTA-
specific antibody (B), and supernatant (sup) and whole cell samples (cell) using an LtaS-specific 
antibody (C). (D) Western blot of LtaS detection in defined S. aureus mutant strains. Strains 
RN4220 (WT), SEJ1 (Δspa), SEJ1 (ΔsbiΔspa)-ANG1755 and 4S5 (ΔltaSΔspa)-ANG1786 were grown 
to mid-log phase and cell fractions prepared and analyzed by western blot using an LtaS-specific 
antibody. Full-length and eLtaS specific bands are indicated on the right of the panel with a square ( ) 
and a star (*) , respectively. Two unspecific bands are present in the ΔltaSΔspa lane. The faint top band 
is of the same mobility as the full-length LtaS, and the bottom band is the Sbi protein annotated with a 
filled circle (). Sizes of protein standards in kDa are shown on the left. Note that the Western blot 11D 
was obtained from N.T. Reichmann.  
 
          Following Atet induction, the cleaved LtaS protein could be detected in the 
supernatant and cell wall fraction of strain ANG514 (Pitet-ltaS) (Fig. 11C). 
Comparable protein amounts were found in samples prepared from the WT S. aureus 
RN4220 control strain, indicating that Atet induced ltaS expression in ANG514 
restores WT protein levels. In contrast, no protein band corresponding to the cleaved 
eLtaS product could be detected when expressed from the weak spac promoter in 
strain ANG499, even in the presence of IPTG. However, a second band with a slightly 
faster mobility as compared to the eLtaS fragment was visible in the supernatant and 
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cell wall fraction of all strains tested (Fig. 11C). Morover, the induced and uninduced 
cell wall fraction samples of strains ANG499 and ANG514 displayed an additional 
protein band that migrated just below 82 kDa (Fig. 11C). Protein A and Sbi are two S. 
aureus proteins known to bind to antibodies. To establish unambiguously, which of 
the bands recognized by the antibody are LtaS-specific, western blot analysis was 
performed on cell fraction samples isolated from WT RN4220, the isogenic protein A 
mutant strain SEJ1 (RN4220Δspa) and the sbi/spa mutant strains (RN4220 ΔsbiΔspa) 
(Fig. 11D). In addition, the protein A negative S. aureus strain 4S5 containing a 
complete ltaS deletion was used in the same experiment. The construction of this 
strain and the reason why this strain can grow in the absence of LTA are described in 
Corrigan et al. (manuscript under review). Two unspecific bands were detected in the 
ltaS deletion strain despite the fact that human IgG was used during all antibody 
incubations to block unspecific antibody binding (Fig. 11D). The faster migrating 
unspecific band corresponds most likely to Sbi, since this band was absent in the 
sample prepared from the sbi mutant strain (Fig. 11D; labeled with a filled circle). A 
second very faint unspecific band, which had the same mobility as the full-length 
LtaS protein, was also observed in this ltaS deletion strain (Fig. 11D; labeled with a 
square). However, the intensity of this top (full-length LtaS) band was drastically 
increased in the LtaS-expressing WT, spa and sbi/spa mutant strains. Therfore the 
protein bands observed in the supernatant and cell wall fraction of strain ANG499 
grown in the presence of IPTG are not LtaS related and hence the protein could not be 
detected in this strain. However, these “undetectable” LtaS protein amounts were 
sufficient for LTA production and growth complementation (Fig. 11A and B). On the 
other hand, the pitet promoter appeared to be leaky, and bacterial growth and LTA 
synthesis of strain ANG514 was observed in medium lacking the inducer (Fig. 11A 
and B).  
 
3.4 LtaS processing is independent of Aur, Ssp, Scp, Spl and 
HtrA proteases 
          From the experiments performed in section 3.2 it was clear that a large fraction 
of the S. aureus LtaS protein is cleaved during bacterial growth (Fig. 8C). S. aureus 
secretes a range of proteases, and to assess their contribution to LtaS processing, LtaS 
protein cleavage was analyzed in S. aureus strains with defined deficiencies in known 
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extracellular proteases. To this end, a previously described S. aureus strain deleted for 
the two surface serine proteases HtrA1 and HtrA2 (RN6390htrA1htrA2) (Rigoulay et 
al, 2005), and the isogenic WT RN6390 control strain were grown to mid-log phase. 
Supernatant and whole cell protein fractions were prepared and the LtaS protein 
detected by western blot. As seen in Fig. 12, LtaS processing was not impaired in the 
protease mutant strains, and similar amounts of cleaved protein were detected in the 
culture supernatant of WT and the htrA double mutant strain.  
 
 
Figure 12: LtaS protein processing in defined S. aureus protease mutant strains. LtaS protein 
detection by western blot. S. aureus strains RN6390, the isogenic RN6390htrA1htrA2 mutant strain, 
LAC* and the isogenic LAC*Δaur ΔsspAB ΔscpA spl::erm mutant strain (LAC* protease KO) were 
grown to mid-log phase and supernatant (sup) and whole cell fractions (cell) prepared as described in 
the Materials and Methods chapter (section 2.5). The LtaS protein was detected by western blot using 
an LtaS-specific antibody and sizes of protein standards separated alongside are given in kDa on the 
left of the panel. A square ( ) indicates full-length LtaS protein and a star (*) denotes the cleaved 
eLtaS protein fragment. The western blot using whole cell samples was exposed 6 times longer than the 
blot with supernatant fraction samples.  
 
          Other known extracellular S. aureus proteases are SspA (a serine protease), 
SplA-F (serine protease like proteins), SspB and ScpA (cysteine proteases) and Aur (a 
metalloprotease). All the corresponding genes were inactivated in the S. aureus strain 
LAC* to create strain AH1919 (LAC* protease KO; this strain was obtained from Dr. 
Alexander Horswill). Again, no difference in the amount of secreted LtaS protein was 
observed in the LAC* protease KO strain as compared to the parental LAC* control 
strain (Fig. 12). This indicates that none of the currently known extracellular S. aureus 
proteases plays a major role in LtaS processing. 
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3.5 S. aureus signal peptidase SpsB is required for efficient 
LtaS processing  
Recently, it was found that treatment of S. epidermidis cultures with the signal 
peptidase specific inhibitor arylomycin causes a reduction in the amount of cleaved 
LtaS protein in the culture supernatant (Powers et al, 2011). In addition, it has been 
reported that processing of the B. subtilis LtaS orthologue YfnI is diminished in the 
combined absence of the two signal peptidases SipT and SipV (Antelmann et al, 
2001). S. aureus contains one active type I signal peptidase, which is encoded by spsB 
and thought to be essential for cell viability (Cregg et al, 1996). To test whether SpsB 
is required for LtaS processing in S. aureus, the RN4220-derived strain ANG2009 
with IPTG inducible spsB expression was constructed (Fig. 13A). In this strain the 
native spsB gene is replaced with an Erm cassette, while a functional spsB copy is 
expressed from the IPTG-inducible spac promoter at a different chromosomal 
location. Strain ANG2009 grew in the presence of IPTG; however 4 h after removal 
of the inducer, the growth rate declined and a growth arrest was seen approximately 
10 h after removal of IPTG, indicating successful depletion of the signal peptidase 
(Fig. 13B). To examine the impact of SpsB depletion on LtaS processing, strain 
ANG2009 was grown for 8 h with or without IPTG. Supernatant and whole cell 
protein fractions were prepared from these cultures and analyzed by western blot. In 
the absence of the inducer, significantly reduced levels of cleaved LtaS protein were 
observed in the supernatant, and a concomitant accumulation of the full-length LtaS 
protein was detected in the whole cell fraction (Fig. 13C). Taken together, these data 
indicate that S. aureus signal peptidase SpsB is required for efficient LtaS processing.  
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Figure 13: S. aureus signal peptidase SpsB is required for efficient LtaS processing. (A) 
Schematic representation of S. aureus strain ANG2009 with IPTG inducible spsB expression. 
Strain ANG2009 carries a copy of the spsB gene under IPTG-inducible spac promoter control, whilst 
the native spsB gene is replaced with an Erm cassette. (B) Bacterial growth curves. Washed overnight 
cultures of S. aureus strain ANG2009 with inducible spsB expression were back-diluted into medium 
with or without IPTG, and bacterial growth monitored by determining OD600 readings at the indicated 
time points. Four h after the initial dilution, cells were washed and back-diluted in fresh medium with 
or without IPTG, and at the 8 h time point cultures were diluted a second time to maintain them in the 
logarithmic growth phase. (C) LtaS detection by western blot. At the 8 h time point, supernatant 
(sup) and whole cell (cell) protein samples were prepared, and the LtaS protein detected by western 
blot using the eLtaS-specific antibody. Sizes of protein standards separated alongside are given in kDa 
on the left of the panel. A square ( ) indicates full-length LtaS protein and a star (*) denotes the 
cleaved eLtaS protein fragment. 
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3.6 The main processing site in S. aureus LtaS is after Ala217 
and a variant with reduced processing retains activity 
          Mass spectrometry analysis of secreted S. aureus proteins suggested that the 
LtaS protein is cleaved following the 5TM domain in the linker region after residues 
215Ala-Leu-Ala217 (Ziebandt et al, 2001). In a recent study, it was suggested that the S. 
epidermidis LtaS protein is cleaved after residues 171Ala-Phe-Ala173, based on analysis 
using the SignalP 3.0 prediction program (Bendtsen et al, 2004; Powers et al, 2011). 
These residues are also present in the S. aureus protein (Fig. 8A). To clarify the site of 
LtaS processing, and to investigate whether cleavage is required for enzyme function, 
the S. aureus LtaS enzyme was expressed as a C-terminal His-tag fusion protein from 
the pitet vector in the RN4220-derived S. aureus strain ANG499. The processed LtaS 
protein products were purified from culture supernatant by nickel affinity 
chromatography, and large amounts of Coomassie stained purified protein were 
obtained (Fig. 14A). The purified protein was subsequently subjected to a standard 
tryptic digest and mass spectrometry analysis at the Taplin Biological Mass 
Spectrometry Facility at the Harvard Medical School.  
 
 
Figure 14: Coomassie stained gel of LtaS protein purified from S. aureus culture supernatant. S. 
aureus strains expressing (A) WT LtaS (ANG587) or (B) the LtaSS218P variant (ANG1370) as C-
terminal His-tag fusion proteins were grown overnight in the presence of Atet after removal of IPTG. 
The following day, proteins were purified from culture supernatants as described in the Materials and 
Methods chapter (section 2.8) and 20 µl aliquots separated on a 10 % (w/v) SDS-PAGE and stained 
with Coomassie brilliant blue. Sizes of protein standards separated alongside are given in kDa on the 
left of the panel. 
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          A tryptic peptide starting at alanine 215 was detected; however, the first strong 
signal for the most N-terminal fragment was obtained for a non-tryptic peptide 
starting at serine 218, suggesting that the main cleavage site in S. aureus LtaS is 
between amino acids Ala217 and Ser218 (Fig. 15D). For signal peptidase substrates, it 
has been established that a proline residue in the +1 position relative to the cleavage 
site prevents processing and converts signal peptidase substrates to competitive 
inhibitors (Barkocy-Gallagher & Bassford, 1992; Bruton et al, 2003). In analogy, it 
was reasoned that it might be possible to prevent LtaS processing by replacing Ser218 
(+1 position) with a proline residue, and that this would allow for the determination of 
whether LtaS processing is required for function. An LtaSS218P variant was constructed 
and expressed from an Atet inducible promoter in S. aureus strain ANG499, which 
contains the native chromosomal ltaS gene under IPTG inducible expression control 
(Fig. 15A). Upon IPTG depletion, strain ANG499 is unable to synthesize LTA and 
ceases to grow unless a functional ltaS allele is expressed, in this case elsewhere on 
the chromosome, from the Atet inducible promoter (Fig. 15A). When this strain is 
grown in the presence of Atet, but absence of IPTG, it can be used to determine both 
the processing behavior of the LtaSS218P variant and its functionality based on its 
ability to complement growth and LTA production. S. aureus ANG499 harboring the 
empty pitet plasmid or expressing WT LtaS were included as negative and positive 
controls, respectively. Compared to WT LtaS, only very small amounts of a processed 
LtaSS218P form were detected in the supernatant fraction, and a concomitant 
accumulation of full-length protein in the whole cell fraction was observed (Fig. 15B). 
The cleaved LtaSS218P form showed a slightly slower mobility on SDS-PAGE gels 
(Fig. 15B), suggesting that this variant is processed at an alternative site closer to the 
5TM domain. Of note, the additional band below the cleaved eLtaS fragment does not 
appear to be LtaS-specific, as it was also present in the negative (no insert) control 
strain (Fig. 15B). To investigate this further, the LtaSS218P variant was expressed as a 
C-terminal His-tag fusion protein, and cleaved protein products were purified from 
culture supernatants (Fig. 14B) and subjected to tryptic digest and mass spectrometry 
analysis as described above for WT LtaS. The most N-terminal fragment detected was 
a non-tryptic peptide starting at residue Lys192, suggesting that the LtaSS218P variant is 
processed between residues Val191 and Lys192 (Fig. 15D). There was no indication that 
the S. aureus LtaS protein is processed at the SignalP 3.0 predicted site following 
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residues 171Ala-Phe-Ala173. Furthermore, mutating the glutamic acid residue at position 
174 to a proline (which would be the +1 position for this cleavage site) did not reduce 
the amount of cleaved LtaS protein compared to WT LtaS (Fig. 15B). It is worth 
noting that two bands were observed for the processed LtaSE174P variant in the cell wall 
fraction, suggesting that the mutated protein is cleaved at multiple sites. However, the 
mutation also abrogated enzyme function, and the protein was no longer capable of 
promoting LTA synthesis (Fig. 15B). It is possible that by abolishing LtaS function 
other cleavage sites, which are normally hidden, become accessible to the protease. In 
summary, these findings indicate that LtaS processing naturally occurs between amino 
acids Ala217 and Ser218. Mutating the conserved LtaS cleavage site blocks protein 
processing at the natural site and results in inefficient processing at the alternative site 
(between amino acids Val191 and Lys192). Expression of the LtaSS218P variant with 
drastically reduced cleavage restored both bacterial growth and LTA production to the 
LtaS depletion strain ANG499 (Fig. 15B and C), indicating that efficient processing is 
not essential for LtaS function under standard laboratory growth conditions. 
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Figure 15: LtaSS218P variant with mutated cleavage site shows reduced processing but retains 
activity. (A) Schematic representation of complementation assay. S. aureus strain(s) used for 
complementation studies contain the chromosomal copy of ltaS gene under IPTG inducible spac 
promoter control, and the LtaS variant under investigation (X) is expressed at ectopic chromosomal 
location from the Atet inducible promoter. (B) Detection of LTA and LtaS by western blot. S. aureus 
strains expressing WT LtaS, the LtaSS218P and the LtaSE174P variants were grown in the presence of Atet, 
after removal of IPTG, for 4 h. As a negative control, an S. aureus strain containing the empty pitet 
vector (no insert) was included in the study. Subsequently, 1 ml culture aliquots were removed and 
samples prepared and analyzed by western blot. A mouse monoclonal anti-LTA antibody was used for 
the detection of LTA in the cell-associated fraction, and the eLtaS-specific antibody was used for the 
detection of LtaS in the supernatant (sup) and the whole cell (cell) fraction. Sizes of protein standards 
separated alongside are given in kDa on the left of the panel. A square ( ) indicates full-length LtaS 
protein and a star (∗)  denotes the cleaved eLtaS protein fragment. S. aureus strains ANG513, 
ANG514, ANG1246 and ANG2184 were used for this experiment. (C) Bacterial growth curves. The 
above strains, excluding the LtaSE174P variant, were induced after removal of IPTG by the addition of 
Atet, and growth of all cultures was monitored by determining OD600 readings at the indicated time 
points. Cultures were back-diluted 1:100 in fresh medium at the 4 h time point, to maintain cultures in 
the logarithmic growth phase. (D) Schematic representation of WT LtaS and the LtaSS218P variant. 
Numbers refer to amino acid positions and arrows indicate the main cleavage sites as identified by 
mass spectrometry analysis. The proline substitution in the LtaSS218P mutant is shown as bold red letter. 
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Chapter 4  
Requirements for LtaS function in vivo 
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4.1 Objective of chapter 4 
          The S. aureus LtaS protein contains five N-terminal transmembrane helices, 
which are highly conserved among LtaS-type enzymes. In this chapter the 
contribution of the LtaS membrane domain to enzyme function was investigated. To 
this end the N-terminal LtaS membrane domain was replaced with single and multiple 
transmembrane helices of other staphylococcal proteins, and the functionality of the 
hybrid proteins was tested in an LtaS in vivo enzyme assay.  
          A previous study has demonstrated that the B. subtilis LtaS orthologues yflE 
and yfnI encode for LTA synthases (Gründling & Schneewind, 2007a). However, 
expression of YfnI in an ltaS depleted S. aureus mutant strain resulted in the 
production of glycerolphosphate polymers with retarded mobility on SDS-PAGE, and 
no growth complementation was observed (Gründling & Schneewind, 2007a). In this 
chapter investigations as to which domain of YfnI (membrane versus enzymatic 
domain) contains the information for the synthesis of a structurally altered LTA 
polymer were undertaken. For this, hybrid fusions between functional (S. aureus LtaS 
and B. subtilis YflE) and the non-functional (B. subtilis YfnI) protein were 
constructed and analysed for in vivo function.  
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4.2 The 5TM domain of LtaS is required for in vivo function 
          Recently, it was shown that the recombinant eLtaS domain retains enzymatic 
activity in an in vitro assay system, and is capable of hydrolyzing fluorescently 
labeled PG lipid to DAG (Karatsa-Dodgson et al, 2010). To investigate if the eLtaS 
domain is sufficient for LTA production, and to determine the contribution and 
specificity of the 5TM domain for in vivo function, a series of fusion proteins with 
different membrane domains were constructed (Fig. 16). A secreted eLtaS variant 
(Sec-eLtaS) was designed by replacing the 5TM domain and linker region with the 
conventional signal sequence of Protein A. A single TM helix, derived from the S. 
aureus sortase A protein, was fused to eLtaS (TMSrtA-eLtaS) in an attempt to anchor 
the eLtaS domain to the membrane. Multiple TM helices, derived from the S. aureus 
LtaA membrane protein, were fused to the linker region and eLtaS domain (5TMLtaA-
eLtaS), while two constructs with shortened LtaS-derived membrane domains were 
made in which the last four (1TM-eLtaS) or the last two (3TM-eLtaS) TM helices of 
LtaS were removed.  
 
 
Figure 16: Schematic representation of the different fusion proteins used for complementation 
analysis. The protein A signal peptide was fused to eLtaS to produce a secreted eLtaS variant (Sec-
eLtaS). The eLtaS domain was fused to the single sortase A TM helix (TMSrtA-eLtaS) and to the first 5 
TM helices of LtaA (5TMLtaA-eLtaS). Shortened LtaS versions with 1 or 3 TM helices were also 
constructed (1TM-eLtaS and 3TM-eLtaS). Protein portions shown in grey are derived from the S. 
aureus LtaS protein, coloured fragments are derived from other S. aureus proteins and fusion sites are 
indicated by yellow stars. Details on the construction of these fusion proteins can be found in the 
Materials and Methods chapter (section 2.12).  
 
          To test the functionality of these five fusion proteins, they were expressed, as 
described in section 3.6 for the LtaSS218P variant, in S. aureus strain ANG499, which is 
unable to synthesize LTA and ceases to grow upon IPTG depletion unless a functional 
LtaS protein is expressed from the Atet inducible promoter (Fig. 15A). In contrast to 
WT LtaS, expression of the five fusion proteins did neither restore bacterial growth 
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nor LTA production, and as observed for the negative control strain containing the 
empty pitet vector, growth of all strains ceased after 4 h, and no LTA specific signal 
was detected on western blots (Fig. 17A - C). Note that only the cell accociated LTA 
of the S. aureus mutant strains expressing the different fusion proteins was analysed. 
It is possible that no LTA could be detected in these strains because the polymer was 
released into the supernatant during the cell lysis process. However, this is very 
unlikely as the technique used to lyze the cells (see Materials and Methods chapter, 
section 2.5) should not separate the membrane fraction fom the cell debris. In 
aggrement with this, cell accociated LTA could be detected in the WT LtaS 
expressing control strain (Fig. 17C). 
           Expression of all fusion proteins was confirmed by western blot using the 
eLtaS-specific antibody (Fig. 17D), albeit protein levels differed greatly. It seems 
unlikely that insufficient protein quantities are the reason for the lack of 
complementation, as non-detectable amounts of WT LtaS expressed from the weak 
spac promoter are sufficient to promote growth and LTA synthesis (Fig. 11A and B). 
Taken together, these experiments demonstrate that the 5TM domain of LtaS is 
essential for enzyme function and polyglycerolphosphate backbone chain production 
in vivo. 
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Figure 17: Complementation of growth and LTA production upon expression of different fusion 
proteins. (A and B) Bacterial growth curves. The fusion proteins indicated in the legend and 
depicted in Fig. 16 were expressed in S. aureus ANG499 by the addition of Atet after removal of IPTG. 
A strain expressing WT LtaS served as a positive control, while a strain containing the empty pitet 
vector (no insert) acted as a negative control. Bacterial growth was monitored by determining OD600 
readings at the indicated time points. All cultures were back-diluted 1:100 at the 4 h time point, and the 
culture with the WT LtaS expressing control strain was back-diluted a second time at the 8 h time 
point, to maintain the cultures in the logarithmic growth phase. (C) LTA and (D) LtaS protein 
detection by western blot. At the 4 h time point 1 ml aliquots were removed from S. aureus cultures 
described above, the LTA in the cell-associated fraction detected using an LTA specific antibody, and 
the LtaS protein in the supernatant (sup) and the whole cell (cell) using an eLtaS-specific antibody. 
Proteins expressed are indicated above each lane, and a square ( ) denotes the cleaved eLtaS protein 
fragment and the assumed full-length LtaS fusion proteins are indicated in each lane separately with a 
star (∗). Sizes of protein standards separated alongside are given in kDa on the left of the panel. Note 
that two different exposure times are shown for the cell fraction sample in order to visualize the full-
length wild type LtaS protein. S. aureus strains ANG513, ANG514, ANG595, ANG1217, ANG1218 
ANG1219 and ANG1220 were used for this experiment. 
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4.3 The 5TM domain of LtaS is needed for the LTA primase 
reaction 
          It is assumed that S. aureus LtaS not only polymerizes the LTA backbone 
chain, but also catalyzes the transfer of the initial glycerolphosphate (GroP) subunit 
onto the glycolipid anchor, resulting in the synthesis of the GroP-Glc2-DAG 
intermediate. This intermediate would not have been detected by the western blot 
analysis described in section 4.2. To test if the eLtaS domain, or any of the other 
fusion proteins with altered TM domains, retain the ability to synthesize the GroP-
glycolipid intermediate, glycolipids produced in S. aureus strains expressing the 
different fusion proteins were analyzed. From studies described in section 7.3, it is 
known that expression of the B. subtilis LTA primase YvgJ, from the Atet inducible 
promoter and a multi-copy plasmid, leads to the clear accumulation of the GroP-Glc2-
DAG glycolipid intermediate. Therefore, all five fusion proteins were expressed from 
the same plasmid system in S. aureus ANG499. Of note, expression of the fusion 
proteins from this multi-copy plasmid did neither restore bacterial growth nor LTA 
production in the S. aureus LtaS depletion strain (Fig. 18A-C).  
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Figure 18: Growth and LTA complementation upon expression of fusion proteins from a high 
copy plasmid. (A and B) Bacterial growth curves. The fusion proteins depicted in Fig. 16 were 
expressed from the high-copy plasmid pCN34 in S. aureus ANG499 by the addition of Atet after 
removal of IPTG. A WT LtaS expressing S. aureus mutant strain was used as a positive control and a 
strain containing the empty pCN34 vector (no insert) acted as a negative control. Bacterial growth was 
followed by OD600 measurements at the indicated time points. All cultures were back-diluted 1:100 at 
the 4 h time point, and the culture with the WT LtaS expressing control strain was back-diluted a 
second time at the 8 h time point, to maintain the cultures in the logarithmic growth phase. (C) LTA 
detection by western blot. At the 4 h time point, 1 ml aliquots were removed from S. aureus cultures 
and LTA samples prepared and analyzed by western blot as described in the Materials and Methods 
chapter (section 2.5). Cell-associated LTA was detected by using an LTA specific antibody. Proteins 
expressed are indicated above each lane and sizes of protein standards separated alongside are given in 
kDa on the left of the panel. S. aureus strains ANG1130, ANG1571, and ANG2165 to ANG2169 were 
used for this experiment. 
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          Total lipids were extracted from mid-log cultures of S. aureus strains either 
expressing the fusion proteins, B. subtilis YvgJ, S. aureus WT LtaS, or containing the 
empty pCN34 vector. Next, the lipids obtained were separated by TLC, and 
glycolipids visualized by staining with α-naphthol and sulphuric acid (Fig. 19). A 
glycolipid band corresponding to Glc2-DAG was detected in all samples. In addition a 
clear accumulation of the lower migrating glycolipid GroP-Glc2-DAG was observed 
in the samples isolated from the YvgJ expressing strain (Fig. 19). However, no signal 
above that obtained from the strain harboring the empty vector (no insert) control was 
seen upon expression of all five LtaS fusion proteins (Fig. 19). These data suggest that 
the eLtaS domain alone is not sufficient to initiate LTA synthesis. Therefore, the 5TM 
domain is, in vivo, critical for both the LTA priming and the polymerization reactions.  
 
 
Figure 19: TLC analysis of glycolipids produced by S. aureus strains expressing different LtaS 
fusion proteins. LtaS fusion proteins indicated above each lane were expressed from a multi-copy 
plasmid by the addition of Atet, after removal of IPTG, in the S. aureus LtaS depletion strain ANG499. 
A strain expressing S. aureus LtaS, B. subtilis YvgJ or a strain containing the empty plasmid pCN34 
(no insert) were used as controls. Cultures were grown to mid-log phase and lipids extracted and 
separated by TLC as described in the Materials and Methods chapter (section 2.10). Glycolipids were 
visualized by staining with α-naphthol/sulphuric acid. The origin is marked with a dashed line and the 
positions of the glycolipids Glc2-DAG (top band) and GroP-Glc2-DAG (bottom band) are indicated 
with an arrow on the right of the panel. S. aureus strains ANG1130, ANG1571, ANG1658, and 
ANG2165 to ANG2169 were used for this experiment. 
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4.4 The 5TM and eLtaS cannot be expressed separately 
without loss of function 
          LtaS is efficiently processed during bacterial growth, and the experiments 
described in sections 4.2 and 4.3 have shown that the 5TM domain is essential for in 
vivo function. To investigate if the LtaS enzyme retains any activity once split into the 
5TM and eLtaS domains, an S. aureus strain was constructed in which these two 
domains were expressed as separate proteins. S. aureus strain ANG595 carries the 
native ltaS gene under IPTG inducible promoter control, while the Sec-eLtaS protein 
is expressed from the Atet inducible promoter (Fig. 20A). A plasmid containing the 
5TM domain under native LtaS promoter control was introduced into this strain, 
allowing for the expression of the 5TM domain and the secreted eLtaS domain as two 
separate fragments, in the absence of IPTG and presence of Atet (Fig. 20A). The 
empty plasmid pCN34 and a plasmid for expression of the full-length LtaS protein 
were also introduced into strain ANG595, and these strains served as controls. No 
growth complementation or LTA production was observed upon expression of the two 
domains as separate fragments in contrast to the expression of the full-length protein 
(Fig. 20B and C). Western blot analysis of supernatant and whole cell fractions 
confirmed the expression and secretion of the eLtaS domain in all strains tested (Fig. 
20D). However, expression of the 5TM domain fragment could not be verified by 
western blot, neither when expressed as C- nor as N-terminal His-tag fusion proteins. 
To overcome this problem, the LtaST300A variant in which the active site threonine is 
mutated to an alanine residue, was expressed in place of the 5TM domain. The 
LtaST300A variant is inactive but stably expressed (Lu et al, 2009) and once cleaved the 
5TM domain will at least be present temporarily in the membrane. To this end, 
plasmid pCN34itet-ltaST300A was introduced into S. aureus ANG595 (Fig. 20A) and 
addition of Atet to this strain resulted in the expression of both the LtaST300A variant 
and the secreted eLtaS domain (Fig. 20D). However, their co-expression also failed to 
promote bacterial growth or LTA production (Fig. 20B and C). These results suggest 
that the 5TM and eLtaS domains cannot be assembled post-synthesis to form a 
functional enzyme, and consequently the LtaS processing step seems to irreversibly 
inactivate the enzyme. 
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Figure 20: LtaS functions as a full-length but not as a 5TM - eLtaS split enzyme. (A) Schematic 
representation of S. aureus strain used for the separate expression of the 5TM domain and the 
eLtaS domain. The secreted eLtaS variant (Sec-eLtaS) was expressed from a chromosomal integration 
vector by the addition of Atet, and the 5TM domain of LtaS (5TM), an inactive full-length LtaS variant 
(LtaST300A) or WT LtaS (LtaS; positive control) were expressed from a multi-copy plasmid. A strain 
containing the empty plasmid vector pCN34 (no insert) was used as negative control. (B) Bacterial 
growth curves. The growth of S. aureus strains described in (A) was monitored by determining OD600 
readings at the indicated time points. Cultures were back-diluted 1:100 into fresh medium at the 4 h 
time point and the culture with the WT LtaS expressing control strain was back-diluted a second time 
at the 8 h time point, to maintain cultures in the logarithmic growth phase. (C) LTA and (D) LtaS 
detection by western blot. Samples were prepared and analyzed by western blot as described in the 
Materials and Methods chapter (section 2.5). Sizes of protein standards separated alongside are given in 
kDa on the left of the panel. A square ( ) indicates full-length LtaS protein and a star (∗) denotes the 
cleaved eLtaS protein fragment. The anti-LtaS western blot with cell samples was exposed twice as 
long as the western blot with supernatant samples. S. aureus strains ANG1226, ANG1227, ANG1228 
and ANG1690 were used for this experiment. 
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4.5 Functional analysis of hybrid fusions between S. aureus 
LtaS and B. subtilis orthologues YflE, YfnI and YqgS 
          BLAST database searches of microbial genomes identified one or more LtaS 
orthologues in Gram-positive bacteria that synthesize polyglycerolphosphate LTA. 
For instance, whereas S. aureus has one ltaS gene, its close relative B. subtilis encodes 
four LtaS orthologues (YflE, YfnI, YqgS and YvgJ) with more than 40 % identity to 
S. aureus LtaS. All four proteins have the same predicted membrane topology and 
domain structure as S. aureus LtaS. In addition, all four proteins contain an Ala-X-Ala 
sequence motif at the end of the conserved linker region, which is reminiscent of and 
has been predicted to be a signal peptidase cleavage site (Antelmann et al, 2001). 
Furthermore, in proteomic studies, processed forms of YflE and YfnI were detected in 
the culture supernatant (Hirose et al, 2000; Tjalsma et al, 2004), showing that at least 
some of the B. subtilis proteins are cleaved, and the enzymatic domains released into 
the culture supernatant similar to what was observed for S. aureus LtaS (Gatlin et al, 
2006; Lu et al, 2009; Ziebandt et al, 2001). By expressing each of the four B. subtilis 
orthologues in an S. aureus ltaS depletion strain, it was revealed that YflE and YfnI 
encode for LTA synthases, capable of producing polyglycerolphosphate polymers 
(Gründling & Schneewind, 2007a). However, YfnI-produced polymers could not 
restore the growth defect of a S. aureus ltaS depleted strain and had an altered 
mobility on SDS-PAGE gels, indicative of structural alterations (Gründling & 
Schneewind, 2007a). No enzyme activity was observed for YqgS or YvgJ. 
          To investigate which part of the YfnI protein (membrane versus enzymatic 
domain) is responsible for the synthesis of structurally altered polyglycerolphosphate 
and for the inability of YfnI to complement staphylococcal growth, hybrid fusions 
between functional LtaS-type proteins (S. aureus LtaS and B. subtilis YflE) and the 
non-functional (in terms of growth complementation) B. subtilis YfnI protein were 
constructed and analyzed for in vivo activity. We also designed and tested two fusions 
between S. aureus LtaS and the non-functional B. subtilis YqgS enzyme. YqgS was 
termed non-functional because of its inability to complement growth and LTA 
production in an S. aureus ltaS depleted strain when expressed from a single copy 
integration vector (Gründling & Schneewind, 2007a). Furthermore, two fusions 
between functional LtaS-type proteins (S. aureus LtaS and B. subtilis YflE) were 
included in the study and served as positive controls. A schematic representation of 
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the hybrid fusions constructed is shown in Fig. 21. Fusion proteins containing 
enzymatic domains of the B. subtilis LtaS-type enzymes were constructed as C-
terminal His-tag proteins for detection purposes, whilst fusions harbouring the S. 
aureus eLtaS domain were detected using an LtaS specific antibody. It was speculated 
that the conserved linker region within LtaS-type enzymes might interact with the 
5TM or with the enzymatic domain in a protein specific manner. It was therefore 
decided to construct multiple hybrid fusions in which the linker region was either 
derived from the 5TM or from the enzymatic domain of the fusion protein.  
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Figure 21: Schematic representation of the different fusions between functional (S. aureus LtaS 
and B. subtilis YflE) and non-functional (B. subtilis YfnI and YqgS) LtaS-type enzymes used for 
complementation studies. Protein portions shown in grey are derived from the S. aureus LtaS protein, 
coloured fragments are derived from the B. subtilis YfnI (red), YqgS (green) and YflE (blue) proteins 
and fusion sites are indicated by yellow stars. Hybrid fusions, which contain the enzymatic domains of 
YflE, YfnI or YqgS, were designed as C-terminal His-tag fusions for protein detection purposes. 
Details on the construction of these fusion proteins can be found in the Materials and Methods chapter 
(section 2.12).  
 
          To test the functionality of the different hybrid fusion proteins, the same 
complementation assay as described for the LtaSS218P variant in section 3.6 was used. 
For this assay, the hybrid fusions were expressed from the Atet inducible pitet 
promoter in S. aureus strain ANG499. Functional complementation of ltaS depletion 
was analyzed by adding Atet to the culture medium after removal of IPTG. S. aureus 
control strains ANG499 harbouring the empty pitet plasmid (negative control) or pitet 
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with WT ltaS (positive control) were included in the experiment. Atet induced 
expression of WT LtaS restored both bacterial growth and LTA synthesis in a ltaS 
depleted S. aureus mutant strain (Fig. 22 and 23A). Similarly, the YflETM-linkeYfnI-His 
fusion partially restored staphylococcal growth, although no LTA signal could be 
detected by western blot using Tris/glycine gels (Fig. 22C and 23A). It is plausible 
that the YflETM-linkeYfnI-His polymer might be very short and thus has a faster 
mobility on SDS-PAGE compared to WT LTA, and was therefore lost during the 
separation process. Indeed, it was possible to detect a YflETM-linkeYfnI-His dependent 
signal for a polyglycerolphosphate polymer by western blot using Trycine gels, which 
provide a higher resolution for low molecular weight proteins than Tris/glycine gels 
(Fig. 23B). However, none of the other eleven hybrid proteins, including domain 
swaps between functional LTA synthases (S. aureus LtaS and B. subtilis YflE), were 
able to complement growth and/or LTA production (Fig 22 and 23A). With the 
exception of the YqgSTMlink-eLtaS construct, expression of all other hybrid fusions was 
confirmed by western blot using the eLtaS-specific antibody or a His-tag specific 
antibody (Fig. 23C). It is possible that the inability to detect the YqgSTMlink-eLtaS 
fusion results from a general instability of the protein. Alternatively, the B. subtilis 
YqgS ribosomal binding site might not be recognized efficiently by the 
staphylococcal translation machinery and therefore translation levels of the hybrid 
fusion protein might be low. Processed forms of some of the hybrid fusions could be 
detected in culture supernatants. In general, constructs containing the eYfnI domain 
were not processed in S. aureus, whereas fusions containing the eLtaS, eYqgS or 
eYflE domain were cleaved. In summary, while these data demonstrate that one of the 
B. subtilis / S. aureus LtaS hybrid proteins, namely YflETM-linkeYfnI-His, retains some 
in vivo enzyme activity, these data also suggest a specific interaction between the 
5TM and the enzymatic domain of LtaS-type enzymes, which is essential for enzyme 
function. This proposed interaction appears to be protein specific, based on the 
observation that hybrid fusions between functional LtaS-type enzymes resulted in 
non-functional proteins. The fact that the YflETM-linkeYfnI-His hybrid fusion could 
partially restore staphylococcal growth and LTA synthesis indicates that the 
interaction between the two domains is, to some extent, repaired in this construct. 
However, the construct only shows in vivo activity if the linker region is derived from 
the YfnI enzyme, as a hybrid fusion containing the same domains but the YflE linker 
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region (YflETMlink-eYfnI-His), proved to be non-functional. These findings indicate 
that the enzymatic domain of LtaS-type enzymes interacts with both the 5TM and the 
linker region in a protein specific manner and that both interactions are required for 
enzyme function.  
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Figure 22: (A-C) Bacterial growth curves of S. aureus mutants expressing hybrid fusions between 
S. aureus/ B. subtilis LtaS-type enzymes. The hybrid fusion proteins depicted in Fig. 21 were 
expressed in S. aureus ANG499 by the addition of Atet, after removal of IPTG. A strain expressing 
WT LtaS served as positive and a strain containing the empty pitet vector (no insert) as a negative 
control. Bacterial growth was monitored by OD600 measurements of staphylococcal cultures. At the 4 h 
time point all cultures and at the 8 h time point WT LtaS expressing cultures were back-diluted 1:100 
in fresh medium, to maintain bacteria in the logarithmic growth phase. S. aureus strains ANG514, 
ANG513 and ANG1340-1351 were used for this experiment. 
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Figure 23: LTA and protein detection in S. aureus mutants expressing hybrid fusions between S. 
aureus/ B. subtilis LtaS-type enzymes. LTA detection by western blot using (A) Tris/glycine gels 
or (B) Trycine gels and (C) detection of hybrid fusion proteins by western blot. Samples from the 
same cultures analyzed for growth complementation in Fig. 22 and the LtaS-His expressing strain 
ANG587 were prepared and analyzed by western blot as described in the Materials and Methods 
chapter (section 2.5). Cell-associated LTA was detected using an LTA specific antibody, and the 
hybrid fusion proteins in the supernatant (sup) and the whole cell (cell) using an eLtaS-specific or a 
anti-His antibody. Sizes of protein standards separated alongside are given in kDa on the left of the 
panel. A square ( ) indicates full-length protein and a star (∗)  denotes the cleaved protein fragment.  
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Chapter 5  
Discussion of chapters 3 and 4 
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          S. aureus polyglycerolphosphate LTA is synthesized by LtaS, a membrane 
protein with five N-terminal transmembrane helices followed by a C-terminal 
extracellular enzymatic domain (eLtaS). The protein is cleaved during bacterial 
growth and the eLtaS domain released from the membrane (Ziebandt et al, 2001). In 
Chapter 3 and 4 evidence was provided that LtaS processing is most likely 
accomplished by the signal peptidase SpsB and serves as mechanism to irreversibly 
inactivate the enzyme so that it can no longer function in the LTA synthesis pathway. 
          In this study, it was shown that the S. aureus LtaS protein is efficiently cleaved 
and the eLtaS domain localizes to the supernatant and cell wall fraction. The main 
processing site in the LtaS protein was identified following residues 215Ala-Leu-Ala217, 
located within the linker region between the 5TM and eLtaS domains (Fig. 15D). 
Further experimental evidence is provided that the essential S. aureus type I signal 
peptidase SpsB is the protease responsible for this processing step, as depletion of 
SpsB leads to an accumulation of the full-length protein, whilst inactivation of any of 
the other currently known extracellular protease does not affect LtaS processing 
(sections 3.4 and 3.5). In addition, introduction of a proline residue at the +1 position 
with respect to the cleavage site, which is known to inhibit signal peptidase-dependent 
cleavage, prevents LtaS processing at this site (Fig. 15B). However, it should be noted 
that LtaS is a very atypical substrate for this type of protease. Usually signal peptidase 
substrates contain an N-terminal signal peptide that consists of a positively charged 
N-terminus, a central hydrophobic region and a polar extracellular C-terminal region, 
which contains the actual cleavage site, often ending with an Ala-X-Ala sequence at 
the -3 to -1 position of which the alanine at position -1 is especially important (van 
Roosmalen et al, 2004). Typically, the cleavage sites are placed 3-7 residues after the 
hydrophobic core, and this spacing is critical, as signal peptidases are integral 
membrane enzymes with an active site in close proximity to the bacterial membrane 
(van Roosmalen et al, 2004). LtaS is cleaved after an Ala-X-Ala motive, and this 
motif is quite conserved among LtaS-type enzymes, in particular the alanine at the -1 
position, which is a typical feature for a signal peptidase substrate. However, the 
motif is not located after an N-terminal signal peptide but following multiple TM 
helices and furthermore, the processing site is more than 40 amino acids after the end 
of the last hydrophobic region. Therefore, we must assume that the binding of the 
eLtaS domain to its lipid substrate PG, or alternatively an interaction between the 
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eLtaS domain and the 5TM domain (discussed below) retains the cleavage site in 
close enough proximity to the membrane for signal peptidase to act upon. Usually it is 
thought that signal peptides are removed either during the translocation step or shortly 
afterwards (van Roosmalen et al, 2004). However, LtaS needs to persist intact long 
enough to perform its function in the LTA synthesis pathway, and therefore a 
mechanism might be in place that determines the exact timing of this processing step.  
          The E. coli MdoB protein is a Mn2+-dependent metal enzyme that performs a 
reaction similar to that of LtaS (Goldberg et al, 1981; Jackson et al, 1984). MdoB 
catalyzes the transfer of GroP subunits from the membrane lipid PG onto periplasmic 
oligosaccharides under low-osmolarity conditions. Interestingly, similar to LtaS, 
MdoB consists of an N-terminal domain with multiple TM helices and a C-terminal 
extracellular enzymatic domain (Lequette et al, 2008). The enzymatic domain of 
MdoB is also cleaved during bacterial growth by a yet unknown protease also 
speculated to be signal peptidase and released from the membrane into the 
periplasmic space (Lequette et al, 2008). Recently, a model was proposed in which 
the full-length MdoB enzyme transfers GroP from the lipid PG onto nascent 
oligosaccharide molecules, whilst the cleaved protein is thought to swap GroP 
subunits from one oligosaccharide molecule to another (Lequette et al, 2008). Thus, it 
is thought that MdoB processing leads to a switch in substrate specificity, but that 
both the full-length and the cleaved forms are necessary for proper substitution of the 
membrane-derived oligosaccharides. It is not assumed that GroP subunits are 
transferred between different LTA chains in S. aureus or onto a different acceptor 
molecule. However, S. aureus LtaS is thought to perform two slightly different 
reactions; LtaS primes LTA synthesis by the addition of a GroP subunit to a hydroxyl 
group of the glycolipid anchor and subsequently polymerizes the LTA chain by the 
addition of GroP subunits to the hydroxyl group of the terminal GroP subunits, 
presumably using PG as substrate for both reaction. However, in contrast to MdoB, 
the data provided in this study suggest that the cleaved eLtaS fragment does not retain 
any activity relevant for the synthesis of LTA, as expression of the eLtaS domain 
alone neither results in polyglycerolphosphate chain formation nor in the production 
of the GroP-glycolipid intermediate (sections 4.2 and 4.3). It cannot formally be 
excluded that the eLtaS domain retains another in vivo activity, which was not 
observed because of the types of assays that were performed. It is possible that eLtaS 
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is still able to hydrolyze the membrane lipid PG without performing a transfer 
reaction. Alternatively, the eLtaS domain might indeed be involved in the transfer of 
GroP subunits between chains, from the LTA chain onto other molecules or the 
release and degradation of LTA chains, all of which is highly speculative. However, 
what seems to be clear is that in the absence of a functional full-length LtaS protein, 
the eLtaS domain alone is not sufficient to promote LTA synthesis and growth of S. 
aureus.  
          The data clearly indicate that the 5TM domain of LtaS plays an essential, yet 
unknown, role in LtaS enzyme function. It is possible that this domain recruits and 
“prepares” the PG lipid substrate for efficient hydrolysis by the active site located in 
the eLtaS domain. Interestingly, two enzymes, which were produced by fusing the 
5TM and eLtaS domains of two functional LtaS-type enzymes, resulted in the 
formation of hybrid proteins that were unable to produce LTA (section 4.5). This 
indicates that very specific protein/protein interactions might occur between the 5TM 
and eLtaS domains and perhaps only through these interactions a fully functional 
active site will be formed. Moreover, it was found that expression of the N- and C-
terminal LtaS domains as one protein is crucial for enzyme function, and the two 
domains cannot be expressed in trans without loss of function. Contrary to LtaS, the 
S. aureus MprF enzyme is composed of two distinct domains that can be physically 
separated, but the split protein remains functional. MprF catalyses the modification of 
PG with L-lysine resulting in the production of Lys-PG, which is thought to protect 
bacteria against antimicrobial peptides. Whilst the C-terminal domain of MprF is 
required for the synthesis of Lys-PG, the N-terminal domain is needed to flip Lys-PG 
from the inner to the outer leaflet of the bacterial membrane where the lysine-lipid is 
thought to function (Ernst et al, 2009). 
          In summary, the data presented in this work provide strong evidence that only 
the full-length LtaS enzyme is functional and active in the LTA synthesis pathway 
(Fig. 24). Furthermore, it is speculated that the LtaS processing step has a regulatory 
role and provides a mechanism for the cell to control LtaS activity. This might be of 
importance during the bacterial cell cycle and division process, or when bacteria enter 
the stationary phase and no longer divide. One can assume that under non-dividing 
conditions a halt in LTA synthesis is essential for bacteria to maintain a normal 
membrane composition and integrity. 
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Figure 24: Model for LtaS enzyme function in vivo. The full-length LtaS protein is enzymatically 
active and synthesizes polyglycerolphosphate LTA. At some point the enzyme is proteolytically 
cleaved by the signal peptidase SpsB, and the eLtaS domain is released from the bacterial membrane. 
The cleaved LtaS protein is enzymatically inactive and no longer contributes to LTA synthesis.  
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Chapter 6  
In vitro enzyme analysis of the B. subtilis LtaS 
orthologues 
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6.1 Objective of chapter 6 
          B. subtilis has four LtaS-like enzymes, namely YflE, YfnI, YqgS and YvgJ. All 
four enzymes show the same membrane topology consisting of five N-terminal 
transmembrane helices followed by a C-terminal extracellular enzymatic domain. In 
this chapter the enzymatic domains of all four B. subtilis LtaS-type enzymes were 
purified as N-terminal His-tag proteins from E. coli extracts and used for in vitro 
studies. A previously established in vitro assay for LtaS-type enzymes was used to 
determine enzyme kinetics of the purified proteins. The substrate specificity and ion 
dependency of all four B. subtilis LtaS-type enzymes was investigated.  
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6.2 All four B. subtilis LtaS orthologues are enzymatically 
active and hydrolyze fluorescently labeled PG 
          Enzymatic activities have previously only been detected for YflE and YfnI, two 
of the four B. subtilis LtaS orthologues (Gründling & Schneewind, 2007a). Recently, 
Karatsa-Dodgson et al developed an in vitro assay to measure S. aureus eLtaS 
enzyme activity (Karatsa-Dodgson et al, 2010). In this assay, purified enzyme was 
incubated with fluorescently labeled NBD-PG lipid, a labeled version of the proposed 
substrate for LtaS-type enzymes. It is assumed that LtaS hydrolyzes the 
glycerolphosphate head group of the lipid PG, and in the in vitro assay this reaction 
would result in the production of glycerolphosphate and fluorescently labeled 
diacylglycerol (NBD-DAG) (Fig. 25A). The input lipid NBD-PG, and the product 
lipid NBD-DAG can be separated on thin layer chromatography (TLC) and visualized 
with a fluorescence imager. Using this assay, it was determined that the purified 
enzymatic domain of S. aureus LtaS, eLtaS, but not the active site variant eLtaS-
T300A, hydrolyzes fluorescently labeled NBD-PG (Karatsa-Dodgson et al, 2010). To 
determine if the B. subtilis LtaS orthologues can perform the same reaction, the 
enzymatic domains of all four B. subtilis proteins were cloned, expressed and purified 
as N-terminal His-tagged versions from E. coli extracts (Fig. 25B). Purified enzymes 
were mixed with NBD-PG lipid and incubated for 3 h in the presence of MnCl2. 
Subsequently, lipids were extracted, separated by TLC and plates scanned using a 
fluorescence imager to visualize lipid bands. As a positive control, the commercially 
available Bacillus cereus phospholipase C (PLC) was used. This enzyme cleaves PG 
resulting in the production of DAG (Shinitzky et al, 1993). When the reactions were 
performed using each of the four B. subtilis proteins, two major fluorescent lipid 
bands were observed (Fig. 25C). The faster migrating band had the same mobility as 
the hydrolysis product produced by PLC, and presumably corresponds to NBD-DAG, 
and the slower migrating band had the mobility of the NBD-PG input lipid. No lipid 
corresponding to NBD-DAG was detected in reactions set up without enzyme. In 
summary, these data demonstrate that all four recombinant B. subtilis proteins are 
enzymatically active, and suggest that all proteins hydrolyze the phosphodiester bond 
of NBD-PG resulting in the production of NBD-DAG. 
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Figure 25: In vitro activity of B. subtilis LtaS-type enzymes. (A) Chemical structures of 
fluorescently labeled NBD-PG and NBD-DAG lipids with known S. aureus LtaS and B. cereus 
PLC cleavage site indicated by an arrow. (B) Coomassie stained gel of purified B. subtilis LtaS-
like proteins. Extracellular enzymatic domains of B. subtilis YflE, YfnI, YqgS and YvgJ were purified 
as N-terminal His-tag fusion proteins, and ten µg purified protein separated on a 10 % (w/v) SDS-
PAGE gel and visualized by staining with Coomassie brilliant blue. Sizes of protein standards in kDa 
are shown on the left. (C) TLC analysis of B. subtilis YflE, YfnI, YvgJ and YqgS in vitro reaction 
products. The NBD-PG lipid substrate was incubated with eYflE, eYfnI, eYvgJ or eYqgS enzyme. 
Subsequently, lipids were extracted and separated by TLC and fluorescent lipid bands visualized by 
scanning plates with a fluorescence imager. As negative and positive controls, reactions were set up 
without enzyme or with the B. cereus PLC enzyme, respectively. Note that only 10 % of the PLC 
reaction was run on the TLC plate. Positions of NBD-PG and presumed NBD-DAG reaction product 
are indicated on the left, and proteins added to each reaction are shown on the top of the panel.  
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          To gain further insight into the relative activity of the four B. subtilis proteins, a 
time course experiment was performed. Reactions were set up as described above, 
samples removed at the indicated time points, and lipid reaction products analyzed 
(Fig. 26A). The amount of the NBD-DAG reaction product obtained was quantified 
using the AIDA software program, and % hydrolysis calculated based on the amount 
of NBD-DAG produced in the PLC control reaction, which proceeds to near 
completion (Fig 25C). Three independent experiments were performed, and the first 
three time points, during which the reaction speed appeared to be linear, were used to 
determine the maximal enzyme activity of the four B. subtilis protein (Fig. 26B). 
Enzyme activities ranging from 0.0067 (YfnI) to 0.0007 (YvgJ) ng lipid hydrolysis / 
[min × µM enzyme] were measured in this in vitro assay set up. These results indicate 
that while all four enzymes are active, YfnI, YflE and YqgS have > 4.6-fold higher 
activity as compared to YvgJ. 
 
 
 
 
Figure 26: Kinetic measurements for recombinant YflE, YfnI, YqgS and YvgJ enzymes. (A) Time 
course experiment. Enzyme reactions were set up as described in the Materials and Methods chapter 
(section 2.9.2), aliquots removed at the indicated time points and reactions stopped by the addition of 
chloroform and methanol. Lipids were separated on TLC plates, and the NBD-DAG reaction product 
quantified. For each time point and enzyme the average value and standard deviation of three values is 
plotted. Three independent experiments were performed and a representative graph is shown. (B) 
Maximal enzyme activity of B. subtilis YflE, YfnI, YqgS and YvgJ. The slope of the linear fit 
through the first three data points of the curve shown in (A) was used to calculate the maximal enzyme 
activity for each B. subtilis LtaS orthologue. Three independent time course experiments were used to 
determine an average value and standard deviation for the maximal enzyme activity and these values 
are plotted.  
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6.3 All four B. subtilis LtaS orthologues are Mn2+-dependent 
enzymes with substrate specificity for NBD-PG 
          S. aureus LtaS is a Mn2+-dependent metal enzyme (Karatsa-Dodgson et al, 
2010). In contrast, structural analysis of the soluble enzymatic domain of the B. 
subtilis YflE protein revealed the presence of a Mg2+ ion in the active center (Schirner 
et al, 2009). However, this ion was also present in the crystallization buffer and as 
such may not reflect the ion relevant for enzyme activity. To test which metal ion is 
required for the activity of the B. subtilis enzymes, in vitro assays were performed in 
the presence of different divalent metal ions, and the signal for the reaction product 
quantified. As presented in Fig. 27, all four proteins showed the highest activity in the 
presence of MnCl2. Addition of MgCl2 or CaCl2 in place of MnCl2 resulted only in 
weak enzyme activity, and no activity above background was seen in the presence of 
ZnCl2.  
 
 
 
Figure 27: B. subtilis LtaS-type enzymes require Mn2+ for activity. In vitro enzyme assays were 
performed with NBD-PG lipid as the substrate in the presence of 10 mM MgCl2, MnCl2, CaCl2 or 
ZnCl2, and reactions initiated by the addition of eYflE (A), eYfnI (B), eYqgS (C) or eYvgJ (D). As 
controls, reactions were set up without enzyme, or without metal ion added. Samples were incubated 
for 3 h at 37°C, lipids extracted and separated by TLC. Plates were scanned and signals of the reaction 
product quantified. Reactions were performed in triplicate, and the average value and standard 
deviation plotted. The average fluorescence reading for the reactions set up with MnCl2 was set to 1 
and other values were adjusted accordingly. 
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          S. aureus LtaS uses NBD-labeled PG lipid as substrate, but not NBD-PC, NBD-
PS or NBD-PE (Karatsa-Dodgson et al, 2010). The substrate specificity of the four B. 
subtilis enzymes was examined, and it was found that these enzymes also only use 
NBD-PG as substrate, and not NBD-PC, NBD-PS or NBD-PE (Fig. 28). Taken 
together, these results strengthen the hypothesis that all members of the lipoteichoic 
acid synthase enzyme family are Mn2+-dependent metal enzymes that only use lipids 
with a glycerolphosphate head group as substrate. 
 
                                        
 
Figure 28: NBD-PG is the sole lipid substrate for B. subtilis YflE, YfnI, YqgS and YvgJ. Standard 
enzyme reactions were set up using NBD-PG, NBD-PS, NBD-PE or NBD-PC as substrate (indicated 
on the left of the panel) and reactions were initiated by the addition of the different B. subtilis enzymes. 
As negative control, lipid substrates were incubated without enzyme (no enzyme) and as a positive 
control, a PLC reaction using NBD-PG as substrate was run alongside on each TLC plate in order to 
determine the mobility of the reaction product. Note that only the upper part of the TLC plates is shown 
with the area of the reaction product. 
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Chapter 7  
In vivo functions of the B. subtilis LtaS orthologues 
 
 
 
 
126 
7.1 Objective of chapter 7 
          In a previous study all four B. subtilis LtaS-type enzymes were expressed in an 
ltaS depleted S. aureus strain, and it was revealed that yflE and yfnI encode for LTA 
synthases (Gründling & Schneewind, 2007a). However, while YflE was able to 
complement staphylococcal growth, YfnI did not, and glycerolphosphate polymers 
synthesized by YfnI displayed an altered mobility on SDS-PAGE compared to WT 
LTA, indicative of structural alterations. No enzyme activity was observed for YqgS 
and YvgJ (Gründling & Schneewind, 2007a). In this chapter a different 
complementation assay was used to identify in vivo functions for YqgS and YvgJ. 
Moreover, the contribution of all four B. subtilis LtaS-type enzymes to LTA synthesis 
in their natural host was investigated in defined B. subtilis mutant strains. In addition, 
LTA was purified from S. aureus strains expressing either WT LtaS or B. subtilis 
YfnI, and the isolated glycerolphosphate polymers were analysed by NMR and 
standard biochemical assays.  
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7.2 B. subtilis YqgS is an LTA synthase, capable of 
producing polyglycerolphosphate  
          The finding that YqgS and YvgJ can cleave NBD-PG is in contrast to a 
previously performed complementation study that showed that YqgS and YvgJ could 
not promote LTA synthesis in S. aureus (Gründling & Schneewind, 2007a). One 
reason why no in vivo activity for YqgS and YvgJ was observed could be insufficient 
expression achieved from the single copy integration vector used in the previous study 
(Gründling & Schneewind, 2007a). To test whether expression of YqgS and YvgJ 
from a multi-copy plasmid would reveal an in vivo enzyme function for these 
proteins, all four B. subtilis genes coding for LtaS-type proteins, as well as the S. 
aureus ltaS gene, were cloned under Atet promoter control into the multi-copy 
plasmid vector pCN34 (Fig. 29A). In addition, the ribosome binding site (RBS) of 
yqgS was replaced with the RBS that precedes the S. aureus ltaS gene, in which a 
string of Gs is located 8 bases in front of the ATG start codon, indicative of a good 
RBS (Vellanoweth & Rabinowitz, 1992). For protein detection purposes, the four B. 
subtilis ltaS orthologues and the S. aureus ltaS gene were cloned as C-terminal his-tag 
fusions under Atet inducible promoter control into pCN34. Resulting plasmids and the 
empty pCN34 vector control were introduced into S. aureus strain ANG499, which 
carries the chromosomal copy of ltaS under IPTG inducible spac promoter control 
(Fig. 10). Functional complementation of ltaS was examined in the resulting strains 
after removal of IPTG by the addition of Atet to the growth medium for expression of 
the different B. subtilis LtaS orthologues. As described previously, YflE was able to 
complement both growth and LTA production in the S. aureus ltaS depletion strain, 
whereas YfnI could only promote polyglycerolphosphate synthesis but not the growth 
of S. aureus (Fig. 29B and C). Interestingly, expression of YqgS under these 
conditions could also restore bacterial growth, albeit to a lesser extent than YflE. 
Furthermore, upon increasing the exposure time of western blots, a YqgS-dependent 
signal for a faster migrating polyglycerolphosphate polymer was detected, next to 
other bands, which were also seen in the negative (no insert) control sample (Fig. 
29C). It is assumed that these other bands, also present in the negative control sample, 
are LTA-specific (as they are detected with a monoclonal antibody) and either due to 
a slight leakiness of the inducible spac promoter system or due to small amounts of 
LTA remaining on the cells even four hours after the shut down of LtaS expression as 
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these bands are absent from samples isolated from a S. aureus strain with a complete 
ltaS deletion (R. Corrigan; unpublished results). In contrast, even under these 
conditions, YvgJ expression did not result in growth of S. aureus or LTA production. 
Expression of YflE, YfnI and YqgS, but not YvgJ was confirmed by western blot 
(Fig. 29D). Interestingly, in contrast to YflE, YfnI and YqgS were not processed in S. 
aureus, and only the full-length proteins were visible in whole cell samples. Taken 
together, these results demonstrate that YqgS functions as a lipoteichoic acid 
synthase, capable of promoting polyglycerolphosphate LTA backbone synthesis. 
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Figure 29: Functional complementation of an S. aureus ltaS-depletion strain with B. subtilis yflE, 
yfnI, yqgS or yvgJ expressed from a multi-copy plasmid. (A) Schematic representation of 
complementation strains. S. aureus strains used for complementation analysis contain the 
chromosomal copy of ltaS under IPTG inducible expression control and harbor a multi-copy plasmid 
(pCN34) for expression of LtaS orthologues from the Atet inducible promoter. (B) Bacterial growth 
curves. Washed overnight cultures of S. aureus strains expressing WT LtaS, B. subtilis YflE, YfnI, 
YqgS or YvgJ and a strain containing the empty pCN34 vector (no insert-negative control) were 
diluted 1:100 into fresh medium containing Atet and growth was monitored by determining OD600 
readings at the indicated time points. All cultures were back-diluted 1:100 at the 4 h time point and 
cultures with strains expressing LtaS, YflE and YqgS were back diluted a second time at the 8 h time 
point, to maintain cultures in the logarithmic growth phase. S. aureus strains ANG1571, ANG1662, 
ANG1573, ANG1654, ANG1662 and ANG1130 were used for this experiment (C) LTA and (D) 
protein detection by western blot. The same S. aureus strains and growth conditions as described 
above were used for LTA analysis by western blot. For protein detection studies, S. aureus strains 
expressing WT LtaS, any of the four B. subtilis orthologues as C-terminal His-tag fusions, and a strain 
containing the empty pCN34 vector (no insert-negative control) were used (strains ANG1572, 1574, 
1655, 1659, 1663 and 1130). Samples were prepared and analyzed by western blot as described in the 
Materials and Methods chapter (section 2.5). Cell associated LTA was detected using a LTA specific 
antibody and proteins in the supernatant (sup) and the whole cell (cell) using an anti-His antibody. 
Sizes of protein standards separated alongside are given in kDa on the left of the panel. A square ( ) 
indicates full-length protein and a star (∗)  denotes the cleaved protein fragment. Note that the LTA 
western blot with samples isolated from S. aureus strains expressing YqgS, YvgJ or containing the 
empty vector (no insert) was exposed 4 times longer, and the anti-His western blot with samples from 
the cell fraction was exposed 4.5 times longer than the blot with the supernatant samples. 
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 7.3 B. subtilis YvgJ functions as an LTA primase 
          Expression of yvgJ from a strong promoter and a multi-copy plasmid did not 
restore growth or LTA production in the S. aureus ltaS depletion strain, and neither 
could the YvgJ protein fused to a C-terminal His-tag be detected by western blot 
(section 7.2). It was therefore assumed that either YvgJ does not function as an LTA 
synthase or that the protein is not expressed in S. aureus. In a previous study, it has 
been shown that the L. monocytogenes LtaS-type protein Lmo0644 encodes for an 
enzyme that can transfer one glycerolphosphate subunit onto the glycolipid anchor 
and hence this enzyme was termed LTA primase (Webb et al, 2009). In S. aureus and 
B. subtilis this reaction would lead to the production of the GroP-Glc2-DAG. To test if 
YvgJ could function as an LTA primase, and to investigate if any of the other B. 
subtilis orthologues are involved in the production of glycolipid intermediates, 
membrane lipids were extracted and analyzed from S. aureus strains expressing B. 
subtilis YflE, YfnI, YqgS, YvgJ or S. aureus LtaS as a control. Lipids were extracted 
from log-phase cultures and 500 µg purified lipids were subsequently separated on 
TLC plates, and glycolipids visualized by staining with α-naphthol/H2SO4 (Fig. 30). 
The LTA glycolipid anchor Glc2-DAG (Top band; see also mass spectrometry 
analysis below) could be detected in all samples. However, the intensity of this 
glycolipid band was reduced in samples isolated from YfnI and YvgJ expressing 
strains, and a concomitant accumulation of the lower glycolipid band was observed. 
This lipid species had the mobility as expected for a GroP-di-saccaride-DAG lipid 
(Webb et al, 2009), which would be consistent with the accumulation of the GroP-
Glc2-DAG intermediate. These experiments demonstrate that despite the fact that 
YvgJ could not by detected by western blot in S. aureus, the protein is expressed and 
involved in the synthesis of an LTA glycolipid intermediate.  
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Figure 30: TLC analysis of glycolipids. S. aureus strains ANG1571 (LtaS-expressing), ANG1662 
(YflE-expressing), ANG1573 (YfnI-expressing), ANG1654 (YqgS-expressing), ANG1658 (YvgJ-
expressing) and ANG1130 (containing empty vector pCN34, no insert as negative control) were grown 
to  mid-log phase and lipids extracted as described in the Materials and Methods chapter (section 2.10). 
Five hundred µg total membrane lipids were separated by TLC, and glycolipids visualized by staining 
with α-naphthol/sulphuric acid. The position of the origin is indicated by a dashed line, positions of 
presumed Glc2-DAG (top band) and GroP-Glc2-DAG  (bottom band) lipids are marked with arrows on 
the right of the panel, and proteins expressed in the different strains are indicated above each lane.  
 
          To provide further experimental evidence for this notion, lipids from S. aureus 
strains expressing YflE (predominantly producing the top glycolipid band) and YvgJ 
(accumulating the bottom glycolipid band) were separated by TLC and lipids 
corresponding to α-naphthol/H2SO4 positive areas extracted and analyzed by MALDI 
TOF mass spectrometry, which was performed as described previously (Webb et al, 
2009). Sodium adducts of the glycolipids Glc2-DAG and GroP-Glc2-DAG with C15 
and C18 acyl-chains have an absolute calculated mass of 929.62 and 1083.72, 
respectively (Table 3). In agreement with these expected masses, m/z signals of 
929.59 and 929.66 were observed for lipids isolated from the top bands of samples 
obtained from YflE and YvgJ expressing strains, respectively (Fig. 31A and C). In 
addition, a strong mass signal of 1083.73, as expected for GroP-Glc2-DAG, was 
obtained for lipids isolated from the bottom band of the YvgJ-expressing strain (Fig. 
31D). A corresponding signal was absent from samples prepared from the YflE 
expressing strains (Fig. 31B), which does not show an accumulation of this 
glycolipid. A complete list of predicted and observed masses for the glycolipids Glc2-
DAG and GroP-Glc2-DAG with varying acyl-chain length is given in Table 3. Taken 
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together, these data suggest that YvgJ functions in vivo as an LTA primase capable of 
transferring the initial glycerolphosphate subunit onto the glycolipid anchor, 
producing GroP-Glc2-DAG. Furthermore, despite the fact that YfnI acts as an LTA 
synthase, it also appears to be very efficient in synthesizing the GroP-Glc2-DAG 
intermediate.  
 
 
 
Figure 31: MALDI-TOF analysis of glycolipids produced by YflE and YvgJ-expressing S. aureus 
strains. A total of 2.5 mg lipids isolated from YflE or YvgJ-expressing S. aureus strains were 
separated by TLC, and lipids corresponding to top and bottom glycolipid bands extracted and analyzed 
by MALDI-TOF mass spectrometry. Spectra were recoded in the reflector positive ion mode and are 
shown for (A) YflE top band, (B) YflE bottom band, (C) YvgJ top band and (D) YvgJ bottom band. 
Maximal signal intensity is shown in the top right corner in each panel. Observed masses 
corresponding to calculated masses of glycolipids are shown in red. S. aureus strains ANG1662 (YflE-
expressing) and ANG1573 (YfnI-expressing) were used for this experiment. Note that the MALDI-
TOF analysis was performed by Dr. A. Gründling.  
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Table 3: Predicted and observed masses of glycolipids isolated from membranes 
of S. aureus strains expressing B. subtilis YflE or YvgJ. 
Data were provided by Dr A. Gründling. 
 
Top Band: Glc2-DAG 
possible 
fatty acid chain length 
chemical 
formula 
predicted 
mass 
observed 
mass - YflE  
observed 
mass – YvgJ 
C15/C15 C45H84Na1O15 887.57 887.54 887.62 
C15/C16 C46H86Na1O15 901.59 901.56 901.62 
C15/C17 C47H88Na1O15 915.60 915.58 915.65 
C15/C18 C48H90Na1O15 929.62 929.59 929.66 
C16/C18 C49H92Na1O15 943.63 943.60 943.67 
C17/C18 C50H94Na1O15 957.65 957.61 957.70 
 
Bottom Band: GroP-Glc2-DAG 
possible 
fatty acid chain length 
chemical 
formula 
predicted 
mass 
observed 
mass - YflE  
observed 
mass – YvgJ 
C15/C15 C48H91Na1O20P1 1041.57 absent 1041.67 
C15/C16 C49H93Na1O20P1 1055.59 absent 1055.70 
C15/C17 C50H95Na1O20P1 1069.61 absent 1069.72 
C15/C18 C51H97Na1O20P1 1083.62 absent 1083.72 
C16/C18 C52H99Na1O20P1 1097.64 absent 1097.73 
C17/C18 C53H101Na1O20P1 1111.65 absent 1111.75 
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7.4 B. subtilis signal peptidase SipT and SipV do not 
promote YfnI cleavage in S. aureus  
          From protein detection analysis described in section 7.2, it became apparent that 
of the four B. subtils LtaS-type enzymes YflE, but not YfnI or YqgS, are processed 
when expressed in S. aureus. Interestingly, only YflE could fully complement growth, 
and LTA production in an S. aureus ltaS depleted mutant strain (Gründling & 
Schneewind, 2007a and Fig. 29B and C) In contrast, YfnI was able to promote LTA 
synthesis but not staphylococcal growth and polymers synthesized by YfnI migrated 
with a different mobility on SDS-PAGE compared to WT LTA. In sections 4.2-4.4 
experimental evidence was provided that the full-length LtaS protein represents the 
active enzyme form, and once the protein is split into 5TM and eLtaS, the enzyme no 
longer functions in the LTA synthesis pathway. It was decided to test whether it 
would be possible to process YfnI in S. aureus, and whether enzyme cleavage would 
have an effect on the enzymatic activity of YfnI. In section 3.5, evidence was 
provided that LtaS cleavage is dependent on the signal peptidase SpsB. In contrast to 
S. aureus, which expresses a single functional signal peptidase enzyme, B. subtilis 
contains five chromosomal encoded signal peptidase (SipS, SipT, SipV, SipU, SipW). 
Proteomic studies on secreted proteins in B. subtilis identified processed forms of 
YflE and YfnI in the culture supernatant (Hirose 2000). Moreover, it was shown that 
YfnI cleavage was diminished in the combined absence of the two signal peptidases 
SipT and SipV, suggesting that either of these proteases recognizes YfnI as substrate 
(Antelmann et al, 2001). Based on this information, it was decided to construct a S. 
aureus strain that expresses both YfnI and SipT or SipV. S. aureus strain ANG1282 
carries the native ltaS gene under IPTG inducible spac promoter control, and the YfnI 
protein fused to a C-terminal His-tag is expressed from the Atet inducible pitet 
promoter (Fig. 32A). A plasmid containing the sipT or sipV gene under the ltaS 
promoter control was introduced into this strain (Fig. 32A). For protein detection 
purposes the two genes coding for the signal peptidases SipT and SipV were 
additionally cloned as C-terminal His-tag fusions under ltaS promoter control, and the 
resulting plasmids (pCN34PltaS-sipT-his, pCN34PltaS-sipV-his) introduced into S. aureus 
strain ANG1282. The empty plasmid pCN34 was introduced into strain ANG587, 
which carries the WT ltaS gene under IPTG inducible promoter control and a second 
ltaS copy fused to a C-terminal his-tag under Atet inducible pitet promoter, and this 
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strain served as a positive control. In addition, the empty pCN34 plasmid was 
electroporated into strain ANG513, which harbors the WT ltaS gene under IPTG 
inducible promoter control and the empty pitet plasmid integrated into the 
chromosome. The resultant strain was used as a negative control in this experiment. 
Coexpression of YfnI and SipT or SipV in S. aureus did not result in YfnI processing, 
and polymers synthesized by YfnI in the presence of SipT or SipV displayed the same 
mobility shift on SDS-PAGE as observed for YfnI polymers produced in the absence 
of SipT and SipV (Fig. 32B and C). Western blot analysis of whole cell samples 
confirmed expression of SipT and SipV in S. aureus (Fig. 33A and B). Next, it was 
examined whether expression of multiple B. subtilis signal peptidases in S. aureus 
would promote YfnI cleavage. To investigate this the B. subtilis sipS gene or sipS 
fused to a C-terminal his-tag were cloned downstream of sipT or sipV into pCN34, 
and the resulting plasmids (pCN34PltaS-sipT/S, pCN34PltaS-sipT/S-his, pCN34PltaS-
sipV/S, pCN34PltaS-sipV/S-his) were introduced into S. aureus strain ANG1282 (see 
strain description above). SipS was chosen for this experiment as the protein is 
classified as a major signal peptidase in B. subtilis and thought to be required for the 
secretion of many proteins (Tjalsma et al, 1998). Again, no processed forms of YfnI 
could be detected in culture supernatants upon its expression in combination with 
SipT/S or SipV/S (Fig. 32D and E). In addition, glycerolphosphate polymers 
synthesized by YfnI in these strains displayed the typical mobility shift on SDS-
PAGE compared to WT LTA. Expression of SipS was verified by western blot 
analysis (Fig. 33C and D). These data are somewhat in contrast to the previous 
observation that YfnI processing in B. subtilis is SipT and SipV dependent. However, 
although we could confirm expression of all signal peptidases, it is possible that these 
enzymes are not functional in the heterologous host S. aureus. Another explanation 
for the above described observation could be that the YfnI enzyme does not assume a 
conformation in S. aureus that is accessible to SipT or SipV.  
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Figure 32: Functional complementation of LTA synthesis in an ltaS depleted S. aureus strain with 
B. subtilis YfnI and SipT, SipV and SipS. (A) Schematic representation of S. aureus strains used 
for the expression of YfnI and SipT, SipV and SipS. The B. subtilis YfnI protein was expressed as 
C-terminal His-tag fusion protein from a chromosomal integration vector by the addition of Atet, and 
the B. subtilis derived signal peptidases SipT, SipV and SipS were expressed from a multi-copy 
plasmid. (B-E) LTA western blot analysis. Washed overnight cultures of S. aureus strains expressing 
YfnI as C-terminal His tag fusion and SipT (A), SipV (B), SipT/S (C) or SipV/S (D) were grown for 4 
h in the presence of Atet and absence of IPTG. A strain expressing LtaS fused to a C-terminal His-tag 
and containing the empty plasmid vector pCN34, and an S. aureus strain harboring the empty pitet and 
pCN34 vectors served as controls. Samples were prepared and analyzed by western blot using an LTA 
specific antibody. Sizes of protein standards separated alongside are given in kDa on the left of the 
panel. Proteins expressed are indicated above each lane and a square ( ) indicates full-length protein 
and a star (∗)  denotes the cleaved protein fragment. S. aureus strains ANG1359-ANG1362, ANG1524, 
ANG1525, ANG1528, ANG1529, ANG1598 and ANG1599 were used for this experiment. 
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Figure 33: Protein detection by western blot. The same S. aureus strains and growth condition as 
described in Fig. 32 were used for protein detection studies. Samples were prepared and analyzed by 
western blot as described in Materials and Methods (section 2.5). Proteins in the whole cell (cell) and 
in the culture supernatant (sup) were visualized using an anti-His antibody. Sizes of protein standards 
separated alongside are given in kDa on the left of the panel, and proteins expressed are indicated 
above each lane. A square ( ) indicates full-length protein and a star (∗)  denotes the cleaved protein 
fragment.  
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7.5 Contribution of YflE, YfnI, YqgS and YvgJ to LTA 
synthesis in B. subtilis 
          A B. subtilis strain deleted of all four ltaS-like genes has been constructed 
previously and is viable (Schirner et al, 2009). Several phenotypes were associated 
with the deletion of these genes; a single yflE mutant formed chains, yflE/yqgS and 
yflE/yvgJ double mutants had sporulation defects, and cells lacking all four genes 
formed long chains and spiraled along their long axis (Schirner et al, 2009). To 
correlate deletions of ltaS-like genes with the cellular LTA content, B. subtilis 168 
mutant strains lacking one, three or all four ltaS-like genes were analyzed. To this 
end, cell extracts were prepared from overnight cultures of WT and mutant B. subtilis 
strains, and the LTA content determined by western blot. Initially we attempted to use 
the mouse monoclonal LTA antibody, which was used for the previously described S. 
aureus experiments (chapters 3 and 4). However, when this antibody was used, the 
western blot signal was not strong enough to detect LTA from B. subtilis. It is 
possible that this is either be due to lower LTA amounts or to the additional sugar 
modifications present on the LTA backbone in B. subtilis. However, when a 
humanized monoclonal LTA-specific antibody was used, which is supplied at a higher 
concentration, an LTA specific signal was obtained for a sample isolated from the 
wild type B. subtilis 168 strain (WT) (Fig. 34). This signal was absent from samples 
isolated from a B. subtilis strain lacking all four ltaS-like genes (4×Δ) or a strain 
expressing YvgJ-only (Fig. 34). Of note, in several samples including the YvgJ-only 
and 4×Δ samples, an additional signal in the 30 kDa area was observed, which is 
assumed to be unrelated to LTA and could be cross-reactivity towards the wall 
teichoic acid polymer, which in B. subtilis 168 is also made up of glycerolphosphate 
subunits (Burger & Glaser, 1964). Indeed, this signal was less abundant in the B. 
subtilis 168 hybrid strain L5703 (Karamata et al, 1987) expressing ribitolphosphate 
WTA (ribitol-Pi WTA) in place of glycerolphosphate WTA (Fig. 34). Deletion of 
yfnI, yqgS or yvgJ alone did not significantly affect LTA production. Interestingly, 
deletion of yflE resulted in the production of LTA with an altered mobility on SDS-
PAGE gels, indicative of structural changes (see below). The production of this 
altered LTA was attributed to the function of YfnI, as a B. subtilis strain expressing 
YfnI-only showed a similar altered LTA profile (Fig. 34). This also indicates that 
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YflE affects the activity of YfnI, revealing an unexpected enzymatic interdependence 
of the activity of two LTA-synthases in B. subtilis.  
          In the case of L. monocytogenes, which produces an LTA primase and one LTA 
synthase, a clear difference in LTA production was seen when the LTA primase was 
inactivated (Webb et al, 2009). In B. subtilis no obvious difference in LTA production 
was observed upon inactivation of the LTA primase YvgJ (Fig. 34; compare LTA 
profile of ΔyvgJ strain with wild type strain). To specifically examine if the B. subtilis 
YvgJ enzyme works together with one of the LTA synthases, LTA production in three 
B. subtilis double mutant strains in which YvgJ is expressed with one of the LTA 
synthase enzymes YflE, YfnI or YqgS, was compared to a strain which expresses the 
synthase alone. No difference in LTA production was observed for any of the LTA 
synthases in the absence of the LTA primase (Fig. 34; compare lanes YflE-only with 
express- YvgJ/YflE; YfnI-only with express-YvgJ/YfnI or YqgS-only with express-
YvgJ/YqgS). This indicates that in contrast to L. monocytogenes all B. subtilis LTA 
synthases can efficiently initiate LTA production even in the absence of a dedicated 
LTA primase. However, as shown above and further analyzed below, in B. subtilis 
YflE affects the function of YfnI. 
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Figure 34: LTA production by WT and mutant B. subtilis strains. Samples for LTA analysis by 
western blot were prepared from overnight cultures of WT and mutant B. subtilis 168 strains, and from 
a B. subtilis 168 hybrid strain expressing ribitolphosphate wall teichoic acid. Samples were separated 
on a 15 % (w/v) SDS-PAGE gel, transferred to a PVDF membrane and LTA detected by western blot 
using the humanized monoclonal LTA-specific antibody (Biosynexus Incorporated), and the HRP-
linked anti-human antibody (DakoCytomation) at 1:10,000 dilutions. Sizes of protein standards 
separated in parallel are indicated in kDa on the left of the panel, and strains used are indicated above 
each lane, with abbreviations given in strain Table 1. 
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7.6 YfnI synthesizes glycerolphosphate polymers of 
increased length 
          Polymers produced by YfnI in the absence of YflE migrate with a slower 
mobility on SDS-PAGE gels, both when synthesized in the natural host B. subtilis 
(Fig. 34) or in the heterologous host S. aureus (Gründling & Schneewind, 2007a and 
Fig. 29C). To gain insight into structural alterations of polymers synthesized by YfnI, 
the LTA from WT B. subtilis and the B. subtilis mutants expressing YflE or YfnI only 
was isolated. As can be seen in Fig. 35 purified LTA from the B. subtilis YfnI only 
expressing strain migrated slower on SDS-PAGE compared to WT and the YflE only 
expressing strain when analyzed by western blot. These data further strengthen the 
hypothesis that YfnI synthesises a polymer with structural alterations not only when 
expressed in S. aureus but also in its natural host B. subtilis.  
 
 
Figure 35: Detection of purified LTA from wild type and mutant B. subtilis strains. LTA was 
extracted from wild type and mutant B. subtilis 168 strains as described in the Materials and Methods 
chapter (section 2.6). Ten µg purified LTA was separated on a 15 % (w/v) SDS-PAGE gel and LTA 
detected by western blot using the humanized monoclonal LTA-specific antibody and the HRP-linked 
anti-human antibody. Sizes of protein standards separated in parallel are given in kDA on the left of the 
panel, and strains used are indicated above each lane, with abbreviations given in strain Table 1. 
 
           The LTA yield obtained from the YfnI only expressing B. subtilis strain was too 
low to allow any structural analysis on the polymer. Based on western blot analysis, it 
appeared that S. aureus produces larger amounts of LTA as compared to B. subtilis, 
and it was therefore decided to extract LTA from an S. aureus YfnI-expressing strain 
and compare its composition to polymers produced by LtaS. LTA was isolated from 
mid-log cultures of S. aureus strains ANG514 (LtaS-expressing) and ANG515 (YfnI-
 
 
142 
expressing) using a 1-butanol extraction method and purified by hydrophobic 
interaction chromatography. LTA was purified from four independently grown 
cultures for each strain and analyzed by nuclear magnetic resonance (NMR) and 
standard biochemical assays (Fig. 36). Representative NMR spectra are shown in Fig. 
36A and B. Based on the NMR analysis of all four independently isolated LTA 
samples, an average glycerolphosphate chain length of 35 ± 6 (LtaS) and 54 ± 6 
(YfnI) and average D-Ala modification of 82 ± 5 % (LtaS) and 74 ± 6 % (YfnI) was 
calculated. The difference in chain length is considered to be statistically significant 
(p-value = 0.0048), while the difference in D-Ala modifications is not statistically 
significant (p-value = 0.083). In addition, standard biochemical assays were used to 
determine the phosphate, glucose and D-Ala content in the purified LTA samples 
(Grassl & Supp, 1995; Kunst et al, 1984; Schnitger et al, 1959). LTA in a wild type S. 
aureus strain is linked nearly exclusively to the glycolipid anchor Glc2-DAG 
(Duckworth et al, 1975) and hence the ratio of the phosphate concentration per 2 
glucose molecules can be used for the chain length determination, while the ratio of 
D-Ala to phosphate concentration gives a measure for % D-alanylation. Applying 
these calculations to LtaS- or YfnI-produced polymers revealed an average chain 
length of 47 ± 9 and 74 ± 14 (Fig. 36C) and % D-alanylation of 62 ± 4 and 68 ± 9 
(Fig. 36D), respectively. This biochemical analysis gives a slightly longer chain 
length for LtaS and YfnI-produced LTA as compared to the NMR analysis. However, 
both methods indicate that YfnI-produced polymers are significantly longer; 1.5 × 
based on NMR or 1.6 × based on biochemical assays than LtaS-produced polymer, 
but remain linked to a glycolipid anchor. On the other hand there does not appear to 
be a statistically significant difference in the amount of D-Ala substitutions. While 
this analysis was performed in S. aureus, we speculate that the observed mobility shift 
of YfnI-produced polymers in the natural host B. subtilis is also due to an increase in 
chain length, suggesting that in the absence of LtaS, YfnI-becomes more efficient in 
LTA synthesis. 
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Figure 36: NMR and biochemical analysis of purified LTA. (A and B) NMR analysis. Large 
cultures of S. aureus strains (A) ANG514 (LtaS-expressing) and (B) ANG515 (YfnI-expressing) were 
grown and LTA purified as described in the Materials and Methods chapter (section 2.11.1). One mg 
purified LTA was suspended and lyophilized several times in D2O to exchange 1H for 2H deuterons and 
1H NMR spectra were recorded at 600 MHz, 300 K. The signals derived from citrate, a buffer 
component used during LTA purification and retained in the samples are marked in grey. The different 
signals previously assigned to LTA components (Morath et al, 2002) are color coded [blue - D-Ala (4 
protons per D-Ala group), green - GroP (5 protons per GroP group), orange - CH2/CH3 groups of fatty 
acids (59 protons per lipid anchor)]. The integration values are shown above each signal. Chain length 
was determined by calculating the ratio of integral values for GroP to CH2/CH3 groups in fatty acids 
and % D-Ala substitution by calculating the ratio of integral values for D-Ala to GroP × 100 and taking 
into account the number of protons for each signal. NMR analysis was performed on four 
independently isolated LTA samples for each strain and a representative result is shown. (C and D) 
Biochemical analysis of LTA. LTA extracted from strains ANG514 (LtaS) and ANG515 (YfnI) was 
subjected to a biochemical analysis. Phosphate, glucose and D-Ala contents were determined as 
described in the experimental procedures section. GroP, D-Ala and glucose solutions of known 
concentrations were used as standards. The chain length in GroP subunits (C) was determined by 
calculation of the ratio of phosphate / ½ glucose concentration and the % D-Ala substitution (D) by 
calculating the ratio of D-Ala / phosphate concentration × 100. Biochemical analysis was performed on 
four independently isolated LTA samples for each strain and the mean and standard deviation is shown. 
The difference in chain length is statistically significant and indicated with an asterisk (∗) (two-tailed p-
value of 0.017; unpaired T-test) while the difference in D-Ala modification is not (two-tailed p-value of 
0.355, unpaired T-test).  
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Chapter 8  
Discussion of chapters 6 and 7 
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        Polyglycerolphosphate LTA is found in the cell wall envelope of many Gram-
positive bacteria. In bacteria that belong to the Firmicutes phylum, the backbone of 
this polymer is synthesized by the lipoteichoic acid synthase enzyme LtaS (Gründling 
& Schneewind, 2007a; Rahman et al, 2009b). In contrast to S. aureus, which produces 
a single lipoteichoic acid synthase, B. subtilis encodes four LtaS-like proteins namely 
YflE, YfnI, YqgS and YvgJ. In chapters 6 and 7, the functions of these four proteins 
were investigated using both in vivo and in vitro enzyme assays. Enzymatic activities 
for all four B. subtilis LtaS orthologues were reported and experimental evidence 
provided that all proteins are either involved in the synthesis of an LTA glycolipid 
intermediate or directly in LTA backbone synthesis (sections 7.2 and 7.3). 
          Recently, Karatsa-Dodgson et al developed an in vitro enzyme system to 
quantify the activity of LtaS-type enzymes (Karatsa-Dodgson et al, 2010). Using this 
in vitro assay it was shown that the three recombinant LTA synthases (YflE, YfnI and 
YqgS) are > 4.5-fold more active compared to the enzymatic domain of the LTA 
primase YvgJ (Fig. 26). A similar observation was made with recombinant versions of 
the L. monocytogenes LTA synthase and LTA primase (Karatsa-Dodgson et al, 2010) 
indicating that there may be a correlation between the activity of these enzymes and 
their ability to produce actual glycerolphosphate polymers. Other general features 
revealed through the use of the in vitro assay system were that LTA synthases and 
primases require Mn2+ for in vitro enzyme activity and only seem to accept lipids with 
a glycerolphosphate head group as substrate but not lipids with other head groups 
such as PC, PE or PS (section 6.3).  
          For the in vivo protein expression studies and LTA analysis by western blot or 
glycolipid analysis by TLC we used both, S. aureus as heterologous host for the 
expression of individual B. subtilis LtaS-like proteins and defined B. subtilis mutants 
lacking individual ltaS-like genes or combinations of the four genes. It has been 
described previously that YflE and YfnI are LTA synthases capable of producing 
polyglycerolphosphate polymers (Gründling & Schneewind, 2007a). Here, it is shown 
that expression of YqgS in S. aureus from a multi-copy plasmid and an inducible 
promoter system leads to the production of a polyglycerolphosphate polymer (section 
7.2), and hence is a bona-fide LTA synthase. Consistent with these expression studies 
in a heterologous host, polyglycerolphosphate polymers could also be detected in B. 
subtilis triple mutants expressing YflE, YfnI or YqgS as sole enzymes (Fig. 34). Only 
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when all three genes were deleted in combination, could the glycerolphosphate 
polymer no longer be detected (Fig. 34). Expression of the fourth protein, YvgJ, either 
as a sole LtaS-like protein in B. subtilis, or from a multi-copy plasmid and a strong 
promoter in S. aureus, did not lead to LTA production, suggesting that YvgJ does not 
function as an LTA synthase. Analysis of the lipid profile of an S. aureus YvgJ-
expressing strain indicated that YvgJ acts as an LTA primase, capable of transferring 
the initial glycerolphosphate subunit onto the glycolipid anchor (section 7.3). The 
presence of an LTA primase enzyme has been described before in L. monocytogenes, 
which expresses two LtaS-like enzymes with distinct functions in LTA synthesis 
(Webb et al, 2009). LtaPLM (Lmo0644) is the LTA primase, which transfers the initial 
glycerolphosphate subunit onto the glycolipid anchor, whereas LtaSLM (Lmo0927) 
functions as an LTA synthase producing the polyglycerolphosphate backbone. 
However, deletion of the dedicated LTA primase YvgJ in B. subtilis does not lead to 
an obvious difference in LTA production, suggesting that all B. subtilis LTA 
synthases are able to efficiently initiate LTA synthesis independent of the activity of a 
dedicated LTA primase (Fig. 34). The role of YvgJ in LTA synthesis is not clear. It is 
possible that YvgJ only contributes to some extent and under certain growth 
conditions to the LTA synthesis process.  
          Expression of B. subtilis YflE, YfnI and YqgS, but not YvgJ in S. aureus could 
be confirmed by western blot. Interestingly, similar to LtaS, YflE is cleaved in S. 
aureus, but no processed forms of YfnI or YqgS could be detected in culture 
supernatant. The fact that only the full-length YfnI protein was visible in the 
heterologous host provided a tool to study which B. subtilis proteases might be 
involved in YfnI cleavage, and whether YfnI processing has an effect on the in vivo 
function of this enzyme. YfnI cleavage in B. subtilis is dependent on the two signal 
peptidases SipT and SipV (Antelmann et al, 2001). However, expression of YfnI and 
SipT or SipV, or multiple B. subtilis signal peptidases did not promote YfnI 
processing in S. aureus. We speculate that either the signal peptidases are not 
functional in the heterologous host, or that YfnI does not adopt a conformation in S. 
aureus that is accessible to SipT or SipV. 
          B. subtilis strains lacking individual ltaS-like genes or combinations of the four 
genes display several phenotypes. For instance, a single yflE mutant formed chains, an 
yflE/yqgS double mutant has a sporulation defect, and cells lacking all four genes 
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form long chains and spiraled along their long axis (Schirner et al, 2009). Here, it is 
shown that the mere presence or absence of polyglycerolphosphate polymers cannot 
account for the observed filamentation and sporulation defect, as a strain deleted for 
yflE or yflE/yqgS is still capable of producing a glycerolphosphate polymer (Fig. 34). 
Previously, both YflE and YqgS expressed as GFP-fusion proteins from an inducible 
promoter system were found to localize preferentially to the division site or 
sporulation septum (Schirner et al, 2009). Taken together with our finding on the 
LTA production in the different mutant strains (Fig. 34), this would indicate that in 
the absence of YflE, YqgS produces functional polyglycerolphosphate polymers at the 
sporulation septum, and that polymers synthesized by YfnI are either not produced at 
the sporulation septum or are not functional due to their structural alterations (see 
below). 
          In this work, it was shown that a B. subtilis yflE deletion strain, as well as a 
strain expressing YfnI as a sole LTA synthase, produces polymers that migrated 
slower on SDS-PAGE gels compared to wild type LTA (Fig. 34). This was also 
observed when yfnI was expressed in an S. aureus ltaS depletion strain (Gründling & 
Schneewind, 2007a and Fig. 29C) and, indicating that the altered mobility of LTA 
produced by YfnI in S. aureus is not an artifact, but reflects the natural property of 
this enzyme. NMR and biochemical analysis of LTA purified from S. aureus strains 
expressing LtaS or YfnI, revealed a 1.5 to 1.6-fold increase in chain length for YfnI-
produced polymers (Fig. 36), and this presumably results in the slower mobility on 
SDS-PAGE gels. The presence of longer polymers in the absence of YflE is 
somewhat puzzling and suggests that either the activity of YfnI changes in the 
presence of YflE, or that YfnI and YflE compete for the PG lipid substrate and that 
YfnI can only synthesize long polymers in the absence of YflE due to an increased 
availability of PG. Alternatively, YflE could trim YfnI-produced polymers and hence 
these long polymers are only seen in the absence of YflE. 
          Currently it is not known if there are any natural conditions under which YfnI 
would be expressed in the absence of YflE and hence lead to the production of 
elongated LTA molecules. A previous study using transcriptional lacZ reporter gene 
fusions, showed low expression of yqgS, yvgJ and yfnI compared to yflE during 
growth of B. subtilis in PAB medium (Schirner et al, 2009), which together with all 
other evidence suggests that YflE is the “house-keeping” LTA synthase. In proteomic 
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studies, processed forms of both YflE and YfnI were detected in the culture 
supernatant of late-exponential phase B. subtilis cultures when grown in minimal 
medium (Hirose et al, 2000) showing that both of these LTA synthases are produced 
under these conditions. In addition, YfnI was found in culture supernatants of 
exponential as well as stationary phase B. subtilis cultures when grown in LB-broth 
(Antelmann et al, 2001). But most notably, it has also been described that yfnI 
expression is controlled by the alternative sigma factor sigma M (Eiamphungporn & 
Helmann, 2008; Jervis et al, 2007) and hence its expression is activated under specific 
stress conditions such as high salt, low pH, heat and presence of certain antibiotics 
(Eiamphungporn & Helmann, 2008; Jervis et al, 2007; Thackray & Moir, 2003). It 
could be that under these conditions LTA of slightly different structure is synthesized 
to better cope with specific stress conditions. However, it has been reported that a yfnI 
deletion strain is not more sensitive to salt stress as compared to a WT strain (Schirner 
et al, 2009). Additional studies are needed to determine if YfnI could indeed be a 
“stress LTA-synthase” (Fig. 37). During sporulation YqgS is essential in the absence 
of the “house-keeping” LTA synthase YflE (Schirner et al, 2009), and therefore could 
be termed sporulation LTA synthase (Fig. 37). The function of the LTA primase YvgJ 
during growth of B. subtilis is least clear, and only the somewhat reduced sporulation 
efficiency in the absence of both YflE and YvgJ would indicate that the GroP-Glc2-
DAG intermediate produced by YvgJ plays are role during the sporulation process 
(Schirner et al, 2009). It is interesting to note that accumulation of the GroP-Glc2-
DAG glycolipid intermediate upon YvgJ expression leads to a concomitant decrease 
in the amount of the glycolipid Glc2-DAG (Fig. 30), suggesting that the total 
glycolipid pool is held constant in the cell, and that GroP-Glc2-DAG is part of this 
glycolipid pool. This could indicate that GroP-Glc2-DAG might still be able to 
traverse the membrane and reach the cytoplasm of the cell where it could cause a 
feedback inhibition on cytoplasmic glycolipid synthesizing enzymes (UgtP in B. 
subtilis or YpfP in S. aureus). 
          In conclusion the results presented in chapters 6 and 7 demonstrate that all four 
B. subtilis LtaS-type proteins are involved in the LTA synthesis process, they have 
distinct enzymatic activities within the cell, and there is a functional interdependency 
of their enzymatic activities.  
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Figure 37: Schematic representation of in vivo activities of the four B. subtilis LtaS-type enzymes. 
(A) B. subtilis YflE is the “house-keeping” LTA synthase, which is active during vegetative growth. 
(B) B. subtilis YfnI is assumed to be the “stress” LTA synthase, as yfnI transcription is controlled by 
sigma M, which is important during cell envelope stress. YfnI is capable of promoting 
polyglycerolphosphate synthesis as well as of producing the GroP-Glc2-DAG glycolipid intermediate. 
Here we show that YfnI activity is influenced by the presence/absence of YflE. Processed forms of 
both, YflE and YfnI have been detected in the culture supernatant, and processing of YfnI is reduced in 
the combined absence of the two signal peptidases SipT and SipV (Antelmann et al, 2001). (C) B. 
subtilis YqgS has LTA synthase activity and is important during the sporulation process. (D) YvgJ 
functions as an LTA primase synthesizing the glycolipid intermediate GroP-Glc2-DAG. Although 
YqgS and YvgJ contain an AXA motif it is not clear if these enzymes are processed in B. subtilis. LTA 
synthases are depicted in blue and LTA primases in red. Numbers refer to amino acid positions and 
arrows indicate cleavage or potential cleavage sites.  
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          Polyglycerolphosphate LTA is a widespread polymer found in the cell wall 
envelope of many Gram-positive bacteria. In bacteria that belong to the phylum 
Firmicutes, the LTA backbone is synthesized by LtaS, the lipoteichoic acid synthase 
(Gründling & Schneewind, 2007a; Rahman et al, 2009b). S. aureus produces a single 
LtaS protein, which is essential for growth and LTA production under standard 
laboratory conditions (Gründling & Schneewind, 2007a). The LtaS protein contains 
five N-terminal transmembrane helices (5TM) and a large C-terminal extracellular 
enzymatic domain (eLtaS). The latter domain is cleaved during bacterial growth and 
released from the membrane. However, despite the fact that the enzyme is efficiently 
processed, only the full-length protein appears to function in the LTA synthesis 
pathway. My work provides evidence that both LtaS domains are required for enzyme 
function and that once the protein is cleaved into 5TM and eLtaS the enzyme no 
longer contributes to LTA synthesis (sections 4.2-4.4). Based on my data it can be 
speculated that LtaS cleavage provides a mechanism to regulate LtaS activity and that 
the LtaS processing step irreversibly inactivates the enzyme.  
          The observation that only the full-length LtaS protein is enzymatically active 
suggests that the LTA polymer remains in close proximity to the membrane at least 
during its synthesis. Recently, the existence of a periplasmic space in Gram-positive 
bacteria was reported (Matias & Beveridge, 2005; Matias & Beveridge, 2006). Based 
on cryotransmission electron microscopy images of unstained, ultrarapid frozen and 
hydrated sections of B. subtilis and S. aureus cells, two distinct cell wall zones could 
be identified. A low-density inner wall zone (IWZ) was observed immediately next to 
the bacterial membrane and this zone was denoted the periplasmic space in Gram-
positive bacteria. Adjacent to the IWZ, a high-density outer wall zone (OWZ) was 
visible, which comprises the peptidoglycan. Whole cell labeling experiments with 
positively charged gold nanoparticles resulted in similar levels of these particles 
bound to the IWZ and OWZ, indicating the existence of large amounts of negatively 
charged components in the periplasm (Matias & Beveridge, 2008). After enzymatic 
hydrolysis of the OWZ, a surface diffuse layer extending from the bacterial membrane 
was observed. This layer was not significantly altered by protease treatment, but could 
be labeled with an LTA specific antibody conjugated to nanogold particles (Matias & 
Beveridge, 2008). These findings strongly suggest that LTA is a major component of 
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the Gram-positive periplasm and thus argue for a physiological function of the 
polymer in close proximity to the membrane (Matias & Beveridge, 2008).  
          Recent literature has highlighted the discovery of polyglycerolphosphate LTA 
in various bacterial species belonging to the phylum Actinomycetes (Rahman et al, 
2009a; Rahman et al, 2009c). However, Actinomycetes appear to lack LtaS 
homologues and thus it was hypothesized that LTA synthesis occurs through an 
alternative pathway in these bacteria (Rahman et al, 2009c). Interestingly, 
Actinomycetes that produce polyglycerolphosphate LTA often also synthesize 
polyglycerolphosphate-type WTA rather than alternative secondary cell wall 
polysaccharides. Based on this observation it was hypothesized that the pathways of 
LTA and WTA synthesis in these bacterial species overlap and utilize a common 
precursor (Rahman et al, 2009b). In the future, it will be interesting to investigate how 
certain bacterial species, such as Actinomycetes, synthesize polyglycerolphosphate 
LTA.  
          In contrast to S. aureus, which has a single LtaS protein, B. subtilis encodes 
four LtaS-like proteins, namely YflE, YfnI, YqgS and YvgJ (Gründling & 
Schneewind, 2007a; Schirner et al, 2009). In this work, I show that all four B. subtilis 
LtaS-like proteins are enzymatically active and that YflE, YfnI and YqgS are bona-
fide LTA synthases that can synthesize glycerolphosphate polymers (section 7.2). In 
contrast, YvgJ is an LTA primase, which uses the glycerolphosphate head group of 
the membrane lipid PG to form the glycolipid GroP-Glc2-DAG (section 7.3), which is 
assumed to be an LTA synthesis intermediate.  
          Two different models have been proposed for lipoteichoic acid biosynthesis that 
differ in the enzyme activity, which is required for the actual linkage of the 
glycerolphosphate polymer to the glycolipid anchor (recently reviewed in Rahman et 
al, 2009b). For one model, it was proposed that an “LTA transferase” moves fully 
synthesized polyglycerolphosphate polymers from a DAG lipid anchor onto a 
glycolipid anchor. This was based on the following observations: In Streptococcus 
sanguis a significant amount of polyglycerolphosphate “intermediates” linked to DAG 
are present in the membrane (Chiu et al, 1993). In the absence of glycolipids due to 
mutations in genes necessary for their synthesis (Button & Hemmings, 1976; Fedtke 
et al, 2007; Kiriukhin et al, 2001) or natural lack of these genes as found in some 
Bacillus sp. (Iwasaki et al, 1986) polyglycerolphosphate polymers are directly linked 
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to DAG. Hence, it was proposed that the DAG-linked polymers are natural LTA 
synthesis intermediates, which are subsequently moved by an LTA transferase 
enzyme onto the glycolipid anchor. In the second model an LTA primase adds the 
first glycerolphosphate subunit to the glycolipid anchor to form the GroP-glycolipid 
intermediate. Subsequently an LTA synthase adds additional glycerolphosphate 
subunits onto this GroP-glycolipid intermediate to produce the LTA backbone chain. 
The discovery of an LTA primase in L. monocytogenes (Webb et al, 2009) and, as 
described in this study, now also in B. subtilis favors the second model. However, it 
appears that the action of an LTA primase and the production of the GroP-glycolipid 
intermediate aid only in some cases and to some extent in the LTA synthesis process. 
In additional to this two-enzyme system, a slightly altered version of the latter model 
in which only a single enzyme is needed for LTA synthesis is proposed here. In this 
model, a single enzyme can directly start and extend the glycerolphosphate chain on 
the glycolipid anchor. It was shown that enzymes with LTA synthases and LTA 
primases activity belong to the same family of proteins (LtaS-type enzymes). 
Members of this protein family show a high degree of identity on the amino acid level 
and have the same predicted membrane topology and domain structure. Therefore, it 
appears that in the genome of S. aureus and several other Gram-positive bacteria, only 
one LtaS-type enzyme is encoded and hence it was suggested that this enzyme 
functions as both an LTA synthase and an LTA primase. In addition, the B. subtilis 
YfnI enzyme produces both polyglycerolphosphate polymers and the GroP-Glc2-DAG 
intermediate (Gründling & Schneewind, 2007a and sections 7.2 and 7.3), providing 
further evidence that the same LtaS-type enzyme can be an LTA synthase and an LTA 
primase. Furthermore, deletion of the dedicated LTA primase YvgJ in B. subtilis does 
not lead to an obvious difference in LTA production suggesting that all B. subtilis 
LTA synthases are able to efficiently initiate LTA synthesis independent of the 
activity of a dedicated LTA primase (Fig. 34). Based on these observations, it can be 
suggested that while LtaS-type enzymes are very selective for their lipid substrate 
(they can only cleave the head group of PG), at least some of them have a relaxed 
specificity towards the acceptor lipid that can be used for the subsequent 
glycerolphosphate transfer reaction. For example, S. aureus LtaS can use DAG, Glc2-
DAG, GroP-Glc2-DAG and the polyglycerolphosphate chain. However the 
efficiencies with which these different acceptor molecules can be used will vary 
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between each individual enzyme and dictate how efficient LTA can be synthesized in 
the absence of glycolipids or a dedicated primase and might also influence the final 
chain length of LTA molecules. 
          Using BLAST homology searches, it was investigated whether it is possible to 
distinguish between LTA synthases and dedicated LTA primases (such as the B. 
subtilis YvgJ and L. monocytogenes Lmo0644 proteins). However, no motif could be 
identified that would allow the prediction of which LtaS-type enzyme is an LTA 
synthase and which protein would only function as an LTA primase. Additional 
structural information on LTA synthases and LTA primases especially in their full-
length membrane form, combined with additional in vitro assay studies investigating 
specifically the glycerolphosphate transfer reaction in the presence of different 
acceptor molecules, would help to shed light on this question. 
          Most Bacillus species produce LTA of the polyglycerolphosphate type (Iwasaki 
et al, 1986; Iwasaki et al, 1989). However, based on literature searches and sequence 
analysis at least Bacillus circulans, Bacillus pseudofirmus OF4 and Bacillus 
halodurans C125 lack the LTA polymer or LtaS-type enzymes. B. circulans falls into 
an ungrouped class of  Bacillaceae species (Xu & Cote, 2003) and the latter two 
strains are alkaliphilic bacteria (Iwasaki et al, 1989; Takami et al, 2000). It has been 
shown that the alkaliphilic strain B. halodurans contains, in place of teichoic acids, 
teichuronopeptides as major cell wall components, which are co-polymers of 
polyglutamic acid and polyglucoronic acid (Takami et al, 2000). Several sequenced 
Bacillus species, namely Bacillus selenitireducens MLS10, Bacillus coagulans 36D1 
and Bacillus coahuilensis m4-4, apparently encode only a single LtaS homologue, 
which should be sufficient for polyglycerolphosphate LTA synthesis. However, the 
majority of Bacillus species encode multiple LtaS-type proteins. At present it is still 
not completely understood why bacteria such as B. subtilis produce multiple proteins. 
However as shown here, all four proteins are involved in the LTA synthesis process, 
they have distinct enzymatic activities within the cell and there is a functional 
interdependency of their enzymatic activities. Presumably the coordinate expression 
and activity of these proteins allows B. subtilis to fine-tune LTA synthesis under 
different growth and stress conditions and during the sporulation process. Based on 
this and previous studies, it is now becoming more and more apparent that LTA 
function is tied to its exact structure, spatial distribution and/or localized synthesis 
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(Schirner et al, 2009). To determine the exact function of LTA for bacterial growth 
and its alterations during different growth conditions warrants further analysis.  
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